

Title	Vitamin biosynthesis in the gut: interplay between mammalian host and its resident microbiota
Authors	Tarracchini, Chiara;Lordan, Cathy;Milani, Christian;Moreira, Luiza P. D.;Alabedallat, Qusai M.;de Moreno de LeBlanc, Alejandra;Turroni, Francesca;Lugli, Gabriele Andrea;Mancabelli, Leonardo;Longhi, Giulia;Brennan, Lorraine;Mahony, Jennifer;LeBlanc, Jean Guy;Nilaweera, Kanishka N.;Cotter, Paul D.;van Sinderen, Douwe;Ventura, Marco
Publication date	2025-04-02
Original Citation	Tarracchini, C., Lordan, C., Milani, C., Moreira, L. P., Alabedallat, Q. M., de Moreno de LeBlanc, A., Turroni, F., Lugli, G. A., Mancabelli, L., Longhi, G., Brennan, L., Mahony, J., LeBlanc, J. G., Nilaweera, K. N., Cotter, P. D., van Sinderen, D. and Ventura, M. (2025) 'Vitamin biosynthesis in the gut: interplay between mammalian host and its resident microbiota', Microbiology and Molecular Biology Reviews, 89(2), e00184-23. https://doi.org/10.1128/mmbr.00184-23
Type of publication	Article (peer-reviewed);journal-article
Link to publisher's version	10.1128/mmbr.00184-23
Rights	© 2025, American Society for Microbiology. - https://creativecommons.org/licenses/by/4.0/
Download date	2026-08-30 15:05:45
Item downloaded from	https://hdl.handle.net/10468/17705



UCC

University College Cork, Ireland
 Coláiste na hOllscoile Corcaigh

**Vitamin biosynthesis in the gut: interplay between mammalian host and its resident
microbiota**

Running title: Vitamins and human microbiome

Key words: microbiome, metagenomics, microbe-microbe interaction

Chiara Tarracchini¹, Cathy Lordan², Christian Milani^{1,3}, Luiza P.D. Moreira², Qusai M.
Alabedallat², Alejandra de Moreno de LeBlanc⁴, Francesca Turroni^{1,3}, Gabriele Andrea Lugli^{1,3},
Leonardo Mancabelli^{3,5}, Giulia Longhi¹, Lorraine Brennan⁶, Jennifer Mahony⁷, Jean Guy
LeBlanc⁴, Kanishka N. Nilaweera², Paul D. Cotter^{2,7,8}, Douwe van Sinderen⁷, Marco Ventura^{1,3}

¹ Laboratory of Probiogenomics, Dept. Chemistry, Life Sciences and Environmental
Sustainability, University of Parma, Italy; ² Teagasc Moorepark Food Research Centre, Fermoy,
County Cork, Ireland; ³ Microbiome Research Hub, University of Parma, Italy; ⁴ Centro de
Referencia para Lactobacilos (CERELA-CONICET), San Miguel de Tucumán, Tucumán,
Argentina; ⁵ Dept. Medicine and Surgery, University of Parma, Italy; ⁶ School of Agriculture and
Food Science, Institute of Food and Health and Conway Institute, University College Dublin,
Dublin, Ireland; ⁷ APC Microbiome Institute and School of Microbiology, Bioscience Institute,
National University of Ireland, Cork, Ireland;
⁸ VistaMilk, Co. Cork, Ireland

Correspondence:

Marco Ventura, Laboratory of Probiogenomics, Department of Chemistry, Life Sciences, and
Environmental Sustainability, University of Parma, Parco Area delle Scienze 11a, 43124 Parma,
Italy. Phone: ++39-521-905666. E-mail: marco.ventura@unipr.it

Douwe van Sinderen, APC Microbiome Institute and School of Microbiology, Bioscience Institute,
National University of Ireland, Cork, Ireland Phone +353 214901365. E-mail:
d.vansinderen@ucc.ie

30	Table of Contents	
31	Abstract	3
32	General introduction	4
33	1. Methodological approaches to measure and predict bacterial vitamin biosynthesis	6
34	2. Genetics of vitamin biosynthesis and transport mechanisms in key members of the human gut	
35	microbiota	18
36	2.1 Thiamine (Vitamin B1)	19
37	2.2 Riboflavin (Vitamin B2).....	21
38	2.3 Niacin (vitamin B3)	23
39	2.4 Pantothenic acid (vitamin B5)	24
40	2.5 Pyridoxine and its derivates (Vitamin B6).....	25
41	2.6 Biotin (vitamin B7).....	27
42	2.7 Folate (vitamin B9).....	29
43	2.8 Cobalamin (Vitamin B12).....	30
44	2.9 Menaquinones (vitamin K2).....	32
45	2.10 Vitamin production by bacterial communities.....	34
46	3. Microbe-derived vitamins throughout human lifespan: focus on early life	42
47	4. Production of vitamins by microbiomes from different human body sites.....	49
48	5. Impact of diet on the vitamin-producing or -consuming gut microbiota.....	52
49	5.1 Thiamine (Vitamin B1)	54
50	5.2 Riboflavin (Vitamin B2).....	56
51	5.3 Niacin (Vitamin B3)	58
52	5.4 Pantothenate (Vitamin B5).....	59
53	5.5 Biotin (Vitamin B7)	60
54	5.6 Folate (Vitamin B9).....	61
55	5.7 Cobalamin (Vitamin B12).....	62
56	5.8 Vitamin K2	63
57	6. Therapeutic and probiotic interventions to modulate vitamin production.....	65
58	Caveats and future perspectives.....	70
59	CONCLUSIONS	71
60	Acknowledgements	74
61	References.....	75
62		

Abstract

In recent years exhaustive efforts have been made to dissect the composition of gut-associated microbial communities and associated interactions with their human host, which are thought to play a crucial role in host development, physiology and metabolic functions. While such studies were initially focused on the description of the compositional shifts in the microbiota that occur between different health conditions, more recently they have provided key insights into the functional and metabolic contribution of the gut microbiota to overall host physiology. In this context, an important metabolic activity of the human gut microbiota is believed to be represented by the synthesis of various vitamins which may elicit considerable benefits to human health. A growing body of scientific literature is now available relating to (predicted) bacterial vitamin biosynthetic abilities, with ever-growing information concerning the prevalence of these biosynthetic abilities among members of the human microbiota. This review is aimed at disentangling if and how cooperative trophic interactions of human microbiota members contribute to vitamin production, and if such gut microbiota-mediated vitamin production varies according to different life stages. Moreover, it offers a brief exploration on how different diets may influence vitamin production by shaping the overall composition and metabolic activity of the human gut microbiota, while also providing preliminary insights into potential correlations between human microbiota-associated vitamin production and occurrence of human diseases and/or metabolic disorders.

General introduction

Vitamins are essential, non-caloric micronutrients involved in a plethora of metabolic and regulatory processes in living micro- and macro-organisms, ranging from bacteria to mammals [1,2]. Typically, most vitamins exist as groups of chemically related, nutritionally active compounds, commonly referred to as vitamers [3]. Vitamins can broadly be classified into two categories based on their solubility properties, which influence their functions and sites of action. Specifically, fat-soluble vitamins, namely, vitamins A, D, E, and K, dissolve in fat or other hydrophobic solvents and are for example important to protect cell membranes against free radical damage and to exert effects within the cell nucleus to regulate gene expression [4]. In contrast, vitamin C and all B group vitamins are water-soluble [5] and typically act as cofactors in a wide variety of biochemical reactions within the cell cytosol [6]. In humans, vitamin solubility also influences their mode of absorption. Indeed, while fat-soluble vitamins require dietary fats and bile acids for absorption, being transported through the lymphatic system before entering the bloodstream, water-soluble, diet-derived vitamins are typically absorbed directly into the bloodstream through the intestinal wall of the small intestine [7,8]. Notably, when intraluminal vitamin availability is low, vitamin absorption processes are facilitated by substrate-specific transport systems, while passive diffusion occurs at higher concentrations [8–10].

Except for vitamin D, which humans can produce endogenously following exposure to ultraviolet light [11], most vitamins must be obtained from external sources. Due to their solubility characteristics, water-soluble vitamins cannot be efficiently stored in the human body, leaving individuals susceptible to deficiencies and necessitating a continuous dietary intake to meet requirements [5]. An exception to this is vitamin B12, which humans can store in substantial amounts in the liver for several years, thereby reducing the risk of vitamin B12 deficiency [12].

Although the diet represents the primary exogenous source of vitamins, the human gut microbiota, which is comprised of trillions of microorganisms, has been recognized as a potential production platform for vitamins, including vitamin K2 (menaquinone) and various B vitamins, such as thiamine (B1), riboflavin (B2), niacin or nicotinic acid (B3), pantothenic acid (B5), pyridoxine (B6), biotin (B7), folate (B9 or B11), and cobalamin (B12) [13]. In fact, while gut bacteria produce vitamins to fulfill their own metabolic needs, any excess or release into the surrounding environment due to spontaneous microbial cell lysis has the potential to become accessible to their human host [14,15]. This concept aligns with evidence from germ-free animal studies, which are more susceptible to vitamin deficiencies, likely because of the absence of vitamin K- and vitamin B-producing bacterial elements of the gut microbiota [16,17]. Unlike conventionally raised animals, germ-free animals require dietary supplementation of these vitamins to prevent deficiency [18]. For instance, vitamin K deficiency was rapidly induced in male germ-free rats maintained on a vitamin K-deficient diet, whereas conventionally bred animals on the same diet did not exhibit signs of deficiency [19]. Remarkably, mono-colonization of germ-free rats with *Escherichia coli*, a known producer of vitamin K2, restored normal levels of this vitamin within 24-48 hours [19]. Similar observations have been reported in human studies, where individuals maintained on a low-vitamin K diet for 3-4 weeks did not develop vitamin K deficiency. However, when these individuals were treated with broad-spectrum antibiotics to suppress the gut microbiota, a significant reduction in plasma prothrombin levels was observed [20], further highlighting the contribution of gut microbiota to the vitamin K status of their host.

Interestingly, while dietary vitamins are generally absorbed in the human small intestine, specialized transport systems localized in the colonic epithelium will provide efficient

supplementary uptake capacity for vitamins produced by the microbial community residing in the colon [21,22], suggesting that gut microbiota-derived vitamins are of nutritional value to the host and especially to the local colonocytes [7].

The extent to which gut microbiome-derived vitamins contribute to host requirements and systemic status remains somewhat unclear. To the best of our knowledge, just a single study has so far addressed this issue across all eight B-group vitamins [23], estimating that 86 %, 37 %, 31 %, and 27 % of the daily recommended intake of vitamin B6, B9, B12, and B3, respectively, can be provided by human gut commensals [23]. However, this study did not account for vitamin-utilizing bacteria, and other research issues about the actual contribution of microbially derived vitamins to the host, particularly vitamin B12. Notably, these latter studies suggest that this vitamin is unlikely to be supplied to the host in significant quantities, as the predominant corrinoids produced by gut microbiota are cobalamin analogues that are inactive in mammalian cells [24,25]. Instead, vitamin B12 appears to play a crucial role in shaping the composition and functionality of human gut microbial communities [17,24,26,27].

In the following sections of this review, we will provide a comprehensive overview of the current body of knowledge on vitamin production by human-gut associated bacteria, focusing on B-group vitamins and vitamin K, which are the most relevant vitamins synthesized by human-gut associated bacteria among the essential (micro)nutrients [13,28]. Notably, the most recent findings in this area are predominantly derived from metagenome- and genome-based studies, offering insights into the genetic and metabolic potential of these microorganisms.

1. Methodological approaches to measure and predict bacterial vitamin biosynthesis

Due to their impact on human health, understanding vitamin biosynthetic abilities of bacteria inhabiting the diverse (micro)ecosystems of the human body has attracted significant interest from

the scientific community [29]. Specifically, the human gut microbiota has emerged as a rich source of microbial taxa capable of producing a wide array of B-group vitamins as well as vitamin K in the form of (mena)quinones [13].

In recent decades, the study of bacterial vitamin production primarily relied on *in vitro* cultivation-based techniques. These methods involve cultivating bacteria under controlled laboratory conditions followed by quantification of microbially synthesized vitamins from either cell extracts or culture supernatants (Figure 1). These approaches are still used today and exploit the strict requirement of certain bacteria for a particular B-group vitamin, with measurements based on the correlation between growth of a vitamin-dependent test microorganism and the physiologically available amount of that vitamin in the medium [30,31] (Figure 1).

In addition to these microbiological assays, there are several analytical approaches available to detect and quantify B vitamins, including immunoassays, including vitamin-specific ELISA tests, spectrophotometry, electrophoresis, fluorimetry, and high-performance liquid chromatography (HPLC) coupled with ultraviolet or fluorescence detection [32] (Figure 1). While enabling rapid, cost-effective, and efficient analysis, most of these methodologies are restricted to assessing samples with unsophisticated background matrices or abundant B vitamin content, such as pharmaceutical formulations and dietary supplements [33,34]. Additionally, despite their high sensitivity and specificity, these approaches are set up to measure levels of individual B vitamins [32,35,36], and rarely provide a comprehensive B vitamin profile. More recently, methods based on liquid chromatography (LC) coupled with tandem mass spectrometry (MS/MS) have emerged as the most frequently used technique for accurate determination of B vitamins, with the advantage of simultaneously detecting multiple structurally diverse, water-soluble vitamins from various food and biological matrices, such as human milk, plasma, whole blood, and feces, as well as

176 bacterial culture supernatants [37–45]. In general, liquid chromatography-tandem mass
177 spectrometry (LC-MS/MS) relies on measuring mass-to-charge (m/z) ratios of ionized molecules,
178 involving a two-stage approach. Firstly, chromatographic separation of target compounds is
179 performed using HPLC. In particular, for the separation of water-soluble vitamins, reversed-phase
180 HPLC (RP-HPLC) employing a non-polar stationary phase and a polar mobile phase [46] is a
181 highly suitable technique due to its ability to yield superior peak shape and robustness of
182 chromatographic columns [47–49]. Among various types of stationary phases (SP) used in RP-
183 HPLC [46], C18-based SP has been widely applied to separate water-soluble vitamins, employing
184 a combination of water and organic solvents as the mobile phase for elution [46]. For example,
185 C18-based SPs have been effectively employed to concurrently distinguish active forms of various
186 B-group vitamins from complex matrices, including pyridoxal, pyridoxamine, pyridoxine, four
187 cobalamins, and folate vitamers [48,50–55].

188 Following chromatographic separation based on increasing hydrophilicity, the fractionated
189 compounds are introduced into a tandem mass spectrometry analyzer for further analysis.
190 Commonly, this analyzer consists of a triple quadrupole mass spectrometer [33], where the
191 compounds are ionized and fragmented, typically by an ionization source such as electrospray
192 ionization (ESI) or atmospheric pressure chemical ionization (APCI) [56–59]. It is currently
193 recognized that water-soluble vitamins exhibit enhanced responsiveness in positive ionization
194 mode, with the notable exception of folic acid and ascorbic acid, which demonstrate higher
195 responsiveness in negative ionization mode [60–62].

196 While these approaches have been utilized to directly assess, quantify, and empirically validate
197 vitamin production in bacteria with high sensitivity [35,63], they can only be applied to gut bacteria
198 cultivated under *in vitro* conditions. Notably, many bacterial species and strains, especially those

microbes referred to as microbial dark matter [64], remain currently uncultured under *in vitro* conditions. This challenge underscores the need for techniques and approaches that do not rely on cultivation of microorganisms under laboratory conditions.

In recent decades, advancements in genome sequencing, the concomitant reduction in DNA sequencing costs and the development of associated bioinformatics tools for sequence analysis platforms have provided valuable insights into the encoded potential of bacterial genomes through comprehensive functional annotation and metabolic reconstruction [65] (Figure 1). These efforts have included the identification of microbial genes associated with vitamin biosynthesis, with a growing body of research correlating genomic data with experimental findings that elucidate genetic pathways and regulatory mechanisms involved in bacterial vitamin biosynthesis [66–72]. Over time, comparative and functional annotation of bacterial genomes has become much more productive due to the development of sophisticated annotation platforms, functional analysis software, and manually curated databases containing publicly accessible genomic, proteomic, transcriptomic, metabolomic and protein structure information. Among these, the most renowned resources are MetaCyc (<https://metacyc.org/>), SEED (<http://www.theseed.org/>), PATRIC (<https://www.patricbrc.org>), the Kyoto Encyclopedia of Genes and Genomes (KEGG, <https://www.genome.jp/kegg/>), and Protein Data Bank (PDB, <https://www.wwpdb.org/>), which allow researchers to browse and obtain a wide variety of data, including genomes, genomic features, protein families and 3D structures, and reconstructed pathways [73–78]. Although none of these metabolic pathway catalogs are exclusively dedicated to the genes involved in microbial vitamin synthesis, they cover a wide range of microbial genomes and annotated gene sequences that can be searched to identify specific genes implicated in vitamin biosynthesis pathways across diverse microbial taxa. Consequently, by applying microbial genomics to the identification of

vitamin-related genes and pathways, scientists can now access not only many cost-effective, high-throughput sequencing services but also an extensive pool of publicly available bioinformatic resources. These resources readily aid in identifying vitamin biosynthesis-associated genes through sequence homology with well-characterized sequences (Figure 1). This approach has proven effective in predicting vitamin-producing potential of both currently culturable and yet unculturable bacterial taxa of the human gut microbiota [70,79–82] (Figure 1). In this regard, recent comparative genomic analyses have significantly contributed to elucidating the occurrence of B-vitamin biosynthetic pathways in bacterial genomes, identifying potential gut commensal producers, and revealing intriguing vitamin-dependent inter-species cross-feeding relationships [70,81,83,84]. The genetic basis underlying the biosynthetic potential of gut microbes is discussed in detail in the following section of this review. To provide a few examples, the riboflavin and niacin biosynthetic pathways have emerged as the most prevalent vitamin production capabilities among members of the human gut microbiome [81]. The reason for the widespread biosynthetic potential of these vitamins has been attributed to their involvement in crucial microbial metabolic functions, ranging from maintaining cellular homeostasis to facilitating critical biochemical processes such as energy production, redox reactions, and DNA repair [85,86].

In contrast, complete biosynthetic pathways for cobalamin appear to be much less common among human gut commensals, most likely because this vitamin is not essential for growth of many bacteria, as they have cobalamin-independent enzymes [82,87]. However, multiple genomic investigations have shown that only a minority of the cobalamin-utilizing microorganisms possess the full biosynthetic pathway for this cofactor [87,88], thus relying, where relevant, on its environmental availability as well as on intricate cross-feeding networks [24,89]. These findings

have led to the hypothesis that certain B-complex vitamins play a crucial role in shaping and driving ecological microbe-microbe relationships within the human gut [80,90,91].

Expanding from the hypothesis which poses that B vitamins influence microbial interactions, genomic data have been used to construct microbial genome-scale models that offer a mechanistic understanding of metabolic traits within microbial communities [76,92–95] (Figure 1). Intriguingly, such validated *in silico* modelling, by integrating data from distinct components such as cells, molecules, and pathways [96], allows for a broadening of perspective from individual microbes to community outcomes, thereby aiding in capturing overall metabolism of entire ecosystems. A compelling example in the context of vitamin production by human-associated microorganisms is illustrated by a recent study, which systematically infers vitamin-associated metabolic abilities of nearly one thousand genomes of common human gut commensals, revealing which vitamins constitute essential or optional nutrients under specific growth conditions [92]. Notably, based on this study, roughly 60 % of the tested enteric bacteria depend on external sources of vitamin B1, followed by vitamins B2 and K2, which were predicted to be essential for more than 40 % of gut microbes. Moreover, integrating requirements and biosynthetic abilities across various gut commensals has shown the presence of complementary profiles of vitamin biosynthesis within microbial communities. Interestingly, these findings demonstrate that vitamin biosynthetic capabilities may explain the recurrent association of specific microbial species, including those underlying the so-called Community State Type (CST) [97], as described in the following section.

However, despite the progress and promising outlook of these model-based approaches, they remain challenging to implement for complex microbial communities and are, therefore, mainly limited to rather simple microbial model systems. Indeed, microbial communities exhibit intricate

networks of interactions where individual species rely on and influence reciprocal activities [84,98,99]. In these highly interactive communities, such as the symbiotic consortia of the human gut microbiota, behavior of individual members is tightly coordinated, often resembling a single functional unit rather than a gathering of independent (micro)organisms. This complexity presents challenges for traditional reductionist approaches and necessitates holistic strategies to fully understand ecological and functional community dynamics.

In this context, the advent and common use of whole-metagenome shotgun sequencing (WMGS) has significantly improved our ability to dissect the intricate dynamics of microbial communities. Indeed, while early sequencing technologies were limited in their output by their ability to generate several million bases of DNA sequence information per run, the current gold standard platforms, such as the Illumina NovaSeq, can generate up to 6 terabases of high-quality nucleotide sequence data per sequencing run [100], vastly expanding our depth of understanding and precision in studying microbial communities. Notably, by employing a technique that entails the untargeted sequencing of all microbial DNA extracted from a given (bio)sample, WMGS sequencing facilitates the cataloging of genes occurring within complex microbial ecosystems. While these technologies are undeniably powerful, they are not entirely unbiased, and incorrect functional annotations may occur due to limitations in reference databases. Ideally, these approaches should be complemented, wherever possible, by cultivation-based methods to experimentally validate and refine *in silico* predictions (Figure 1). When used to analyze sequences related to vitamin biosynthesis in the fecal metagenome, commonly employed as a proxy for the distal colon microbiota [101,102], this powerful tool represents a cornerstone for readily delving into the vitaminogenic potential encoded by the human gut microbiota [103] (Figure 1). Despite the current lack of specific resources to identify vitamin biosynthetic genes within complex

microbial communities, the functional annotation, as well as the estimation of prevalence and relative abundance of microbial genes associated with vitamin biosynthesis, can be achieved by inferring homology between decoded metagenomic data and the extensive range of comprehensive reference databases of bacterial sequences (Figure 1). In this regard, well-annotated sequence resources commonly used to functionally annotate metagenomes in terms of vitamin biosynthesis are fundamentally the same as mentioned above as used in genome-level investigations, e.g., KEGG, Gene Ontology (GO), and Metacyc databases. Specifically, within these huge catalogs, functional information is curated to enable the assignment of genes to biological processes or pathways. Accordingly, in metagenomic analyses of vitamin biosynthesis, query read sequences can be matched with reference genes in the database, enabling precise mapping of these sequences to their corresponding metabolic pathways.

A common procedure to functionally characterize metagenomic samples involves *de novo* assembly of reads into contigs, followed by gene prediction and annotation, usually through comparisons with reference catalogs containing genes of known function (Figure 1). Notably, when these databases include sequence information related to vitamin-related genes, the presence of these structures can be rapidly identified in the newly assembled genome. However, compared to individual genomes, gene characterization from metagenome-assembled sequences provides additional challenges, mainly due to the possible vast numbers of genomic fragments involved, which increases the probability of incomplete annotation. In this context, well-established tools for metagenome assembly and annotation, such as MetaProdigal [104], MEGAHIT [105], MetaGeneMark [106], and metaSPAdes [107], try to address this issue. Notwithstanding, they may limit the discovery and characterization of vitamin-related genes from low-abundant

microorganisms, as attempts to reconstruct these genomes often result in incomplete or fragmented assemblies due to insufficient read coverage [64,108].

Metagenomic assembly may not always be feasible or reliable, as it is significantly impacted by factors such as the number of sequence reads (depth of sequencing), as well as the richness and evenness of the microbial species comprising the metagenome [109,110]. Consequently, likely due to these considerations, some researchers frequently opt to perform metagenome functional annotation by directly comparing individual short reads to annotated gene sequence repositories, thus bypassing the assembly step [111] (Figure 1). In fact, by mapping decoded metagenomic data to a reference database of known vitamin biosynthesis sequences, it is possible to estimate the prevalence and relative abundance of gut microbiota-derived genes, including the identification of vitamin metabolic pathways, as well as the assessment of the contribution of each bacterial species to the vitamin biosynthetic capacity of the whole microbial consortium [112–114].

Consistently, publicly available workflows for read mapping-based annotation have been developed, including HUMAnN3 [115], METAnnotatorX2 [116], and MG-RAST [117]. These bioinformatic pipelines generally rely on BLAST-like tools such as DIAMOND [118], as well as the read aligners Bowtie2 and BWA [119,120], to associate short reads directly with a reference catalog of microbial sequences, enabling the estimation of comprehensive functional profiles.

Although the relative abundance of individual functionally annotated genes can sometimes be informative [100], microbial vitamin-related functional abilities are likely better described as pathways, implying the need to simultaneously consider multiple, intertwined genes [121]. This task is particularly challenging in functional explorations of the human gut microbiome due to the inherent variability of microbial genomes typically found in fecal metagenomic samples [122,123]. Indeed, individual genes can participate in multiple pathways, complicating the attribution of

specific functions to distinct metabolic processes. Additionally, genes associated with certain vitamin biosynthesis pathways may be conserved across different microbial species, while others may be absent or replaced by functional analogs [81,124,125]. This heterogeneity necessitates a complete awareness of the presence of homologous and non-homologous but functionally analogous gene counterparts in the reference collection, upon which the accuracy of identification and quantification of vitamin-related genes within metagenomes depends. In this context, some of the read-mapping annotation tools, such as HUMAnN3, offer the ability to estimate a single abundance measure of microbial pathways from metagenomic data by exploiting associations between genes and biological processes documented in the MetaCyc database [115].

Alternatively, with prior metabolic pathway knowledge, the abundance of a given enzymatic pathway can be estimated by summing the number of metagenomic sequences mapped to all participating genes of that pathway, provided that the length of the individually mapped genes is taken into account. Moreover, by calculating the coverage of each pathway as the number of steps for which the associated enzyme-encoding gene was detected within the metagenome, divided by the total number of steps constituting the pathway, this procedure allows coverage-based evaluation of pathway completeness [126]. Notably, an enzyme-mediated, multi-step reaction can be reasonably considered present and complete if it meets a predetermined global coverage threshold [126], or, alternatively, if a subset of well-established essential and conserved enzymes is identified. Indeed, as B-group vitamin biosynthetic pathways may encompass alternative biochemical routes with enzyme variants, a subgroup of vitamin-related genes, previously identified as strictly necessary for the *de novo* biosynthesis [70], can be effectively evaluated in order to assess the completeness and variability of such biosynthetic routes within metagenomic samples from the human gut (for detailed information on B-vitamin biosynthetic pathways and

genes, please refer to the following section of this review). For example, although the initial steps of cobalamin biosynthesis can proceed via either aerobic or anaerobic pathways, thus involving different enzyme variants, the subsequent downstream steps are universally conserved across various cobalamin-producing commensal species of the human gut [70]. Similarly, based on the amino acid precursors, alternative routes have been identified for the *de novo* generation of the intermediate quinolinate as part of the biosynthetic pathway to produce the active form of vitamin B3, while the final biochemical steps to synthesize this vitamin involve conserved enzymes/genes [70]. Moreover, likely due to its fundamental role in cells, this latter cofactor can be obtained by various salvage routes, which deserve consideration as they enable intracellular production of this vitamin without the requirement for a complete *de novo* biosynthetic pathway [70].

Such extensive genetic diversity can be effectively scrutinized and managed through metagenomic approaches supported by comprehensively designed databases, addressing crucial questions regarding the prevalence, abundance, and variation of B-group vitamin-producing species across various human populations, as well as the influence of external factors, such as diet, age, and lifestyle, on B vitamin biosynthetic potential (Figure 1). For instance, by comparing metagenomic functional profiles across different populations, recent research has unveiled country-specific potential for gut microbiota-mediated B vitamin biosynthesis, with Chinese individuals showing a significantly higher relative abundance of genes for B-group and K2 vitamins when compared to subjects from other countries, including the USA, Spain, Denmark, and India [112,127].

Similarly, by using DIAMOND to map metagenomic read sequences to the KEGG database, the relative abundance of vitamin biosynthetic pathways has also been evaluated across different human disease cohorts, highlighting, for instance, disparities between healthy individuals and

those with type 2 diabetes, with the latter group showing a higher relative abundance of metabolic pathways involved in vitamin K2 biosynthesis [112,114].

Besides uncovering functional characteristics of human-associated microbial communities in relation to host factors, metagenomics offers the ability to gain insight into microbe-microbe interactions governing the microbial consortium ecology. Indeed, abundance and taxonomic data derived from metagenomic sequencing can be used to predict correlation-based networks, identifying co-occurring or mutually exclusive relationships among different organisms in ecosystems [128–131]. These relationships can then be represented as network nodes, corresponding to individual microbial species, with edges connecting taxa exhibiting significant correlation patterns. Focusing specifically on vitamin biosynthesis, such correlation-based networks have demonstrated significant predictive ability in identifying microorganisms pivotal for B vitamin provision within a complex microbial community. Indeed, in recent studies, the construction of metagenome-informed networks enabled the estimation of the significance of predicted vitamin-producing bacteria in shaping the microbial interactions within their local environment [113,132], revealing, for example, cobalamin and folate producers as central hubs in the microbial networks of adult and infant gut microbiomes, respectively [133].

Despite its numerous advantages, metagenomics still faces certain limitations. One of its primary shortfalls is the inability to elucidate what genes are actively expressed to produce functional proteins [134]. To bridge this gap, metagenomic information can be complemented and enhanced by metatranscriptomics [135–137] and metaproteomics [137–139], which enable assessment of gene expression or protein abundance, respectively. In this way, patterns of vitamin-related genes can be identified across various physiological conditions or, for example, in response to dietary

changes, providing a real-time depiction of the microbial vitamin biosynthesis status rather than the genetic potential offered by metagenomics.

Nevertheless, despite the potential of these technologies, the application of omics-based methodologies to discover microbial vitamin-related genes in the human gut microbiota remains largely underrepresented, underscoring the need for more extensive and integrated omics-based research efforts in this area. Continued efforts to integrate omics data, computational modeling, and experimental validation are required to enhance our understanding of human-associated microbial vitamin biosynthetic activities.

2. Genetics of vitamin biosynthesis and transport mechanisms in key members of the human gut microbiota

As previously mentioned, certain bacteria can produce B-group and K2 vitamins through dedicated *de novo* biosynthetic pathways, which are summarized below. In this context, referring to one or more B-vitamins, virtually individual microorganisms can be categorized as either a B-vitamin-producer, reflecting its prototrophic capabilities, or a B-vitamin-acquirer, i.e., being auxotrophic and thereby needing to obtaining B-vitamins from the surrounding environment [129,140]. Additionally, in the absence of key genetic features, microorganisms can scavenge essential vitamins *via* salvage pathways, which enable them to recover and recycle vitamins and/or their precursors from the environment [92]. However, salvage mechanisms have also been frequently identified in prototrophic bacteria. In these microorganisms, such pathways represent a chance to adopt an opportunistic lifestyle, switching from the energetically costly *de novo* synthesis to a more economical salvage route, depending on the availability of vitamins in the environment [70].

Historically, identification and understanding of metabolic pathways involved in the biosynthesis of ubiquitous cofactors and their precursors (vitamins) were largely confined to a few model organisms, such as the Gram-negative *Escherichia coli* and the Gram-positive *Bacillus subtilis*. Knowledge of the genetic requirements for vitamin production by these model organisms can be used to interrogate the currently available extensive genomic data in order to determine the presence or absence of vitamin biosynthetic pathways across a multitude of species.

Consistently, recent comparative analyses within reference collections of human-associated bacterial genomes [70,81,92] have revealed a notable variability in the structure of vitamin biosynthetic pathways, even among different prototrophic species, reflecting diverse metabolic capabilities and environmental adaptations. For instance, some bacteria may employ alternative enzymes to catalyze identical biochemical reactions, or certain (accessory) enzymes may be present or absent without affecting the overall biosynthetic capability for a specific vitamin [70]. However, core gene sets involved in the biosynthesis of each active cofactor have been identified as conserved across several prototrophic species [70].

In this section, we discuss available data regarding the conservation level of the genetic background necessary for *de novo* vitamin synthesis across common human-associated bacteria, including members of the gut [141], skin [142,143], and oral microbiomes [144] (Figure 2).

2.1 Thiamine (Vitamin B1)

Vitamin B1, also referred to as thiamine monochloride, thiamine chloride, or aneurine, plays an essential role in carbohydrate and branched-chain amino acid metabolism by acting as a cofactor for both pyruvate dehydrogenase and α -ketoglutarate dehydrogenase in glycolysis and the tricarboxylic acid (TCA) cycle [145–147].

449 The human colonic microbiota can synthesize *de novo* both free B1 vitamin and its active
450 phosphorylated form (thiamine pyrophosphate, TPP) [97]. Specifically, in bacteria, thiamine
451 synthesis utilizes a branched pathway leading to the separate synthesis of two precursors: thiazole
452 phosphate (THZ-P moiety) and pyrimidine pyrophosphate (HMP-PP moiety) [148]. The thiazole
453 moiety can be derived from an oxidative condensation of 1-deoxy-D-xylulose 5-phosphate (DXP),
454 cysteine, and glycine or tyrosine [148], and two alternative routes were identified in bacteria for
455 its synthesis (Figure 2). The THZ-P and HMP-PP moieties are then condensed and phosphorylated
456 by thiamine phosphate synthase and thiamine monophosphate kinase, respectively, to generate the
457 biologically active form of thiamine (Figure 2) [148].

458 Notable key commensals of the human gut, including members of the *Bacteroides* and
459 *Bifidobacterium* genera, *Prevotella copri*, *Agathobacter rectalis* (formerly *Eubacterium rectale*),
460 and some members of the *Ruminococcus* genus, have been predicted to synthesize this vitamin, as
461 revealed by *in silico* analyses of their genomes [149,150]. Additionally, certain opportunistic
462 pathogenic species from the Pseudomonadota phylum (formerly Proteobacteria), such as those
463 belonging to the *Pseudomonas* and *Klebsiella* genera, as well as *E. coli*, are also capable of
464 producing thiamine. In contrast, despite the requirement of vitamin B1 for its metabolism,
465 including the conversion of pyruvate to acetyl-CoA in the butyrate production pathway,
466 *Faecalibacterium prausnitzii* lacks an intact thiamin biosynthetic pathway, indicating its
467 dependence on environmental sources of thiamin or by establishing trophic interaction (e.g., cross-
468 feeding activities) with other members of the human gut microbiota [83,149]. Moreover, among
469 various bacterial species isolated from the human nasopharynx and oral cavity [142,143] only a
470 minority of the species from the *Streptococcus*, *Veillonella*, and *Actinomyces* genera are capable
471 of synthesizing vitamin B1 [81]. Similarly, only a few members of the human skin microbiota

[151] possess the thiamin biosynthetic genes. These include *Cutibacterium acnes* (formerly classified as *Propionibacterium acnes*), and certain species belonging to the *Staphylococcus*, *Corynebacterium* genera [81].

TPP synthesized by the microbiota within the large intestine was historically regarded as nutritionally insignificant to the host because of the prevailing notion that the intestinal absorptive epithelia lacked the ability to transport such a large, hydrophilic, and charged molecule across their phospholipid bilayer, prior to its enzymatic hydrolysis into free thiamine [152]. However, subsequent scientific data has suggested that human colonocytes can acquire microbiota-derived thiamine either *via* a process similar to that functioning in the small intestine for free thiamine or through specific and high affinity TPP transporters, such as TPPT-1 (encoded by the SLC44A4 gene [153–155]. Intriguingly, the finding of competent uptake mechanisms in human colonocytes for both free thiamine and its phosphorylated TPP form clearly indicates that microbially produced thiamine has the potential to contribute meaningfully to thiamine nutrition of the host, particularly enhancing the cellular (micro)nutrition and health of the colonocytes.

2.2 Riboflavin (Vitamin B2)

Riboflavin, also known as vitamin B2, plays a pivotal role in diverse biochemical reactions within living cells, serving as a precursor for two essential coenzymes, i.e., flavin adenine dinucleotide (FAD) or flavin mononucleotide (FMN). These coenzymes are crucial electron carriers in flavoprotein-mediated redox reactions and are involved in a variety of metabolic processes, including the electron transport chain, the TCA cycle, fatty acid oxidization (β -oxidization), and redox homeostasis [156]. Moreover, in bacteria, riboflavin, its biochemical precursors and

derivates are involved in several extracellular processes, including quorum sensing signaling and host-microbe cross-talk [157,158].

Bacteria can *de novo* synthesize free riboflavin through five enzymatic steps utilizing guanosine-5'-triphosphate (GTP) derived from the purine biosynthesis pathway, and ribulose-5-phosphate (R5P), an intermediate from the pentose phosphate pathway [159,160] (Figure 2). However, when riboflavin is environmentally available, bacteria usually repress their endogenous biosynthesis *via* an FMN-sensing mRNA riboswitch, which also transcriptionally controls the genes responsible for riboflavin transport from the extracellular environment [161–164].

Although the pathway for riboflavin biosynthesis, when present, is well conserved across bacteria, variations exist among different evolutionary lineages regarding the structure and organization of the riboflavin biosynthesis proteins (Rib) and corresponding *rib* genes. For instance, *E. coli* utilizes two distinct monofunctional enzymes, RibA and RibB, to process the precursors GTP and R5P separately [165,166] (Figure 2). In contrast, *Bacillus subtilis* employs a bifunctional enzyme named RibA, encompassing both GTP cyclohydrolase II and dihydroxybutanone phosphate synthase activities for the same biosynthetic reactions [167] (Figure 2). By exploiting sequence homology with these well-characterized genes in model microorganisms, genome comparative analyses showed that all assessed genomes of the Fusobacteria and Bacteroidota (formerly Bacteroidetes), essentially all Pseudomonadota, and a large portion of the currently known Bacillota (formerly Firmicutes) possess the genetic capacity to produce riboflavin [81], making riboflavin the most prevalent B vitamin produced across these phyla. Specifically, among the bacterial elements of the human gut microbiota, all currently known species from the *Bacteroides* genus (including species reclassified into the genus *Phocaeicola*), *Anaerobutyricum hallii* (formerly *Eubacterium hallii*), *P. copri*, and some members of the *Ruminococcus* genus are

equipped with complete pathways for vitamin B2 synthesis [70,81]. In contrast, the ability to produce *de novo* riboflavin is less prevalent among gut-associated Actinomycetota (formerly Actinobacteria), being absent in the *Collinsella* and *Bifidobacterium* genera, with the exception of the *Bifidobacterium longum* subsp. *infantis* species [35]. Nevertheless, although prominent gut commensals appear able to produce riboflavin, only 3% of the daily reference intake (DRI) of this vitamin was estimated to be derived from the gut microbiota [81].

Endogenous riboflavin biosynthesis was also found conserved in *C. acnes*, as well as members of the *Corynebacterium* and *Staphylococcus* genera of the human skin microbiome [70,81,142]. Additionally, riboflavin genes are present in examined *Prevotella* and *Veillonella* species typical of the human oral microbiome, but notably absent in members of the *Streptococcus* genus [168].

2.3 Niacin (vitamin B3)

Niacin, also known as vitamin B3, is the generic name for nicotinamide (NAM), nicotinic acid (NA), and related derivatives, such as nicotinamide riboside. Metabolically active forms of this vitamin are nicotinamide adenine dinucleotide (NAD⁺), nicotinamide adenine dinucleotide phosphate (NADP⁺), and their respective reduced forms [NAD(P)H], which provide reducing equivalents for cellular biochemistry and energy metabolism [169,170]

Several gut microbial species can synthesize vitamin B3 from tryptophan (Figure 2) [171]. However, based on recent reconstructions of vitamin biosynthetic pathways among human gut commensals, the amino acid aspartate is most commonly used to synthesize the quinolinate precursor of NAD⁺ (Figure 2) [70,172]. In contrast, downstream of this intermediate, the genes involved in NAD⁺ synthesis, namely *nadC*, *nadD*, and *nadE* (Figure 2), are highly conserved in bacterial prototrophs for niacin [70,81].

It has been estimated that the human gut microbiota can provide 27% of the RDI of niacin through corresponding *de novo* biosynthesis pathways, which are present in the majority of the genomes associated with the human gut microbiota [81]. Generally, the phyla Actinomycetota and Bacillota contain lower ratios of *de novo* producers when compared to assessed members of the phyla Pseudomonadota, Fusobacteria, and Bacteroidota [81]. However, niacin can be produced in the human gut by *P. copri* and species from the *Bacteroides*, *Bifidobacterium*, *Ruminococcus*, *Clostridium*, and various recently reclassified genera which had previously been assigned to the genus *Eubacterium* [29,92]. Additionally, this essential micronutrient is produced by *Neisseria* and *Prevotella* species in the oral microbiome, as well as *Corynebacterium* and *Acinetobacter* species from the skin microbial community. In contrast, the *de novo* niacin biosynthesis pathway is predicted to be absent in most species belonging to *Faecalibacterium*, *Veillonella*, *Enterococcus*, *Streptococcus*, and *Staphylococcus* genera [172].

2.4 Pantothenic acid (vitamin B5)

Pantothenate, also known as vitamin B5, is a crucial precursor for the biosynthesis of coenzyme A (CoA) which represents a universal and essential cofactor involved in numerous cellular metabolic processes, including the synthesis and degradation of fatty acids, the synthesis of phospholipids, and the functioning of the tricarboxylic acid (TCA) cycle [173].

In bacteria, *de novo* synthesis of pantothenate requires the intermediate pantoate, obtained from the valine biosynthetic pathway via the enzyme encoded by the *panB* gene, and the amino acid aspartate, which is converted into β -alanine by the product of the *panD* gene (Figure 2) [173]. Pantoate and β -alanine precursors are ultimately condensed by the pantothenate synthetase (the *panC* gene product) to yield pantothenate, which is released from the cell or subjected to the downstream enzymatic steps leading to the CoA synthesis (Figure 2) [173]. Interestingly, while

panB and *panC* are contained within a relatively conserved operon, comparative analyses have shown that some bacterial prototrophs lack the *panD* gene [70]. This suggests that β -alanine could be acquired exogenously through a salvage pathway or synthesized through an as yet uncharacterized, alternative pathway.

Assessments of reference collections of human-associated bacteria have predicted pantothenate biosynthetic abilities in approximately all genomes from Bacteroidota and Pseudomonadota, as well as half of Bacillota and only a minority of Actinomycetota. Specifically, key human gut commensals such as *Enterococcus faecalis*, *P. copri*, *E. coli*, as well as members of the *Bacteroides* and (species previously assigned to the) *Eubacterium* genera, possess the complete pathway for *de novo* vitamin B5 synthesis [81,92]. However, the lack of direct evidence supporting the absorption of pantothenic acid in the colon leaves open the question of whether or not bacterially synthesized pantothenic acid is nutritionally relevant to the host.

Similarly, among bacteria associated with the human oral cavity, the *Porphyromonas*, *Prevotella*, and *Actinomyces* genera are identified as primary producers of pantothenate, whereas in the skin microbiota, bacteria predicted to autonomously produce vitamin B5 include those belonging to the genera *Acinetobacter*, *Staphylococcus*, and *Corynebacterium* [81].

2.5 Pyridoxine and its derivatives (Vitamin B6)

Vitamin B6 exists in several forms, including pyridoxine (PN), pyridoxal (PL), and pyridoxamine (PM), all of which can be phosphorylated at the 5' position to generate three additional vitamers: pyridoxine phosphate (PNP), pyridoxal phosphate (PLP), and pyridoxamine phosphate (PMP). Among these, pyridoxal 5'-phosphate (PLP) is the most biologically active form, serving as a cofactor in many important enzymatic reactions of living organisms [174]. PLP-dependent enzymes exist within five of the seven enzymes classes defined by the International Union of

589 Biochemistry (<https://iubmb.qmul.ac.uk/enzyme/>), i.e., oxidoreductases EC 1; transferases EC 2;
590 hydrolases EC 3; lyases EC 4; isomerases EC 5, underlining the wide variety of biochemical
591 reactions which PLP supports in cells [175,176].

592 In the human gut, vitamin B6 is synthesized as PLP using two alternative routes, identified as
593 deoxyxylulose 5-phosphate (DXP)-dependent pathway and DXP-independent pathway [177]. The
594 first route condenses DXP with 4-phosphohydroxy-l-threonine to produce PNP, which is then
595 oxidized to PLP by the enzyme encoded by the *pdxH* gene (Figure 2). In the DXP-independent
596 pathway, the PLP synthase complex (encoded by the *pdxS* gene) uses D-ribose 5-phosphate (R5P),
597 glutamine (Gln), and glyceraldehyde 3-phosphate (G3P) as precursors to directly generate PLP
598 (Figure 2). Members of the Bacteroidota and Pseudomonadota phyla predominantly utilize the
599 DXP-dependent pathway for vitamin B6 biosynthesis, while Actinomycetota are more likely to
600 use the DXP-independent route [81], underscoring lineage-dependent metabolic strategies.

601 Regardless of the pathway employed, members of the *Bifidobacterium*, *Bacteroides*, and
602 *Prevotella* genera, as well as many Pseudomonadota and several Bacillota, are predicted to
603 synthesize vitamin B6 in the colon [70,81]. However, other key human gut bacteria, such as
604 members of the *Veillonella* genus members, *E. faecalis*, as well as the butyrate-producing *F.*
605 *prausnitzii*, and *Roseburia inulinivorans*, are auxotrophic for B6 vitamers and rely on salvage
606 enzymes, primarily represented by the PL/PN/PM kinase (*PdxK*) or PL kinase (*PdxY*) depending
607 on their substrate specificities (Figure 2), to recover environmental vitamin B6 [178,179].

608 Dietary and bacterially synthesized PLP is hydrolyzed to free vitamin B6 in the intestine, where it
609 is absorbed by specialized and regulated transporters expressed by human colonocytes [180,181].
610 Interestingly, while hydrolysis of vitamin B6 is necessary for its intestinal absorption, this process
611 may be favored by an acidic intestinal pH [181,182]. Accordingly, it is reasonable to suggest that

the presence of lactic acid-producing bacteria, such as enteric lactobacilli residing in the small intestine may enhance dietary vitamin B6 bioavailability in this area of by lowering luminal pH [183]. However, scientific literature on this topic is still scarce, and further investigations are needed to confirm the potential role of these bacteria in facilitating vitamin B6 absorption.

2.6 Biotin (vitamin B7)

Biotin, also referred to as vitamin B7 or vitamin H, is a crucial cofactor for six biotin-dependent carboxylases: acetyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, pyruvate carboxylase, urea carboxylase, geranyl-CoA carboxylase, and propionyl-CoA carboxylase [184]. These enzymes are vital for the metabolism of fatty acids, carbohydrates, and amino acids, and are widely distributed across nature [184].

In addition to dietary sources, humans are also exposed to bacterial sources of vitamin B7. Indeed, intestinal bacteria can synthesize this micronutrient *de novo* as free biotin through a biochemical pathway that can be divided into two stages. The first stage involves the generation of the pimelate moiety, which contributes to seven of the ten carbon atoms in biotin, followed by the assembly of the biotin rings (Figure 2). While the genes involved in the latter step are conserved across various biotin-producing bacterial species, the synthesis of the pimelate intermediate can proceed via two alternative routes. Among these, the first well-characterized pathway, found in *E. coli*, is a modified fatty acid synthetic route that requires the action of the *bioC* and *bioH* genes, encoding a malonyl-ACP methyltransferase and a pimeloyl-ACP methyl esterase, respectively [185,186] (Figure 2). Based on current genomic data, this pathway appears to be predominant among bacteria. However, several evolutionary distinct *bioH* functional equivalents, including *bioG*, *bioJ*, *bioK*, and *bioV* [187,188] (Figure 2), have been identified in diverse bacterial species, increasing the diversity and complexity of genetic features in biotin synthesis.

Another well-studied route for pimelic acid synthesis, being quite distinct from the BioC-BioH mechanism in *E. coli*, has been identified in *Bacillus subtilis* and involves the enzyme bioW, a pimeloyl-CoA synthetase, which directly generates pimeloyl-CoA [185,189,190] (Figure 2).

Biotin has biological activity only when it is covalently linked to a biotin-accepting enzyme via a specific lysine residue [7,191]. Therefore, once synthesized, the newly formed biotin molecule is covalently attached to its cognate polypeptide by an enzyme known as biotin protein ligase, in a process analogous to reactions catalyzed by aminoacyl-tRNA synthetases [192].

Comparative genomic analyses predict that only a minority of representative organisms within the human gut microbiota can synthesize vitamin B7 *de novo*, with members of the *Bacteroides* and many *Pseudomonadota* being the primary contributors. Consistently, the human gut microbiota is estimated to provide just 4.5% of the DRI for biotin [81]. However, some gut-associated microorganisms, such as *Akkermansia muciniphila*, are expected to produce biotin when provided with exogenous supply of pimeloyl, as they possess the downstream biotin biosynthesis genes [70].

Interestingly, *Bifidobacterium longum* has been shown to produce pimelate *in vivo* [193], thereby potentially supplying biotin precursors to other microbial community members. Although *B. longum*, like most *Actinomycetota*, apparently lacks a (complete) genetic pathway to produce biotin, they have compensated for this functional deficiency with the presence of the BioY transporter, found in approximately 80% of *Actinomycetota* genomes [70]. This enables bifidobacteria to internalize vitamin B7 from the environment, likely produced by co-occurring microorganisms, thus facilitating complex trophic interactions based on the sharing of precursors and final products of the vitamin B7 biosynthetic pathway.

Utilizing the knowledge of bacterial species that can produce vitamin B7 and the genetic pathways involved, it is also possible to predict biotin biosynthesis capability in certain oral species from the

Veillonella and *Porphyromonas* genera, as well as in *Staphylococcus epidermidis* and *C. acnes* as members of the human skin microbiome [81].

2.7 Folate (vitamin B9)

Naturally occurring folate, or its synthetic counterpart folic acid, is essential for one-carbon metabolism, which includes transferring carbon units during RNA and DNA biosynthesis and repair, DNA methylation, as well as amino acid metabolism [194]. The active form of vitamin B9 is known as tetrahydrofolate (THF), although other naturally occurring folates include the polyglutamate forms of 5-methyl THF, and 10-formyl THF [195].

Intestinal bacteria synthesize THF *de novo* as either mono- or polyglutamates by condensing the 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (DHPPP) and the para-aminobenzoic acid (pABA) intermediates (Figure 2), which therefore are both required for folate production [196]. However, as detailed previously [70,196], some microorganisms lack the ability to independently synthesize pABA. Although such microorganisms should, therefore, be considered auxotrophs for folate, they can still produce this vitamin when pABA is available in the environment. This is the case for various species within the *Lactobacillus* and *Bifidobacterium* genera, which can produce folate by scavenging pABA from host dietary metabolites or other community members [72,197]. Interestingly, *in vitro* assays have demonstrated that bifidobacteria isolated from the human gut are generally capable of producing folate, unlike non-human-associated strains [197,198]. High-folate, pABA-dependent producers have been identified in certain infant gut-specialized species, including *Bifidobacterium bifidum* and *B. longum* subsp. *infantis* [196,199], reinforcing the notion of host-microbe coevolution and the importance of such symbiotic relationships from early infancy. Indeed, microbe-derived folate is easily processed by mammalian cells, and there is direct evidence that microbial folates are absorbed by the host through a proton-coupled folate transporter

in the colon, which functions optimally at an acidic-pH [22,200]. Beyond bifidobacteria, other bacteria such as *Veillonella*, *E. faecalis*, and *R. inulinivorans* have been predicted to produce folate in the presence of pABA, while the complete pathway for vitamin B9 biosynthesis has been identified in members of the *Bacteroides*, and *Ruminococcus* genera, most of Pseudomonadota, as well as *P. copri* and *A. muciniphila* [70]. Within the human oral cavity and skin microbiomes, bacteria of the *Prevotella* genus, along with *Staphylococcus* and *Acinetobacter* species, are known to possess the complete capability to autonomously produce folate [81].

2.8 Cobalamin (Vitamin B12)

Vitamin B12, commonly referred to as cobalamin, encompasses a family of chemically complex vitamers, including hydroxy-, methyl-, deoxyadenosyl-, and cyano-cobalamin, all of which contain the mineral cobalt [201]. The cyano form, being the most stable, is widely used in supplements and fortified foods, while the natural forms, methyl-, and deoxyadenosyl-cobalamin (AdoCbl), are synthesized exclusively by prokaryotes [68]. Similar to folate, cobalamin functions as a cofactor in biochemical reactions involving methyl group transfer, which are vital for nucleic acid synthesis as well as protein and lipid metabolism, including the production of short-chain fatty acids (SCFAs) [82,202,203]. As anticipated, bacteria inhabiting the human gut can produce cobalamin and various corrinoid analogs in the colon [204]. Bacterial *de novo* vitamin B12 biosynthesis can proceed through either an aerobic or an anaerobic pathway, both starting from the precursor uroporphyrinogen III (Figure 2). In the aerobic pathway, molecular oxygen is utilized in several steps, including cobalt insertion, whereas in the anaerobic route, cobalt insertion occurs earlier and is oxygen-independent (Figure 2). Despite the possible presence of lineage-specific non-homologous alternatives that have as yet to be identified, comprehensive comparative analyses of experimentally validated cobalamin-producing bacteria have identified three

conserved genes essential for corrin ring synthesis, namely *cbiL*, *cbiF*, and *cbiC* in the anaerobic pathway, which are orthologous to *cobI*, *cobM*, and *cobH*, respectively, in the aerobic pathway [82] (Figure 2).

Bacterial cobalamin synthesis is a highly complex and energy-intensive process, requiring approximately 30 enzymatic steps [205]. This complexity likely explains why relatively few metabolic pathways depend on cobalamin, and why some bacteria do not require it for growth, while others exhibit auxotrophy for this micronutrient. Recent metabolic reconstructions of vitamin biosynthesis abilities in over 2,000 representative genomes of the human gut microbiota have shown that up to 60-80% of these genomes lack the cobalamin biosynthetic pathway [70,92]. Certain bacteria, such as members of the *Bacteroides*, *Veillonella*, *Clostridium*, *Klebsiella*, *Ruminococcus* genera, as well as the butyrate-producing *Roseburia intestinalis*, *Ag. rectale*, and *F. prausnitzii*, have been predicted to produce cobalamin. However, members of the *Bifidobacterium* and *Prevotella* genera, and *Bacteroides thetaiotaomicron* appear to lack this capability [70,82], while *E. coli* synthesizes cobalamin only when provided with the intermediate cobinamide [206]. Within the phylum Actinomycetota, the capability to produce vitamin B12 appears nearly exclusive to species of human skin microbiota, including those of the *Corynebacterium* genera and *C. acnes* [68,70]

Given the considerable metabolic and energy cost required for *de novo* vitamin B12 synthesis, some cobalamin-dependent species have evolved the ability to salvage intermediates or the final cobalamin product from other species, generating intricate networks of microbial interactions centered around the acquisition of this micronutrient [24,82]. In this context, the BtuBFCD transporter is recognized as the primary mechanism for vitamin B12 transport in bacteria [87,207]. However, recent research efforts have identified multiple functionally distinct cobamide

transporters in bacteria, with up to three distinct systems in *Bacteroides thetaiotaomicron* [87]. While all these transport mechanisms can bind cobalamin, each exhibits additional specialization for other corrinoids, reflecting the diverse array of cobamides that can be environmentally available [87].

2.9 Menaquinones (vitamin K2)

Vitamin K2, also known as menaquinone, is a lipid-soluble vitamin playing several critical roles in human health, primarily by activating specific proteins involved in calcium metabolism and blood coagulation. Structurally, menaquinones are a group of 2-methyl-1,4-naphthoquinone structures that differ in the length of their polyisoprenyl side chain (MK-n, with “n” indicating the number of polyprenyl units, ranging from 4 to 13). While the naphthoquinone ring allows for electron-transfer, the polyisoprenoid side chain imparts the lipophilic properties of the quinones [208]. The most recognized forms of menaquinone are menaquinone-4 (MK-4) and menaquinone-7 (MK-7). However, while long-chain menaquinones (MK-7, MK-8, and MK-9) are primarily produced by microbial metabolism, MK-4 is predominantly sourced from animal-based foods [209].

In bacteria, MK-n are integral components of the electron transfer chain within the cytoplasmic membrane. In particular, most Gram-positive and anaerobic Gram-negative bacteria rely exclusively on MK-n as their electron carriers [210]. In addition, MK-n also contribute to sporulation, as seen in Gram-positive bacteria, such as *Bacillus subtilis*, and contribute to the pathogenicity of certain bacteria, including *Staphylococcus aureus* and *Mycobacterium tuberculosis* [211].

752 Various bacterial species involved in food fermentation generate MK-n as an integral part of their
753 energy metabolism. The naphthoquinone ring of MK-n is synthesized *via* the o-succinylbenzoate
754 (OSB) or futasine pathway [208], which shares the precursor chorismate (Figure 2), supplied by
755 the shikimate pathway. The polyisoprenyl side chain of menaquinones can be synthesized by either
756 the 2-C-methyl-D-erythritol-4-phosphate (MEP) or mevalonate (MVA) pathway (Figure 2).
757 Regardless the specific pathway utilized for MK-n synthesis, the naphthoquinone ring precursor
758 and the isoprenyl side chain are synthesized separately and subsequently condensed by the
759 prenyltransferase enzyme (MenG/UbiE) to form the functional menaquinone molecule (Figure 2).
760 This newly synthesized molecule may then undergo further modifications, producing different
761 MK-n variants depending on the length of the isoprenoid side chain [212]

762 The ability to synthesize menaquinones *de novo* appears to be relatively rare among bacteria, with
763 only a minority of Bacillota and Actinomycetota, and slightly more than half of Bacteroidota and
764 Pseudomonadota predicted to possess this capability [70,92]. Long-chain MKs, such as MK-6,
765 MK-7, MK-8, MK-10, MK-11, and MK-13 are expected to be produced by different bacteria
766 resident in the human large intestine, such as members of the *Bacteroides*, *Prevotella*,
767 *Enterococcus*, and *Veillonella* genera [81,92,212,213]. Conversely, species from the
768 *Bifidobacterium*, *Collinsella aerofaciens* and most of the butyrogenic bacteria, including *R.*
769 *intestinalis*, as well as some strains from the species *F. prausnitzii*, and *Ag. rectale*, lack the genetic
770 capability to endogenously produce MKs [92]. Although the potential production of vitamin K2
771 has been largely focused on enteric microbes due to the intriguing possibility that bacterial-derived
772 menaquinones may contribute to the host's vitamin K status, other bacteria also possess this
773 capability. This includes *C. acnes* and members of the *Staphylococcus* genus within the human

skin microbiota [212], as well as in *Streptococcus mitis*, *Streptococcus oralis*, and *Streptococcus mutans* associated with the human oral cavity [70,81].

2.10 Vitamin production by bacterial communities

While virtually all microbial communities inhabiting different parts of the human body can produce vitamins, a substantial body of research has focused on uncovering the functional potential of the human gut microbiota, owing to its significant impact on human physiology [214–216]. A relatively recent attempt to address the vast interindividual variability of the human gut microbiota has introduced the concept of “enterotypes”, which proposes the existence of recurrent bacterial patterns among gut microbial communities [97]. These patterns, initially defined as three discrete clusters based on the dominance of key bacterial taxa, such as *Bacteroides*, *Prevotella*, or *Ruminococcaceae*, provide a framework to stratify microbiota data and to simplify its inherent complexity [97]. The classification of gut microbiota into three distinct enterotypes has been met with both enthusiasm and criticism, with much of the debate arising from alternative perspectives suggesting the existence of smooth abundance gradients among key genera rather than sharply defined clusters [217–219]. Additionally, the prevalence and composition of enterotypes have been shown to vary based on cohort characteristics, geographical regions, methodological approaches, and taxonomic resolution, raising doubts about the analytical foundation of enterotypes. Accordingly, since the publication of the original work, numerous independent studies have followed, employing clustering methods and alternative approaches to replicate enterotypes in new datasets and even extending the concept to other ecosystems, such as the vaginal microbiota [220–222], and host organisms [223–226]. While some research has highlighted different numbers of microbial clusters or the absence of discernible structures [227,228], others identified enterotype-like patterns similar to the original definition, with *Bacteroides* and *Prevotella* consistently

798 emerging as central drivers of variation in the human gut microbiota [228–231]. These taxa exhibit
799 significant variability in relative abundance and are mutually negatively correlated, suggesting
800 distinct ecological niches and competitive interactions [131,219,232,233]. Despite limitations, and
801 the fact that the resulting clustering only partially reflects the more complex structure within the
802 population, the three-enterotypes concept remains the most widely used and referenced model,
803 providing a conceptual framework which we used below in our discussion of the heterogeneity in
804 human gut microbiome functional capacities related to vitamin biosynthesis.

805 Accordingly, under the widely accepted assumption that certain configurations of relative
806 microbial abundance occur more frequently than others [131,228], the aggregation of specific
807 bacterial species has been shown to uniquely shape the functional potential of the microbial
808 community, including those related to the synthesis of essential vitamins. When functional
809 variations were explored among the first-defined enterotypes, it was shown that enterotype 1,
810 dominated by *Bacteroides* genus in co-occurrence with *Parabacteroides*, *Roseburia*, and
811 *Faecalibacterium* genera, is enriched in genes essential for the synthesis of vitamins B7, B2, and
812 B5 [97] (Figure 3). In contrast, genes for vitamin B1 and B9 biosynthesis are more abundant in
813 enterotype 2, which is overrepresented by the *Prevotella* genus, along with members of the
814 *Enterococcus*, *Streptococcus*, and *Desulfovibrio* genera [97] (Figure 3). Moreover, no specific
815 vitamin synthesis was significantly associated with enterotype 3. This is in agreement with the
816 observation that the composition of this microbial cluster varies across studies, resulting in a less
817 well-defined community but generally distinguished by an overrepresentation of Firmicutes and,
818 in some cases, a high abundance of the *Ruminococcus* genus [97]. However, the greater diversity
819 of species enriched within this cluster, according to the original enterotype definition, suggests
820 diverse vitamin production capabilities (Figure 3).

821 Recently, *in silico* metabolic modeling has examined vitamin requirements and biosynthetic
822 capabilities across a comprehensive collection of human-associated bacterial genomes [92]. When
823 applied to the enterotype framework, these findings reveal the intriguing presence of
824 complementary vitamin production capabilities among members of the same microbial community
825 [92]. For example, members of the *Streptococcus* and *Enterococcus* genera, which are associated
826 with the *Prevotella*-dominated enterotype [97], exhibit vitamin synthesis profiles that have been
827 observed to complement the metabolic limitations of the *Prevotella* genus. Specifically,
828 *Streptococcus thermophilus* and *Enterococcus faecalis* may compensate for the absence of
829 biosynthetic pathways for vitamins B1, B5, and K2, which are essential for growth of *P. copri*, as
830 predicted by *in-silico* analyses [92]. In turn, these microbial groups may benefit from the
831 biosynthetic potential for vitamins B2, B3, B5, and B6, provided by *P. copri* [92]. In contrast, no
832 complementary abilities were observed between genomes from the *Prevotella* genus and members
833 of the *Bacteroides*, *Anaerostipes*, or *Parabacteroides* genera, all of which have been linked with
834 the *Bacteroides*-dominated enterotype [92]. While the limitations associated with the use of
835 discrete enterotypes and the potential biases of *in-silico* prediction must be acknowledged, as also
836 discussed above, this compelling evidence nonetheless raises the possibility that B vitamins act as
837 essential mediators of microbe-microbe cross-feeding, thereby contributing to the assembly of gut
838 microbial communities [24,80,89,129]. This interplay is particularly evident in the case of vitamin
839 B12. Indeed, this vitamin and its derivatives have been proposed to be involved in extensive cross-
840 feeding activities among co-inhabiting bacterial species due to the high energy expenditure
841 required for its *de novo* synthesis and the resulting significant proportion of auxotrophies [87].
842 Consistently, a relatively high abundance of vitamin B12 prototrophs has been identified in all
843 three established enterotypes (Figure 3), including members of the *Blautia*, *Faecalibacterium*,

Anaerostipes, and *Bacteroides* genera, which potentially supply B12 to auxotrophic species, allowing fecal communities to function without the need for exogenous B12 sources [89].

In parallel with metagenomic studies, recent comparative genome analyses have contributed to understanding the vitamin biosynthetic potential of various human-associated microbes, as summarized in Figures 3 and 4. These studies, utilizing a reference catalogue of over 2,000 bacterial chromosomes, have highlighted that the distribution of vitamin biosynthetic pathways is not homogeneous across bacterial phyla. Specifically, while the Bacteroidota and Pseudomonadota phyla encompass the majority of prototrophs, biosynthetic capabilities for B vitamin production are generally less prevalent among members of the Bacillota and Actinomycetota (Figure 3).

More in detail, all studies concur in identifying human gut commensals of the *Bacteroides* genus as prototrophic for all required B-group vitamins, except for cobalamin (vitamin B12) and menaquinones (vitamin K2) in a small number of strains [81,92] (Figure 3). For this reason, members of the *Bacteroides* genus are proposed to serve as key vitamin suppliers within the human gut microbiota, supporting survival and growth of numerous auxotrophic microbial taxa [70] (Figure 3). Similarly, various genera from the Pseudomonadota phylum, including well-known human gut commensals such as members of the *Enterobacter*, *Pseudomonas*, and *Klebsiella* genera, as well as *E. coli*, have been identified *in silico* as multi-prototrophs. Specifically, according to separate studies using a reference collection of human gut commensals [81,92] these taxa may produce menaquinones and B-group vitamins, except for thiamin, whose predicted biosynthetic pathway appears to be operational in only a minority of Pseudomonadota (Figure 3). In contrast, a multi-auxotrophy was detected *in silico* and confirmed *in vitro* for the human butyrate-producing *F. prausnitzii* [70,80,81] which, therefore, was designated as a prominent B-

vitamin consumer in microbial gut communities (Figure 3). Among the genomes of other butyrate producers commonly found in the human gut, such as members of the *Eubacterium*, *Roseburia*, *Anaerostipes*, and *Coproccoccus* genera, the most prevalent B-vitamin biosynthetic pathways were those for vitamin B2, B3, and B12, followed by vitamin B1, B5, and B6 (Figure 3). These *in silico*-predicted vitamin-related biosynthetic abilities were validated by growth on *in vitro* culture conditions, demonstrating, for instance, the need for vitamin B1 to support growth of *R. inulinivorans* or vitamin B9 to allow growth of *F. prausnitzii* and *Ag. rectale* [83]. In contrast, most investigated butyrate-producing strains are able to grow in the absence of cobalamin, niacin, pantothenate, pyridoxine, and riboflavin [83], reflecting prototrophies for these micronutrients or the lack of such vitamin requirement.

Interestingly, growth of butyrate-producing bacteria that are auxotrophic for a specific vitamin has been demonstrated to be sustained *in vitro* by the concomitant presence of a prototrophic species [83]. This illustrates that complementary vitamin biosynthetic potential can indeed lead to the effective sharing of essential micronutrients, thereby sustaining co-occurring strains and expanding the array of B-vitamins available to the host.

Alongside butyrogenic gut commensals, certain strains of bifidobacteria have garnered significant interest for their beneficial functions in the human gut, particularly in promoting gastrointestinal roles by enhancing nutrient absorption, mitigating digestive and systemic disorders, supporting immune functions, and producing B vitamins [234–242].

Members of the *Bifidobacterium* genus, such as *B. longum* subsp. *longum*, *B. longum* subsp. *infantis*, *B. bifidum*, *B. breve*, are recognized as key constituents of the infant gut microbiome [243,244]. However, some bifidobacterial species, including *B. longum*, persist throughout the

entire host lifespan in the human gut microbiota, although at a lower abundance [245,246]. In this context, elucidating vitamin biosynthesis capabilities of this bacterial group has been a research goal.

The *Bifidobacterium* genus has generally been recognized for their ability to synthesize several B-group vitamins, including thiamine, riboflavin, nicotinic acid, pyridoxine, and folate [29] (Figure 4), though differences and specificities among various species are evident, as detailed in the following section. While bifidobacteria have not been reported to produce vitamin K, some species such as *B. longum* subsp. *longum*, require menaquinone-4 for *in vitro* growth [247]. Regarding vitamin B2 biosynthesis, it should be noted that the complete gene set needed for *de novo* riboflavin production has been found primarily in bifidobacterial strains isolated from primates [35]. The only exception to this is the human-associated *B. longum* subsp. *infantis* (sub)species, whose genomes incorporate a complete *rib* operon for riboflavin biosynthesis [35]. In contrast, all human-origin bifidobacteria possess the ability to synthesize folate under *in vitro* conditions (Figure 4), with *B. adolescentis*, *B. catenulatum*, and *B. pseudocatenulatum* producing particularly high levels of folate. In contrast, *in vitro* folate production by non-human bifidobacterial species was generally lower [198]. Interestingly, the administration of high folate-producing bifidobacterial strains has been shown to increase fecal and serum folate levels in both rats and humans [248,249], providing evidence of how beneficial compounds produced by members of this taxa can contribute to host physiology.

Vitamin production capabilities have also been extensively explored in lactobacilli, as they are present in fermented foods and thus ingested by humans through diet, subsequently colonizing the gastrointestinal tract, at least transiently. This phenomenon has recently been investigated in the

bacterial component of raw milk cheeses, demonstrating that such bacteria can effectively be transferred from food to the gut microbiota of consumers [250], potentially exerting a functional impact on the gut microbiome, including vitamin production [251]. Moreover, the widely accepted and long-standing assumption that lactobacilli establish stable and numerically significant populations in the upper intestinal tract, where they are thought to associate with the epithelium and where most vitamin absorption occurs [7,252,253], underscores their potential role in host vitamin metabolism within this critical gut region. Numerous studies indicate that lactobacilli are capable of synthesizing various vitamins (Figure 4) [67]. Among these, the most prevalent are cobalamin and menaquinone, with their biosynthetic pathways identified in approximately 60% of lactobacilli, based on recent genome investigations [92]. Moreover, while certain lactobacilli potentially synthesize vitamin B9 given exogenous supplies of the essential intermediate pABA [70,196,254], other species of lactobacilli lack the genetic repertoire for *de novo* synthesis of DHPPP precursors and are therefore expected to remain incapable of folate production even in the presence of pABA [196]. In contrast, the biosynthetic pathways for niacin and pyridoxal are less widespread in lactobacilli genomes.

In addition to their presence in fermented foods intended for human consumption, members of the *Lactobacillus* genus are a fundamental component of the normal microbiota of the human vaginal tract. Similar to the microbial community inhabiting the human gut, also the vaginal microbiota of healthy non-pregnant women has been investigated through the concept of community state types, or clusters of recurrent microbial profiles. Originally, based on 16S rRNA gene profiling, this bacterial community has been classified into five compositional patterns [220], known as vaginotypes. These classifications have been revisited in subsequent publications [221,255,256], and, more recently, re-evaluated using whole-metagenome shotgun sequencing [222].

These studies consistently highlight that three vaginotypes tendentially reflect mixtures of lactobacilli, with a marked dominance of a single *Lactobacillus* species, i.e., *Lactobacillus crispatus*, *Lactobacillus iners*, or *Lactobacillus jensenii*, respectively. Moreover, the majority of works identified a fourth CST, with high abundance of *Lactobacillus gasseri* [257]. In contrast, the fifth vaginotype, is characterized by a more heterogeneous bacterial population, with low abundance of the *Lactobacillus* genus [221,255,256]. However, its composition lacks consistency across studies. While the original work characterizes this vaginotype by high proportions of *Prevotella*, *Dialister*, *Atopobium*, *Gardnerella* and other strictly anaerobic bacteria [220], other reports have further subdivided this non-*Lactobacillus* community into diverse sub-structures that capture variations and describe less common compositions, including those containing genera such as *Streptococcus*, *Anaerococcus*, and *Corynebacterium* genera [221,255,258].

So far, microbial vitamin production has not been extensively investigated within the vaginal microbiome, nor has sufficient evidence been provided regarding the potential role that bacterially-produced vitamins may play from a host perspective in the vaginal environment. [259,260]. However, considering the key microbial constituents identified through vaginal microbiome clustering, it is plausible to hypothesize distinct vitamin biosynthetic potentials, while acknowledging the limitations imposed by dimensionality reduction and the inherent temporal variability of the vaginal microbiome [221,261,262]. These predictions should not be regarded as absolute but rather as indicative trends based on a few dominant microbial species within each community. As illustrated in Figure 4, the four *Lactobacillus*-dominated vaginotypes display specific vitamin biosynthetic capabilities. For instance, the genomes of *L. crispatus* and *L. jensenii* have been shown to encode genes for vitamin B2 biosynthesis, whereas *L. iners* is predicted to produce folate, and *L. gasseri* harbors genes enabling *de novo* biosynthesis of vitamin B1. In

contrast, the non-*Lactobacillus*-dominated vaginotype is expected to exhibit a broader range of vitamin synthesis potential, encompassing thiamine, pantothenic acid, and folate, reflecting the presence of multiple co-inhabiting species within this microbial community, as opposed to the more homogenous *Lactobacillus*-dominated vaginotypes. Nevertheless, based on currently available scientific literature, no clinical relevance has yet been attributed to the production of vitamins by different microbial communities within the vaginal microbiome. Accordingly, further research is needed to elucidate whether or not metabolic abilities encoded by these communities, particularly pertaining to vitamin biosynthesis, play a role in vaginal or systemic health.

3. Microbe-derived vitamins throughout human lifespan: focus on early life

The early life gut microbiota plays a significant role in shaping health status and immune system development [263]. Many factors are known to influence the composition of this microbial community, including gestational age (full-term or pre-term), birth mode (vaginal or Caesarean section), feeding practice (breastfed or formula-fed), early environment exposure (hospital or home birth), and geographical location [264–267]. Human milk is the primary nutrient source for breast-fed infants, providing the developing neonate with a rich supply of carbohydrates in the form of lactose and the more complex human milk oligosaccharides (HMOs), which reach the large intestine structurally intact [268–270]. In addition, breast milk is a source of micronutrients, such as minerals, proteins, growth factors, and vitamins [271]. The vitamins included in this rich compendium include vitamins A and D, and various B vitamins, e.g., B1, B2, B6, and B12 [272,273]. Moreover, breast milk contains its own microbial community, whose taxonomic composition has been shown to vary based on host factors, such as maternal diet and gestational age [272,274]. Commonly detected human milk microorganisms belong to genera such as *Bifidobacterium*, *Streptococcus*, *Veillonella*, members of the genus formerly known as

Lactobacillus, and *Staphylococcus* [272,274]. Although mother-to-infant vertical transmission of microbes predominantly involves intestinal bacteria, there is also evidence suggesting that microbial strains can be transferred from the mother's milk to the infant [275,276], contributing to the establishment and development of the microbial gut community in the offspring. Specifically, strains from the genera *Bifidobacterium* and *Bacteroides* (including species recently reassigned to the *Phocaeicola* genus) have been shown to exhibit the highest transmission rates from mother to infant [277–280]. These strains have also been shown to effectively colonize and adapt to the infant's intestinal environment, primarily due to their ability to metabolize human milk oligosaccharides (HMOs) [281,282], which represent an essential nutrient source for bacteria nutrition during the milk-based diet phase [283,284].

Given the well-documented significant changes and evolution of the microbiota from birth through old age [285], it is reasonable to consider that the production of vitamins by this microbial community may also undergo analogous fluctuations [133,141]. Indeed, following the first three years after birth and throughout adulthood, the microbiota achieves and maintains a relatively stable state characterized by high biodiversity, although it remains subject to changes influenced by diet, lifestyle, and medical interventions [286–289]. In contrast, the elderly often experience a decline in microbial diversity and a shift towards a more imbalanced microbial state, which can impact/affect the community's ability to produce essential vitamins and potentially contribute to deficiencies commonly observed in older populations [133,290]. Consistent with this assumption, metagenomic-based functional analysis of the human gut microbiome throughout the human lifespan shows an initially limited capacity for vitamin production during infancy, which expands and peaks in adulthood, followed by a marked decline in the elderly population (Figure 5a) [133].

As discussed below, host age not only influences the overall microbial capacity to produce vitamins but also alters their profiles, with certain vitamins being associated with specific life stages rather than others (Figure 5a) [133,291].

Focusing on early-life, during which the foundation for subsequent gut microbiome structure and functional potential is formed, it has been elucidated that many early gut microbes can *de novo* synthesize certain vitamins, thus perhaps contributing to the host's vitamin requirements and supporting growth of other auxotrophic gut residents (Figure 5b). In particular, *Bifidobacterium* members and LAB possess metabolic capacities to produce certain B vitamins, although strain-level variations are evident [198], while high levels of vitamin K2 synthesis genes have been correlated with high abundances of the *Bacteroides/Phocaeicola* and *Escherichia/Shigella* genera [292] (Figure 5b). Interestingly, a recent study has highlighted differences in the biosynthetic potential of vitamin K2 and cobalamin based on geographical origin. Specifically, an increased abundance of genes for the production of these two cofactors was found in the gut microbiomes of infants from the US, which correlated with higher levels of *Bacteroides/Phocaeicola* and *E. coli* [133].

Variation in biosynthetic abilities was also observed as a result of the infant diet. Specifically, the gut microbiota of infants exclusively breastfed until the age of six months was shown to exhibit an enhanced capacity for adenosyl-cobalamin (vitamin B12) biosynthesis when compared to that of infants who had not been breastfed [293]. Consistently, LAB, some of which can produce vitamin B12 [294], were found in higher relative abundance in breastfed infants, indicating that the presence of lactic acid bacteria (LAB) may contribute to vitamin B12 availability in these

infants [293]. Moreover, vitamin B12 production in the infant gut has been linked to the presence of *Blautia* species [295].

It has been reported that *Bifidobacterium* members, many of which are among the first bacteria to colonize the infant gut, possess the biosynthetic ability to produce vitamins B2, B6, B9, and B12 [35,198] (Figure 5b). In this regard, Rodionov *et al.* [70] determined through metabolic genotype reconstruction that 62 *Bifidobacterium* strains possess an incomplete B1 biosynthetic pathway, in which an iminoglycine synthase-encoding gene appears to be lacking (the product of the *thiO* or *thiH* genes, Figure 2), while the genes of all other B1 synthesizing enzymes were identified. Therefore, the authors proposed that alternative enzymes or additional uncharacterized factors may still need to be identified for vitamin biosynthesis pathways employed by certain bacteria [70].

Within the *Bifidobacterium* genus, strains of *B. longum* subsp. *infantis* have been identified as capable of synthesizing riboflavin [35,296]. This biosynthesis is achieved by the products of the *rib* cluster as has been described for the *B. longum* subsp. *infantis* ATCC 15697 genome, although this ability does not appear to be widespread across the genus [35]. As *B. longum* subsp. *infantis* is a typical infant gut colonizer and a fervent HMO degrader, an additional riboflavin supply may be required when dominant in this environment as this vitamin is a precursor of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), essential co-factors in redox reactions of cell metabolism [294]. Additionally, *B. bifidum*, a species typically associated with the early-life gut microbiota and breastfeeding [297] has been shown to convert dietary A vitamin to the metabolite retinoic acid via an aldehyde dehydrogenase activity [298].

Folate is an important co-factor especially during embryogenesis and in early life, which are characterized by rapid cell divisions. For this reason, folic acid supplementation is regularly

advised by health authorities to pregnant women or women trying to conceive to ensure a healthy pregnancy. Specifically, the World Health Organization recommends that women of childbearing age consume 400 µg/day of folate, with an increase to 600 µg/day during the periconceptional period [299]. Although human breast milk, with an average folate concentration of 85 µg/l, is generally sufficient to meet the daily folate requirements of a newborn, certain situations, such as premature birth, can increase the need for this micronutrient [300,301].

Several elements of the infant gut microbiota possess the intrinsic ability to generate folate, suggesting the importance of folate prototrophs among early life microbiota members (Figure 5b).

Among these, members of the *Bifidobacterium* genus, e.g., *B. adolescentis* [199], *B. longum* subsp. *infantis* [198], *B. longum* subsp. *longum* [198], *B. breve* [198], and *Bifidobacterium catenulatum* [302], have folate production capabilities. However, the ability of *Bifidobacterium* strains to produce folate has previously been reported to be strain-specific [198,199,302]. Moreover, non-*Bifidobacterium* species associated with the infant gut microbiome, including those belonging to the *Collinsella*, *Veillonella*, and *Prevotella* genera may have the potential to contribute to intestinal folate levels in infants within the first 2-4 months after birth [303] (Figure 5b).

Consistently, high levels of *de novo* folate biosynthesis genes have been significantly associated with infants, whereas adults showed a higher proportion of genes assigned to metabolizing dietary folate [304].

For certain microbes, vitamin production may be important for cross-feeding purposes, including the exchange of B vitamins and their precursors [70], thereby aiding the development and enhancing the stability of the gut microbial community. Moreover, B vitamins are vital co-factors in metabolic processes directly involved in immune system development of the host. In this

context, vitamin production by early life gut bacteria may assist in the maturation of the intestinal (micro)environment and the associated microbiota by providing metabolites for other microorganisms typically detected in older infants and adults. For example, *F. prausnitzii*, a prominent butyrate producer in the adult gut and an early colonizer of the infant gut following the introduction of solid foods [265,305], depends on thiamine as a co-enzyme for butyrate production, and potentially requires riboflavin as part of the electron transfer flavoprotein complex of butyryl-CoA dehydrogenase [83,149,306]. Consistently, *F. prausnitzii*, is predicted to be auxotroph for thiamine and appears to encode a thiamine transporter (ThiT) [70,307] for the environmental acquisition of this micronutrient. Interestingly, as previously mentioned, bifidobacteria associated with the infant gut are generally capable of producing thiamin, which can be released extracellularly during cell lysis as part of normal cellular turnover (Figure 4, Figure 5b) [308]. Meanwhile, *Bacteroides* species and *E. coli* have been shown to provide riboflavin (Figure 5b), possibly promoting *F. prausnitzii* growth, which in turn supports the overall health and development of the infant gut microbiome [309]. Although the specific amount of riboflavin produced by *E. coli* or *Bacteroides* has not been directly demonstrated to be sufficient for *F. prausnitzii* growth, recent studies have provided *in vitro* evidence for the existence of cross-feeding interactions between B vitamin auxotrophs and prototrophs in synthetic microbial communities [83,89,310]. Specifically, *F. prausnitzii*, whose growth was shown to be reduced in the absence of thiamine, is able to maintain its relative abundance in a thiamine-free medium when co-cultured with a verified thiamine-prototrophic strain [83]. Moreover, *B. bifidum*, and various species from the *Bacteroides* and *Blautia* genera, have been revealed as potential folate cross-feeders of other auxotroph species, such as *Roseburia intestinalis*, and *Roseburia faecis* [83,310]. While these findings are based on small-scale experiments involving a limited number of strains, they do not

preclude the possibility that similar cross-feeding interactions occur for other vitamins and among additional co-occurring partners within the gut microbiome.

Differences in the infant gut microbiota composition before and after the introduction of solid food and cessation of breastfeeding, i.e., weaning, have been noted [293,311,312]. Solid food promotes growth of a more diverse collection of microbes, which translates to an increased functional repertoire of the gut microbiota [312]. For example, in infant samples where *B. longum* subsp. *longum* was present, there was a noticeable shift in HMO-utilizing genes before and after weaning, with fewer genes detected after weaning [313]. Mancabelli *et al.* [141] observed variations in the enzymes associated with B vitamin synthesis and the age group of the participants in their study. They observed a positive correlation with enzymes required for niacin and thiamine biosynthesis and the group aged 1-4 years old, in contrast to the other three groups: 5-17 years, 18-64 years, and 65+ [141]. The defining microbes present in the microbiota of the 1-4-year-old group were shown to be *Bifidobacterium* species, specifically *B. breve*, *B. longum* subsp. *longum*, and *B. bifidum* as well as *Veillonella parvula* and *E. coli* [141]. This suggests the existence of a connection between the species present and generated vitamins, which are required for host development and changes across the lifespan. Similar age-related differences in relation to gut microbial vitamin production and early life have been noted, such as genes for the synthesis of vitamin B5, B7, and B9 being significantly enriched in newborns compared to older infants [292,304]. In contrast, increasing levels of genes related to the biosynthesis of vitamin B1, B6, and B12, have been observed with age [292,304] (Figure 5). Among these, cobalamin has been proposed to play a crucial role in maintaining the balance and stability of the gut microbial community in healthy adults [133] (Figure 5). Indeed, vitamin B12, which escapes host absorption or is derived from prototrophic gut commensals, appears to trigger a complex web of interactions within the gut

microbiota [314]. On the one hand, competition for cobalamin can occur among gut bacteria, influencing the relative abundance and community structure of the microbiota [87]. On the other hand, collaborative interactions also arise from this dependency. Bacteria capable of producing cobalamin can support growth of cobalamin-dependent species through mutualistic relationships, thereby enhancing the stability and functionality of the microbial community [80].

These observations prompt reflection on how certain microbial species and their metabolic products influence the host at particular life stages, underscoring the dynamic nature of the gut microbiome and its adaptive capacity to meet the host's nutritional needs.

4. Production of vitamins by microbiomes from different human body sites

Although the human gut attracts significant interest from the scientific community due to its high bacterial density and complex microbial interactions implicated in various human diseases [315–317] other human body anatomical compartments, including the skin, oral cavity, airways, and vaginal tract, also provide habitats for organized microbial communities. Similar to intestinal microbial communities, these bacterial consortia are implicated in various aspects of host health, as their dysbiosis, or compositional imbalance, has been associated with a range of diseases. For example, dysbiosis of skin microbiota has been linked to dermatological conditions like eczema and psoriasis, while imbalances in the oral microbiota are associated with periodontal disease and systemic conditions, including cardiovascular disease [318,319]. Similarly, disturbances in the lung microbiota are connected to respiratory issues such as asthma, chronic obstructive pulmonary disease (COPD), and SARS-CoV-2 infections [320,321]. Alterations in the vaginal microbiota can also lead to infections and reproductive health problems, including infertility and pre-term birth [322].

1143 For this reason, in recent decades, extensive metagenomic efforts have been directed to elucidate
1144 the composition and functional roles of commensal consortia across various anatomical sites,
1145 extending beyond those associated with the gut.

1146 As described above, the occurrence of vitamin biosynthetic genes in prominent individual
1147 members of the oral, skin, and vaginal microbiota has been revealed through recent genome
1148 investigations using public genome reference collections [70,81,83]. Nevertheless, comprehensive
1149 data on the vitamin production potential of entire microbial communities across the human body
1150 remain scarce or even lacking. To address this gap, we integrated data from recent shotgun
1151 metagenomic sequencing efforts of various human-associated microbial communities, including
1152 those of the oral cavity, skin, vaginal tract, and lung, to extrapolate information on the capacity for
1153 vitamin biosynthesis within various microbiomes, providing a more complete view of the
1154 functional roles that microbiota may play in this regard beyond the gut. As depicted in Figure 6,
1155 the concerted vitamin biosynthetic potential within the human skin commensals reveals a high
1156 prevalence of genes for riboflavin production, which has been proposed to play an important role
1157 in skin barrier integrity [323]. Indeed, extracellular bacteria-derived intermediates of riboflavin
1158 biosynthesis have been shown to be recognized by specific host immune cells, known as mucosal-
1159 associated invariant T (MAIT) cells, which play a crucial role in protecting against cutaneous
1160 pathogens and promoting tissue repair [324]. Consistently, a recent study performed in mice have
1161 demonstrated that skin-resident MAIT cells are activated in response to exposure to [325]. In
1162 contrast, a mutant strain of this microorganism, lacking the crucial gene *ribD* involved in riboflavin
1163 biosynthesis (Figure 2), failed to induce a MAIT cell response [325], supporting the idea that
1164 microbially synthesized riboflavin is required to elicit a local MAIT-cells immunosurveillance
1165 activation in the human skin.

A similar mechanism has been proposed for various microbial B-vitamin metabolic products within the pulmonary microbiome [326]. Specifically, microbial derivatives of riboflavin and folic acid degradation are taken up by antigen presenting cells (APCs) via MR1, a highly conserved major histocompatibility complex (MHC) class I-related protein [323]. These metabolites are subsequently presented to MAIT cells, which express T-cell receptors (TCRs) that recognize bacterial antigens presented by MR1 [327]. Although the bacterial load in this human (sub)niche is notoriously low, it is typically inhabited by members of the *Streptococcus*, *Veillonella*, and *Prevotella* genera [328,329], which are capable of producing riboflavin and folate, leading to a relatively high proportion of genes involved in the synthesis of these B vitamins (Figure 6). Notably, pulmonary bacterial infection models have highlighted that microbial riboflavin and folate metabolites are important in the early MAIT-cell control of *Streptococcus pneumoniae*, and *Klebsiella pneumoniae* infection [326]. In this context, these vitamin-derived metabolites represent a potential mechanism through which MAIT cells sense microbial activity across mucosal membranes, thereby potentially modulating local immune responses and mucosal barrier functions.

As demonstrated by the presence of microbial genes for B vitamin production in metagenomic studies, the vaginal and oral microbiomes are also able to produce various B vitamins (Figure 6), potentially contributing to host health. However, despite these insights, significant gaps remain in our understanding of the role and effect of bacteria-derived vitamins in these body districts. This underscores a critical need for future research in this area, as gaining such insights could significantly advance our knowledge of host-microbiome interactions and their implications for human health.

1189

1190 **5. Impact of diet on the vitamin-producing or -consuming gut microbiota**

1191 The bioavailability of vitamins for the host depends on the dietary supply and how this supply is
1192 modified by the microbes in the gut that can produce, consume and/or cross-feed vitamins (Figure
1193 7). It is well established that dairy, meat, and plants provide a good source of vitamins for the host
1194 [330–334]. Beyond the role of food as carriers of vitamins to the host, the dietary macronutrients,
1195 micronutrients, fibers, and their associated bioactive compounds can affect the composition of the
1196 gut microbiota, and their activity linked to the production or consumption of vitamins [335,336].
1197 These effects are further influenced by lifestyle, gender, and age [335,337,338]. For example, it
1198 has been recently highlighted in a (male) mouse model that dietary fibers, such as inulin, can boost
1199 microbiota-derived B vitamin availability in the host [339].

1200 Given the limited genetic capacity for *de novo* vitamin biosynthesis among members of the
1201 Actinomycetota and Bacillota phyla, as discussed above, one would then expect that bacteria
1202 within these phyla may rely on exogenous sources of various vitamins, represented by amount of
1203 vitamins that escapes from host absorption. Consistently, a substantial body of literature
1204 demonstrates that dietary vitamins serve as powerful modulators of the gut microbiome [340]. The
1205 intake of individual vitamins has been linked to distinct alterations in gut microbiota composition,
1206 highlighting the nuanced interplay between specific micronutrients and microbial communities
1207 [341–345].

1208 Vitamins available in the gut environment can also originate from co-occurring bacterial
1209 producers. This phenomenon has been demonstrated *in vitro*, where Bacillota bacteria were shown
1210 to survive in environments deficient in vitamins B1 and B12 when co-cultured with vitamin-
1211 producing members of the same phylum [83,89].

Consistent with these reports, various studies have in recent decades revealed membrane transport systems in these bacteria, which are required for the uptake of exogenous sources of various vitamins (Figure 7). However, despite the critical importance of vitamin-related molecules in prokaryotes, our understanding of the mechanisms underlying the uptake of B vitamins and their precursors remains limited. Comparative genomic approaches have significantly advanced the (tentative) identification of vitamin transporters in both prototrophic and auxotrophic bacteria, suggesting their broad distribution across diverse taxa and reinforcing the concept of B vitamin-mediated cross-feeding within the microbiota [70,87,125,161,163,346–361] (Figure 7).

One of the most well-studied cases involves the genetic arsenal of *Bacteroides thetaiotaomicron* for the uptake of cobalamin and other corrinoids. This species is equipped with three distinct genetic loci dedicated to vitamin B12 uptake, in contrast to the Gram-negative model organism *E. coli*, which harbors just a single locus for this function [87,362,363]. The presence of multiple outer membrane vitamin B12 transporters is a common feature in the *Bacteroides* genus, highlighting the critical role of B12 uptake for this taxon [364].

More recently, it has been observed that bacterial extracellular vesicles produced by *B. thetaiotaomicron* contain multiple high-affinity vitamin B12 binding proteins [27], suggesting that vesicle-mediated mechanisms play a critical role in scavenging vitamins from the environment and further highlighting the sophisticated strategies employed by gut bacteria to acquire essential nutrients.

Thus, ultimately, the interactions between bacterial vitamin producers, consumers, and cross-feeders orchestrates the supply of vitamins to the gut microbiota shaping the overall availability of these crucial molecules to the host beyond dietary intake.

In the following sections, the effects of dietary vitamins (including supplements) and other dietary components on gut microbiota members are discussed in detail for each vitamin.

5.1 Thiamine (Vitamin B1)

Beyond *de novo* synthesis from amino acids (Cys, and Tyr, or Gly), bacteria can also produce TPP following uptake of this vitamin or pathway-associated precursors, such as the THZ and HMP moiety, by 26 known transporters which differ based on substrate specificity [70].

Consistent with the role of amino acids in vitamin B1 production, the type of diet and associated food matrix significantly influence the gut microbiota's ability to produce, consume, or cross-feed on this vitamin. Interestingly, compared to children (mean age of 9.8 years), adults with a mean age of 56.8 years were shown to possess a higher microbial pathway presence related to vitamin B1 biosynthesis [365]. Additionally, healthy individuals who consumed a vegetarian diet were shown to exhibit significantly higher abundances of certain B-vitamin-producing bacteria compared to those on an omnivorous diet [127]. These bacteria were primarily from the phylum Bacillota, which relies on vitamin B1 for its metabolic processes and are considered consumers and cross-feeders (producers-consumers) (Figure 7). The Bacillota identified include various members of the *Ruminococcus* genus, along with *Clostridium leptum*, *Eubacterium ventriosum*, *Clostridium symbiosum*, *Anaerostipes hadrus*, and *Blautia glucerasea*. In addition, a higher abundance of multi-prototrophs Bacteroidota (*Parabacteroides goldsteinii* and *Bacteroides intestinalis*), and *Pseudomonadota* (*Parasutterella excrementihominis*) were observed in the vegetarian group. Although an omnivorous diet can provide vitamin B1, with pork meat as the highest source, vegetarian diets offer a higher thiamine content, primarily from sources such as whole grains (including oats, wheat, brown rice, millet, sorghum, and soybeans), enriched or

1257 fortified foods, nuts, whole-grain products, baker's yeast and bread [366,367]. To investigate the
1258 potential association between vitamin B1 intake and gut microbiota composition, a correlative
1259 analysis between thiamine intake and bacterial species was performed in healthy individuals,
1260 which showed effects primarily on Bacillota. Specific correlations were observed with *Roseburia*
1261 spp., *Veillonella rogosae*, *V. parvula*, *F. prausnitzii*, and *Veillonella infantium*. Extending this line
1262 of investigation, the consumption of thiamine correlated with an increased abundance of
1263 *Ruminococcaceae* in the gut of healthy individuals, as well as with higher fecal butyrate
1264 production, whereas total dietary fiber intake from the diet did not show this correlation [149].
1265 Indeed, vitamin B1 plays a crucial role in butyrate synthesis by acting as a cofactor in the
1266 conversion of pyruvate to acetyl-CoA [83], where this SCFA provides many health benefits such
1267 as causing satiety and improved gut integrity [368,369]. By using a vitamin B1-deficient diet,
1268 which reduced the abundance *Ruminococcaceae* in mice [149], the necessity of exogenous
1269 thiamine for growth and stability of these bacteria and for maintaining butyrate production in the
1270 gut was established.

1271 The effect of diet on other phyla has also been observed regarding the potential of the gut
1272 microbiota to produce vitamin B1. Of note, intake of guar gum, an indigestible soluble
1273 polysaccharide (galactomannan family), activated microbial B-vitamin metabolic pathways [370],
1274 including thiamine phosphate formation from pyrithiamine and oxythiamine (degradation
1275 pathway) and thiamine diphosphate salvage II, which involves the phosphorylation, conversion,
1276 and recycling of thiamine derivatives to maintain self-regulation and nutrient homeostasis,
1277 confirming thiamine prototrophy of bacteria. These changes were accompanied by alterations in
1278 the composition of the gut microbial community, with an increase in Bacteroidota
1279 (*Parabacteroides distasonis*, *Barnesiella intestinihominis*, *Bacteroides ovatus*, *Bacteroides*

caccae, *Parabacteroides merdae*, *Bacteroides finegoldii*), Bacillota (*Ruminococcus bicirculans*, *Lachnospira pectinoschiza*, and *Ruminococcus torques*), Verrucomicrobia (*A. muciniphila*) and Actinomycetota (*Collinsella aerofaciens*) [370]. Whilst vitamin B1 intake has been shown to correlate with Pseudomonadota (*Haemophilus parainfluenzae*), Actinomycetota (*B. pseudocatenulatum*), and Bacterioidetes (*Bacteroides xylanisolvens*) [371], further studies are needed to ascertain the functional role of these microbes for production and consumption of thiamine, and how any changes in the dietary supply can influence the host, as has been demonstrated for Bacillota.

5.2 Riboflavin (Vitamin B2)

Vitamin B2 plays a crucial role in many biochemical reactions, exerting antioxidant and anti-inflammatory functions in the host [372]. This micronutrient is abundantly found in eggs, fruits, dairy products, meat, and green vegetables in the form of FMN and FAD [373]. Whilst the only known riboflavin biosynthetic pathway was shown to be absent in most Actinomycetota and half of Bacillota, as we described above, the associated microorganisms were shown to be able to internalize vitamin B2 from the environment using the RibU riboflavin transporter or carry other genes with predicted roles in riboflavin uptake or salvage, which indicates their reliance on riboflavin-derived cofactors for growth [70,81].

In assessing the impact of diet, including vitamin intake, on microbial communities, it has been shown that a four-week colon-targeted vitamin B2 supplementation improved the α -diversity of gut microbiota, significantly increased the abundance of *Alistipes* and *Clostridium*, and decreased the abundance of *Faecalibacterium* in healthy individuals [374]. Notably, in this study, faecal and plasma levels of riboflavin were measured. There was an increase in fecal vitamin B2 content

compared with the baseline, while the vitamin level in the plasma did not change. A negative correlation has been reported between the abundance of *Streptococcus* and riboflavin intake [375]. Reducing vitamin B2 supplementation to two weeks in healthy individuals increased the abundance of *F. prausnitzii* per gram of feces as compared to the extended supplementation [343]. *F. prausnitzii* is a major butyrate producer in the human gut, known for its anti-inflammatory and gut barrier-enhancing properties [376,377]. In addition to the findings for *F. prausnitzii*, an increase in *Roseburia* species and a decrease in *E. coli* were observed, perhaps reflecting enhanced anaerobic conditions and redox status in the gut [343]. Active forms of vitamin B2 are required by glutathione reductase, which protects cells from reactive oxygen species (ROS). Consequently, vitamin B2 may indirectly act as an antioxidant, reducing luminal ROS, and creating conditions that favor growth of *F. prausnitzii* and other strict anaerobes, perhaps at the expense of *E. coli* [343]. The role of this vitamin in electron transfer flavoprotein complex with butyryl-CoA dehydrogenase is established, which directly affects butyrate production [83,378], and in turn, host health [379]. Indeed, several studies have shown that vitamin B2 supplementation significantly increases butyrate production in humans [343,375,380,381]. In contrast to these findings, Chinese individuals with natural long-life spans have more SCFA- and lactic acid-producing bacteria but show reduced activity of genetic pathways associated with vitamin B2 biosynthesis [382], whereas the gut microbiotas of Italian centenarians have an enrichment of microbial vitamin B2 biosynthesis pathways and SCFA production [382]. Additionally, it has been shown that the Western diet is linked to vitamin biosynthesis [383,384]. These findings suggest that dietary differences amongst individuals living in different parts of the world, as well as their age and associated health, influence the interaction between dietary and microbial supply of riboflavin.

Utilizing the knowledge on bacterial species that can produce vitamin B2, and the genetic pathways involved, several studies have attempted to isolate and identify strains that over-produce this vitamin. Of note, strain *Lactiplantibacillus plantarum* M5MA1-B2, originally derived from maize-based fermented alcohol beverage, was shown to over-produce riboflavin and to survive an *in vitro* gastro-intestinal environment [385,386]. Similarly, the human isolate *Limosilactobacillus reuteri* AMBV339, a natural riboflavin overproducer capable of synthesizing and excreting surplus amounts of this vitamin beyond its own metabolic requirements, was shown to act as a strong food biofortification candidate, especially in coconut beverages and buttermilk fermentations. The strain demonstrated remarkable resilience to survive in gastric juice as well as inhibiting growth of an enteric bacterial pathogen under *in vitro* conditions [387]. The data highlights the importance of modulating microbial riboflavin production through genetic manipulation or diet to improve human health outcomes beyond SCFA production. Notably, the biologically active forms of vitamin B2, FMN and FAD, are considered important co-factors in energy production reactions associated with carbohydrate, fat, and protein metabolism, as well as in the synthesis and activation of other essential vitamins such as pyridoxine and folate [159,294,388].

5.3 Niacin (Vitamin B3)

In accordance with their low ratio of *de novo* producers, the phyla Actinomycetota and Bacillota, were predicted to convert exogenous vitamin B3 into NAD through niacin salvage pathways, which are absent in the Bacteroidota genomes [334]. Consistently, systems for the uptake of nicotinamide and nicotinic acid are highly prevalent in Bacillota, but also in bacteria belonging to Pseudomonadota and Fusobacterium, suggesting that they consume this vitamin [81].

In a study assessing the effect of vitamin B3 on the fecal microbiome, 10 metabolically healthy volunteers received daily delayed-release microcapsules, delivering nicotinic acid and nicotinamide to the ileocolonic region to directly target the gut microbiome in this region for six weeks, with weekly increasing dose. A significant increase in the abundance of Bacteroidota was observed in the nicotinic acid supplementation group, whereas no significant changes were observed in the nicotinamide group [345]. Since nicotinamide metabolism requires two functional enzymes, namely nicotinamidase (PncA) and nicotinamide phosphoribosyltransferase (NadV), and since assessed Bacteroidota members lack these two genes, these findings may explain the observed difference in the microbiome-modulating ability of nicotinic acid and nicotinamide [389].

5.4 Pantothenate (Vitamin B5)

It is estimated that just 0.078% of colonic pantothenate is produced by the human gut microbiota, contributing to 4.5% of the DRI of this vitamin [81], while the remaining pantothenate is presumed to be derived from dietary sources. Despite its crucial role in the host and the gut microbiota, studies investigating its effects on healthy humans remain limited. A study found that fiber guar gum consumption modulated phosphopantothenate biosynthesis in healthy individuals [370]. This metabolic pathway is related to the synthesis of phosphopantothenate, which requires the activity of 14 genes, with an additional three genes involved in the uptake of pantothenate and coenzyme A (CoA) precursors [70]. Notably, similar to vitamin B1, the activity of microbial vitamin B5 biosynthetic pathways increased in adults (with a mean age of 56.8 years) compared to children (with a mean age of 9.8 years) [365]. These effects were shown to be accompanied by lower microbial diversity in children, and an overrepresentation of glycan degradation, in contrast to adult microbiomes which showed higher abundances of carbohydrate metabolism pathways [365].

However, at the genus level, the relative abundance of *Bacteroides* increased in the gut microbiota of children, while a higher relative abundance of Bacillota was noted in adults [365]. The difference in relative abundance of species in the Bacteroidota and Bacillota phyla may be related to the type of polysaccharides consumed in the two age groups. Indeed, *Bacteroides* can utilize both plant and host-derived polysaccharides, as well as metabolize various glycans [390,391]. Consistent with these effects, the provision of a sulfated polysaccharide from *Sargassum fusiforme* to cultures grown in a simulated digestion tract environment, led to an increase in the relative abundance of Bacteroidota and decrease the relative abundance of Bacillota [392]. Notably, the relative abundance of *Bacteroides* increased, accompanied by enhanced production of SCFAs and pantothenic acid, suggesting a functional relationship between the type of polysaccharide environmentally available and microbial production of pantothenate [392].

5.5 Biotin (Vitamin B7)

The contribution of the human gut microbiota to the host biotin status is influenced by diet and host health. The impact of fiber, specifically guar gum (8g/day for 18 days), on healthy individuals demonstrated an increase in microbial activity related to vitamin B7 biosynthesis in the gut [370]. This pathway involves several enzymatic steps to convert biotin to its final form, suggesting that this fiber can stimulate vitamin B7 production by the gut microbiota. Additionally, another study found that biotin and fiber intake from the diet correlated with Operational Taxonomic Units (OTUs) and reduced visceral fat mass in older female twins (age 68.33 ± 9.76 ; BMI 25.87 ± 4.37) [393]. Interestingly, the OTUs were strongly correlated with reduced visceral fat compared to nutrient intake alone. Overall, these findings suggest that fiber consumption affects vitamin B7 metabolism and its production by the gut microbiota and that a clear synergistic relationship between dietary biotin and fiber exists, which emphasizes the importance of nourishing the gut

microbiota with these combined nutrients to enhance microbial biotin production, with potential benefits for host health.

5.6 Folate (Vitamin B9)

The interplay between diet, folate intake, nutrient metabolism and gut microbiota is highly complex, intricate, and interdependent. Vitamin B9 levels are influenced by diet, gut microbiota composition and microbiome activity, which all contribute to production and/or availability of this vitamin.

Specific dietary folate patterns, categorized into healthy and Western, influenced the gut microbiota composition in adult men and women. Higher folate intake (406 ± 190 vs. 297 ± 112 $\mu\text{g/d}$), and the potential for vitamin B9 production by fecal microbiota were shown to be associated with the healthy diet group [394]. In this study, bacterial genera with high potential for folate production included *Bacteroides* (*Ba. coprocola*), *Sutterella* (*S. wadsworthensis*), *Parasutterella*, members of the *Prevotellaceae* family and Proteobacteria (*E. coli* Nissle) [66]. Conversely, bacterial taxa whose members were associated with low vitamin B9 production potential include the *Christensenellaceae* group, *Akkermansia* (*A. muciniphila*), *Alistipes*, and the *Ruminococcus* genus [199]. At the species level, *P. copri* showed a positive association with folate production potential, while *F. prausnitzii* had a negative correlation [66]. In addition, while in this study the overall diet quality did not prove to be associated with the folate production potential of gut microbiota, the intake of specific macronutrients, such as fat and simple carbohydrate intake, were negatively associated with folate synthesis potential [66]. Therefore, these outcomes confirm that specific dietary habits influence folate synthesis by the gut microbiota [394]. However, bacterial vitamin B9 production does not appear to significantly influence circulating folate levels in humans [394]. This suggests that endogenous microbial synthesis may have a limited impact on

overall folate bioavailability, with dietary intake likely playing a more dominant role in maintaining systemic levels of vitamin B9. Nevertheless, it is worth noting that dietary probiotic supplementation, particularly with bifidobacteria and lactobacilli, has been associated with increased serum and plasma folate levels in both rats and humans, highlighting a potential role for specific bacteria in modulating host folate status [199,395].

As part of a healthy diet, fiber intake has been linked with vitamin B9 metabolism. Specifically, guar gum (8g/day for 18 days) has been shown to influence the metabolism of this vitamin in healthy individuals by enhancing key bacterial pathways, such as folate transformations II and III [370], which play a crucial role in increasing cellular retention of vitamin B9, improving its function as a coenzyme, and facilitating its reduction to tetrahydrofolate by bacterial enzymes, followed by methylation to form active folate derivatives like 5-methyl-THF [396]. This enhancement is associated with guar gum fermentation in the colon, which may alter the composition and activity of gut microbiota, promoting growth of folate-producing bacteria. Therefore, these findings demonstrate that a healthy diet including vegetables, whole grains, and fiber or fermented food using starter cultures with LAB strains such as *La. plantarum*, *Latilactobacillus sakei*, and *S. thermophilus* [69], may modulate the gut microbiota and maintain folate metabolism, promoting beneficial effects on the host's overall metabolism.

5.7 Cobalamin (Vitamin B12)

Beyond *de novo* production, the microbial contribution of vitamin B12 to the host is indirectly influenced by the microbial consumption involving 22 genes associated with the uptake of this vitamin [81] as well as the impact of food matrix associated with diet, and its interaction with other nutrients (e.g. folate). Notably, vitamin B12 intake from the diet is positively correlated with the

gut microbial genus *Clostridium* which also shows a positive correlation with meat consumption by healthy individuals [371]. Similarly, *S. thermophilus* was positively correlated with vitamin B12 intake and showed positive associations with lactose, calcium, vitamin B2, and a strong positive association with galactose [371]. These findings suggest that an increased consumption of meat and dairy products (such as milk) is a primary source of vitamin B12 [367]. On the other hand, *Lachnospira eligens* (formerly *Eubacterium eligens*) is associated with vitamin B12 intake and correlated with the consumption of food groups containing eggs, vegetables, nuts, and fruits. Notably, the species mentioned belong to the phylum Bacillota (and some Bacteroidota), and their adaptability to survive in the absence of cobalamin was also demonstrated. This finding stems from *in vitro* culturing of the gut microbiota from healthy adult-donors, which survived in media lacking vitamin B12 [89]. Whilst the α - and β -diversities were not affected by the culture medium, the availability of vitamin B12 in the media had subtle effects on bacterial growth. Notably, *Lactobacillus* and *Barnesiella intestinihominis* grew in media lacking cobalamin [89]. Conversely, adding excess vitamin B12 to the medium increased the abundance of *P. distasonis*. Furthermore, metabolic effects were observed under these conditions, particularly with regards to propionate production, where vitamin B12 is known to act as a cofactor in the conversion of succinate to propionate [89]. These observations suggest potential health benefits of vitamin B12 supplementation in the diet as a way to increase the host bioavailability and enhance propionate-mediated health effects [368,369,397].

5.8 Vitamin K2

Elucidating the impact of diet on the bioavailability of vitamin K has been hampered by the fact that the bacterial-derived form (menaquinone or vitamin K2) differs from that derived from plants (phyloquinone or vitamin K1). Moreover, vitamin K2 exists in 15 isoforms (MKs) [332,398]

which differ in the structure of their side chains. While much of the MKs produced are thought to be absorbed in the lower part of the intestine, host tissues are also able to produce these isoforms from the conversion of vitamin K1 [332,398]. Given the diverse MKs that exist in the gut and in tissues, it is no surprise that the effects of vitamin K extend beyond coagulation to include roles in cognition and fat metabolism [332,399]. Among dietary factors influencing the bioavailability of vitamin K1, intake of green leafy vegetables has been shown to increase circulatory levels of vitamin K1 in adult obese humans, with the effect observed in both sexes [400]. Interestingly, the vitamin level did not correlate with the microbial communities. Removing the confounding effects of obesity, Karl *et al.* explored the relationship between diet, gut microbiota, and K2 vitamin forms (MK5-13) derived from bacteria in healthy humans [401]. The study showed decreased fecal level of vitamin K2 with intake of whole-grain rich diets compared to refined grain rich diets, where the differences can be attributed to the changes in the gut microbiota. Further analysis showed contributions by *Bacteroides* and *Prevotella* for this variability [401]. Additionally, in healthy adult females, dietary supply of vitamin K was significantly correlated with an increase in fecal relative abundance of *Bifidobacterium* and negatively correlated with the relative abundance of *Bacteroides* [341]. The increased relative abundance of *Bifidobacterium*, known to promote gut health, may be due to vitamin K2 and certain derivatives being recognized as growth factors of these bacteria under *in vitro* conditions [402]. Collectively, these studies in healthy humans suggest contrasting effects of dietary factors and vitamin K supplementation on the bioavailability of vitamin K for the host, either through direct supply to circulation or indirectly via changes in the gut microbiota, including those of different phyla. Extending this line of investigation to include the impact of aging and associated decline in diet and health, it has been shown that the microbial potential to produce MKs is associated with differences in cognitive performance in this age

category [403]. Notably, positive associations were obtained for MKs 6, 12 and 13 with cognitive functions, whereas negative associations were obtained for MKs 4, 8, 9 and 10 with health outcomes. The study further showed that a greater abundance of *Prevotella* (producing MK-11, -12 and -13), *Paraprevotella* (producing MK-10, -11, -12 and -13), and *Barnesiella* (producing MK-11 and -12), all being members of the phylum Bacteroidota, were associated with highest cognitive performance [403]. While this study does not provide sufficient evidence to confirm cause and effect relationships, the data nonetheless indicate that changes in diet and age can affect the bioavailability of vitamin K through microbial effects.

6. Therapeutic and probiotic interventions to modulate vitamin production

The role of microbiota on human health has been extensively reviewed and new studies continue to demonstrate that dysbiosis of microbiota may not only be a consequence of a particular disease but may also be a contributing factor [214,404]. In this sense, alterations in composition of the gut microbial community have been associated with obesity, type 2 diabetes, non-alcoholic liver disease, cardio-metabolic diseases, and inflammatory bowel diseases (IBD), [214,405], as well as other diseases like bladder, colorectal and breast cancer, arthritis, autism, depression, anxiety, sleep disorder, and hypertension [406–408] and very recently with neurodegenerative diseases (such as Alzheimer’s and Parkinson’s) through the gut-brain axis [315,409].

The severity of these diseases has also been shown to be related to vitamin concentrations in the bloodstream, thereby supporting the inclusion of vitamin supplementation in certain treatment protocols.

The effects of vitamin B2 have been studied in various pathologies such as age-related cataracts, diabetes, sepsis and septic shock, kidney, liver and lung injuries, and cardiovascular diseases [410–

417]. For example, a colonic inflammation model using female rats has shown that the antioxidant and anti-inflammatory activities of this vitamin help restore the antioxidant status of the colonic tissue and mitigate oxidative damage associated with colonic injury [418]. Similarly, another study found that riboflavin effectively reversed chemically induced hepatic lesions in male rats in a dose dependent manner [419]. Regarding vitamin B9, recent investigations have revealed that folate fortification, while primarily aimed at preventing neural tube defects in newborns when administered to pregnant women, also provides additional unintended benefits, including improved hemoglobin concentrations, decreased risk of cardiovascular diseases, and improved cognitive function [420]. Moreover, various studies have demonstrated the anti-inflammatory effect of supplementation with this vitamin. In this regard, experimental evidence includes findings from animal models, such as female mice with allergic dermatitis [421] and alcoholic fatty liver disease [422] as well as humans studies conducted in small cohorts of both female and male individuals with hypertension [423], and children suffering from obesity [424]. A synergic antioxidant effect of this vitamin and vitamin B12 was also demonstrated in a model of nicotine-induced pancreatic damage in male rats [425]. Regarding IBD, some studies have shown that this condition may be associated with folate deficiency and that folic acid supplementation may reduce the risk of developing colorectal cancer in these patients [426]. Specifically, a recent meta-analysis involving nearly 40,000 male and female IBD patients found that high folate intake may reduce colorectal cancer risk, particularly in US and European individuals with high alcohol consumption, although no similar effect was observed for rectal cancer [427].

Vitamin B9 has also been shown to influence the composition of the gut microbiota, promoting species known for their beneficial effects on host health. A recent study using an *in vitro* intestinal mimicking media demonstrated that high doses of folic acid reduced the proportion of *Bacteroides*

while increasing the proportion of butyrate-producing members of the *Faecalibacterium* genus [428]. Another study categorized healthy male participants into high- versus low-intake of B vitamins, including vitamin B9, based on their daily consumption of certain nutrients [428]. Bacterial taxonomic analysis of colonic biopsies revealed an increased abundance of the *Akkermansia* genus in individuals with high folate intake [428]. Notably, this taxon has been associated in other studies with seizure prevention in epilepsy, improved intestinal barrier integrity, and mitigation of experimental alcoholic liver disease [429].

In Parkinson's Disease (PD) patients, B-group vitamins are often described as dietary factors that would be involved in the etiology of this disease [430]. A benefit of the intestinal microbiota for the human host is the production of vitamins and it was seen that microorganisms involved in the biosynthesis of certain B vitamins, such as B7, B2, B1, and B9, are decreased in patients with PD [97]. Consistently, vitamin B2 is decreased in many patients with PD, and it was shown that the administration of high doses of this vitamin could reverse some of the symptoms of the disease by acting against oxidative stress, mitochondrial dysfunction and neuroinflammation that are associated with the pathogenesis of PD [431,432]. On the other hand, PD treatments, such as the use of levodopa can cause deficiencies of vitamin B12, vitamin B6 and folates [433,434], which are crucially involved in harmful homocysteine (Hcy) concentrations, thus highlighting the potential benefit of nutritional interventions to prevent side effects related to this treatment.

Thus, modulating the intestinal microbiota is being evaluated as a means to increase vitamin intake and not only treat certain diseases, but also to prevent them or to decrease their severity. In this respect, the intestinal microbiota can be modulated using prebiotics, probiotics, synbiotics and even postbiotics [435]. While the concepts of probiotics, defined as beneficial live microorganisms, and prebiotics, which are non-digestible food components that promote the

1558 growth of beneficial bacteria, as well as their combination into a single product known as
1559 symbiotics, are well-established, the concept of postbiotics is a more recent development.
1560 Specifically, the term “postbiotic” refers to bioactive compounds produced by probiotic bacteria
1561 during fermentation. These metabolites can include SCFAs, enzymes, peptides, polysaccharides,
1562 and cell wall fragments, all of which may exert beneficial effects on host health even in the absence
1563 of live microorganisms [436]. Postbiotics are emerging as a promising area of research due to their
1564 stability, safety, and potential health benefits. Indeed, unlike probiotics, postbiotics do not need to
1565 survive the digestive tract, making them more versatile for incorporation into a wide range of food
1566 products and dietary supplements [437].

1567 The use of vitamin-producing probiotics has been shown to be effective in the prevention and
1568 treatment of numerous diseases using cell culture and animal models, especially in intestinal
1569 inflammatory diseases and colorectal cancer [see reviews [438], [439] [69] and [440]]. In this
1570 context, the riboflavin-producing strain *La. plantarum* CRL2130 has been shown to prevent
1571 excessive increase of pro-inflammatory cytokines (IL-6, IFN- γ , IL-17, and TNF- α), thereby
1572 mitigating the symptoms of ulcerative colitis [441], and intestinal mucositis [442] in chemically
1573 induced female mice models. Similarly, folate-producing LAB, such as *S. thermophilus* CRL808
1574 and CRL415, have been shown to inhibit pro-inflammatory cytokines, reducing chemically
1575 induced mucositis in female mice [443]. The combination of a riboflavin-producing strain with a
1576 folate producer has been described to be effective not only in improving breast cancer therapy in
1577 cell cultures and in mice, but also decreasing one of the undesirable side effects (mucositis) that
1578 often limits the continuation of chemotherapy [443].

1579 The potential neuroprotective properties of *La. plantarum* CRL2130, a strain that overproduces
1580 vitamin B2, were confirmed in an *in vivo* murine model of Parkinson’s disease (PD) [444], in

which the administration of *La. plantarum* CRL2130 attenuated motor deficits and prevented dopaminergic neuronal death in male mice. In the study, these effects were partially attributed to the antioxidant/anti-inflammatory properties riboflavin produced by this strain, as improvements in motor skills were similarly observed in a group of male mice receiving commercial vitamin B2. Likewise, orally administration of *La. plantarum* CRL1905, a high vitamin B1-producing strain, was shown to ameliorate motor deficits in a male mouse PD model, producing effects comparable to those of commercial vitamin B1 [444]. These benefits were linked to a reduction in pro-inflammatory cytokines in serum, along with localized anti-inflammatory effects in the brain [444]. In another work, a combination of *La. plantarum* CRL2130 producing vitamin B2, the folate producer *S. thermophilus* CRL808, and the strain *S. thermophilus* CRL807 with immunomodulatory properties was evaluated in a chronic parkinsonism (male) mouse model [445]. In this study, the neuroprotective effect associated with this mixture of selected Lactic Acid Bacteria (LAB) was related to the modulation of the immune response in male mice, altered by the presence of the neurotoxin. Furthermore, the effect of levodopa-benserazide treatment was maintained and, in some cases, improved in the presence of the LAB mixture [445]. Finally, treatment with this LAB mixture in combination with levodopa-benserazide was able to partially modulate the dysbiosis associated with the model, approaching the conditions observed in healthy controls [445].

Although these results appear to suggest a promising use of LAB to complement strategies for neurodegenerative disease treatments, the application of such vitamin-producing bacteria must be performed in human studies in order to demonstrate their effectiveness. Furthermore, the use of postbiotics, consisting of microbial synthesized substances, including vitamins, also holds a significant therapeutical potential. These microbial-derived substances could be incorporated into

regular diets or used as therapeutic agents to prevent or manage diseases associated with, or exacerbated by, insufficient vitamin intake [446]. Additionally, many existing studies in animal models predominantly use male animals [419,425,444,445], revealing an opportunity to further explore vitamin metabolism and its implications in female populations, which have been comparatively less represented in current research.

Caveats and future perspectives

It is important to acknowledge that many studies referenced in this review have inherent limitations that warrant careful consideration. These include challenges such as low sequencing depth, which may restrict the resolution of microbial taxonomic and functional profiles, and reduced sample sizes, which may limit the generalizability and robustness of some findings. Additionally, the variability in methodologies, including differences in bioinformatic pipelines, reference databases, and experimental conditions, further complicates the interpretation and comparison of results across studies.

Microbiome-based research is rapidly evolving, with new tools and technologies incessantly being developed. Advances such as long-read sequencing, and integrated multi-omics approaches have the potential to dramatically enhance our understanding of the gut microbiome and its functional roles, including vitamin biosynthesis. These innovations may provide deeper insights into microbial interactions, host-microbiota crosstalk, and previously uncharacterized microbial taxa or pathways, potentially revising or refining current conclusions. As we learn more about the complexities of the gut microbiome, it is likely that future research will address many of the current limitations, offering a more comprehensive and detailed understanding of microbial contributions

to vitamin synthesis. This progression emphasizes the need to continuously revise hypotheses as new evidence emerges.

CONCLUSIONS

The human body is home to very complex microbial communities that engage in molecular interactions, both among themselves and with the host, producing significant effects on human health. In this context, it has already been extensively documented how microbes deliver compounds, such as small molecules or metabolic end products, which are crucial for establishing and maintaining the climax of microbial consortia. Among microbe-synthesized molecules, vitamins are increasingly capturing the interest of the scientific community [62,243,337]. However, even though vitamin production has long been demonstrated in single-microorganism cultures, recent attention has shifted towards understanding how concerted metabolic interactions within complex microbial communities might be responsible for the biosynthesis of vitamins that ultimately may be partially utilized by the host or other microorganisms following extracellular diffusion or cell lysis. On the other hand, the presence of vitamins in the gut has been shown to significantly modulate the diversity and composition of the gut microbial communities in both animal models and humans [447]. Notably, compelling evidence shows that vitamin D supplementation increases the abundance of beneficial microbes such as *Bifidobacterium* and *Akkermansia* while reducing populations of *Veillonella* and *Pseudomonadota* [448,449]. The mechanism behind this modulation involves the nuclear vitamin D receptor (VDR) that binds vitamin D. Upon binding vitamin D and its activation, the VDR functions as a transcriptional regulator, influencing the expression of genes involved in various biological processes, which ultimately can indirectly shape the composition and metabolic functions of the gut microbiome [448].

Among the objectives of this research is to explore how the natural fluctuations and variations in gut microbiota composition, which occur throughout its development from infancy through adulthood to old age, impact its capacity to produce vitamins. For instance, a microbiota dominated by bifidobacteria in the first stages of life until weaning clearly shows a relatively high biosynthetic potential for thiamine, pantothenate, biotin, folate and menaquinone [133]. This potential is then enhanced and complemented by biosynthetic abilities for riboflavin and cobalamin at later stages of life [133]. Notably, in the elderly population, the gut microbiota is largely depleted of vitamin microbial producers, which could impact gut inflammation, which is a typical physiological condition of the elderly [450]. By understanding these variations, researchers aim to gain insights into how age-specific shifts in microbial communities influence overall vitamin production, potentially informing strategies for optimizing nutritional health across different life stages. Additionally, a novel frontier of research could be directed to explore how the onset or progression of certain diseases may be linked to a reduction or loss of microbially synthesized vitamins due to disruptions in the composition of microbial consortia [451–453]. Moreover, since a large part of the human microbiome is still far from being precisely characterized, i.e., the human microbial dark matter, it is very plausible that novel microbial vitamin synthesizers will be discovered as part of this still unknown microbiome. This represents a novel frontier not only in human microbiome science but also in the establishment of novel microbial-based biotechnological applications that are useful for the prevention or treatment of vitamin deficiency conditions.

Another highly interesting hot topic is related to the understanding of the production of vitamins by microbes residing in various human body compartments. In fact, while most of the currently available information on this matter focuses on the human gut, other regions, such as the oral cavity, lung, skin, and vaginal tract, are also densely colonized by microbes with the capacity to

synthesize a range of essential vitamins [454]. For instance, certain bacteria associated with the human skin and airways can produce B vitamins, such as riboflavin and folate, which are crucial for maintaining skin barrier integrity and informing immune responses [81].

The ability of these non-gut microbial communities to produce vitamins underscores their potential impact on overall health and highlights their importance beyond the traditional focus on gut microbiota. Despite these findings, the full extent of vitamin production by microbiota inhabiting other (sub)niches in the human body beyond the gut and how they influence host health remains underexplored. Given the crucial roles these microbial communities play in maintaining physiological balance and their potential implications for health and disease [455], expanding our understanding of their vitamin-related functionalities could reveal novel insights into how skin, oral, vaginal, and pulmonary microbiota contribute to host health and could pave the way for new treatments for microbiota-related disorders and enhance personalized medicine approaches.

Recently, significant advancements in research have highlighted the role of food not only as a source of nutrients and organoleptic features but also as a carrier of functional microbes that provide key metabolites and vitamins to the human gut [250,251,456]. This paradigm shift recognizes foods as vehicles for microbes that can directly impact human health by introducing novel vitamin producers to the gut microbiota, thereby expanding the vitamin biosynthesis capacity of resident microbes, at least transiently. For instance, certain fermented foods are rich in microorganisms capable of producing B-group vitamins, such as folate and riboflavin, which are essential for various physiological functions. By incorporating these microbes into the diet, individuals may temporarily improve their vitamin status and overall health. This field of study represents a promising but largely unexplored frontier. Thus, future research should continue to

explore how different foods, and their associated microbes can influence vitamin biosynthesis and contribute to overall health. This exploration could lead to new dietary strategies and interventions aimed at harnessing the full potential of functional foods to support human well-being.

In the context of developing novel translational outcomes in microbiome science, the vitamin-supplementing activities of the human microbiota represent a promising new area of research. In this regard, the establishment of synthetic microbiota composed of cooperative vitamin-producing microbes could have significant applications in disease prevention and treatment. This approach requires careful evaluation of vitamin metabolic pathways, and the development of bioinformatics tools aimed at modeling metabolic interactions within the whole microbial community rather than focusing on single strains. In this context, although the concept of synthetic microbiotas is still in its infancy, their potential as vitamin suppliers under various conditions, such as unbalanced diets or increased vitamin requirements due to diseases, represents a novel frontier in microbiome-based science.

Acknowledgements

M.V. and postdoctoral research fellowship of C.T. were funded by the European Union, NextGeneration EU, PNRR-M4C2- I1.1, PRIN 2022 - Project Code 20229LEB99 - CUP Code D53D23014150006, Project title: Disentangling the molecular interplay between the gut microbiota and the host in the first stages of life (I-MAP). P.D.C., J.M., and D.v.S. are members of APC Microbiome Ireland, which is funded by Science Foundation Ireland (SFI) under Grant Numbers 12/RC/2273 and 16/SP/3827.

References

- [1] Barker T. Vitamins and Human Health: Systematic Reviews and Original Research. *Nutrients* 2023;15. <https://doi.org/10.3390/NU15132888>.
- [2] Espinosa-Salas S, Gonzalez-Arias M. Nutrition: Micronutrient Intake, Imbalances, and Interventions. *StatPearls* 2023.
- [3] Gregory JF. Accounting for differences in the bioactivity and bioavailability of vitamins. *Food Nutr Res* 2012;56. <https://doi.org/10.3402/FNR.V56I0.5809>.
- [4] Youness RA, Dawoud A, ElTahtawy O, Farag MA. Fat-soluble vitamins: updated review of their role and orchestration in human nutrition throughout life cycle with sex differences. *Nutr Metab (Lond)* 2022;19. <https://doi.org/10.1186/S12986-022-00696-Y>.
- [5] Lykstad J, Sharma S. Biochemistry, Water Soluble Vitamins. *StatPearls* 2024.
- [6] Hanna M, Jaqua E, Nguyen V, Clay J. B Vitamins: Functions and Uses in Medicine. *Perm J* 2022;26:89–97. <https://doi.org/10.7812/TPP/21.204>.
- [7] Said HM. Intestinal absorption of water-soluble vitamins in health and disease. *Biochem J* 2011;437:357–72. <https://doi.org/10.1042/BJ20110326>.
- [8] Said HM, Nexo E. Gastrointestinal Handling of Water-Soluble Vitamins. *Compr Physiol* 2018;8:1291–311. <https://doi.org/10.1002/CPHY.C170054>.
- [9] Said HM, Mohammed ZM. Intestinal absorption of water-soluble vitamins: an update. *Curr Opin Gastroenterol* 2006;22:140–6. <https://doi.org/10.1097/01.MOG.0000203870.22706.52>.
- [10] Suter PM. The B-vitamins. *Essential and Toxic Trace Elements and Vitamins in Human Health* 2020:217–39. <https://doi.org/10.1016/B978-0-12-805378-2.00017-6>.
- [11] Raymond-Lezman JR, Riskin SI. Benefits and Risks of Sun Exposure to Maintain Adequate Vitamin D Levels. *Cureus* 2023;15. <https://doi.org/10.7759/CUREUS.38578>.
- [12] Ankar A, Bhimji SS. Vitamin B12 Deficiency. *StatPearls* 2022.
- [13] Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. *Eur J Nutr* 2018;57. <https://doi.org/10.1007/S00394-017-1445-8>.
- [14] LeBlanc JG, Chain F, Martín R, Bermúdez-Humarán LG, Courau S, Langella P. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. *Microb Cell Fact* 2017;16. <https://doi.org/10.1186/S12934-017-0691-Z>.
- [15] Brauer-Nikonow A, Zimmermann M. How the gut microbiota helps keep us vitaminized. *Cell Host Microbe* 2022;30:1063–6. <https://doi.org/10.1016/J.CHOM.2022.07.010>.

- [16] Gustafsson BE. Vitamin K deficiency in germfree rats. *Ann N Y Acad Sci* 1959;78:166–74. <https://doi.org/10.1111/J.1749-6632.1959.TB53101.X>.
- [17] Sumi Y, Miyakawa M, Kanzaki M, Kotake Y. Vitamin B-6 deficiency in germfree rats. *J Nutr* 1977;107:1707–14. <https://doi.org/10.1093/JN/107.9.1707>.
- [18] Fiebigler U, Bereswill S, Heimesaat MM. Dissecting the Interplay Between Intestinal Microbiota and Host Immunity in Health and Disease: Lessons Learned from Germfree and Gnotobiotic Animal Models. *Eur J Microbiol Immunol (Bp)* 2016;6:253–71. <https://doi.org/10.1556/1886.2016.00036>.
- [19] Gustafsson BE, Daft FS, Mcdaniel EG, Smith JC, Fitzgerald RJ. Effects of vitamin K-active compounds and intestinal microorganisms in vitamin K-deficient germfree rats. *J Nutr* 1962;78:461–8. <https://doi.org/10.1093/JN/78.4.461>.
- [20] Frick PG, Riedler G, Brögli H. Dose response and minimal daily requirement for vitamin K in man. *J Appl Physiol* 1967;23:387–9. <https://doi.org/10.1152/JAPPL.1967.23.3.387>.
- [21] Said HM. Recent advances in transport of water-soluble vitamins in organs of the digestive system: a focus on the colon and the pancreas. *Am J Physiol Gastrointest Liver Physiol* 2013;305. <https://doi.org/10.1152/AJPGI.00231.2013>.
- [22] Lakoff A, Fazili Z, Aufreiter S, Pfeiffer CM, Connolly B, Gregory JF, et al. Folate is absorbed across the human colon: evidence by using enteric-coated caplets containing ¹³C-labeled [6S]-5-formyltetrahydrofolate. *Am J Clin Nutr* 2014;100:1278–86. <https://doi.org/10.3945/AJCN.114.091785>.
- [23] Magnúsdóttir S, Ravcheev D, De Crécy-Lagard V, Thiele I. Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. *Front Genet* 2015;6. <https://doi.org/10.3389/FGENE.2015.00148>.
- [24] Degnan PH, Taga ME, Goodman AL. Vitamin B12 as a modulator of gut microbial ecology. *Cell Metab* 2014;20:769–78. <https://doi.org/10.1016/J.CMET.2014.10.002>.
- [25] Allen RH, Stabler SP. Identification and quantitation of cobalamin and cobalamin analogues in human feces. *Am J Clin Nutr* 2008;87:1324–35. <https://doi.org/10.1093/AJCN/87.5.1324>.
- [26] Sonnenburg ED, Sonnenburg JL. Gut microbes take their vitamins. *Cell Host Microbe* 2014;15:5–6. <https://doi.org/10.1016/J.CHOM.2013.12.011>.
- [27] Juodeikis R, Jones E, Deery E, Beal DM, Stentz R, Kräutler B, et al. Nutrient smuggling: Commensal gut bacteria-derived extracellular vesicles scavenge vitamin B12 and related cobamides for microbe and host acquisition. *Journal of Extracellular Biology* 2022;1. <https://doi.org/10.1002/JEX2.61>.
- [28] Hill MJ. Intestinal flora and endogenous vitamin synthesis. *Eur J Cancer Prev* 1997;6 Suppl 1. <https://doi.org/10.1097/00008469-199703001-00009>.

- [29] Yoshii K, Hosomi K, Sawane K, Kunisawa J. Metabolism of dietary and microbial vitamin b family in the regulation of host immunity. *Front Nutr* 2019;6. <https://doi.org/10.3389/fnut.2019.00048>.
- [30] Zhang H, Lan F, Shi Y, Wan ZG, Yue ZF, Fan F, et al. A “three-in-one” sample preparation method for simultaneous determination of B-group water-soluble vitamins in infant formula using VitaFast(®) kits. *Food Chem* 2014;153:371–7. <https://doi.org/10.1016/J.FOODCHEM.2013.12.088>.
- [31] Microbiological assay for vitamin B n.d. https://www.researchgate.net/publication/285675266_Microbiological_assay_for_vitamin_B (accessed September 17, 2024).
- [32] Zhang Y, Zhou WE, Yan JQ, Liu M, Zhou Y, Shen X, et al. A Review of the Extraction and Determination Methods of Thirteen Essential Vitamins to the Human Body: An Update from 2010. *Molecules* 2018;23. <https://doi.org/10.3390/MOLECULES23061484>.
- [33] Fatima Z, Jin X, Zou Y, Kaw HY, Quinto M, Li D. Recent trends in analytical methods for water-soluble vitamins. *J Chromatogr A* 2019;1606. <https://doi.org/10.1016/J.CHROMA.2019.05.025>.
- [34] Yang J, Wilson I, Rainville P. Evaluation of hybrid surface technology for the analysis of the B-group vitamins by LC-ESI-MS/MS. *J Chromatogr B Analyt Technol Biomed Life Sci* 2022;1204. <https://doi.org/10.1016/J.JCHROMB.2022.123336>.
- [35] Solopova A, Bottacini F, Venturi degli Esposti E, Amaretti A, Raimondi S, Rossi M, et al. Riboflavin Biosynthesis and Overproduction by a Derivative of the Human Gut Commensal *Bifidobacterium longum* subsp. *infantis* ATCC 15697. *Front Microbiol* 2020;11. <https://doi.org/10.3389/FMICB.2020.573335>.
- [36] Roelofsen-de Beer RJAC, van Zelst BD, Wardle R, Kooij PG, de Rijke YB. Simultaneous measurement of whole blood vitamin B1 and vitamin B6 using LC-ESI-MS/MS. *J Chromatogr B Analyt Technol Biomed Life Sci* 2017;1063:67–73. <https://doi.org/10.1016/J.JCHROMB.2017.08.011>.
- [37] Bruns S, Wienhausen G, Scholz-Böttcher B, Wilkes H. Simultaneous quantification of all B vitamins and selected biosynthetic precursors in seawater and bacteria by means of different mass spectrometric approaches. *Anal Bioanal Chem* 2022;414:7839–54. <https://doi.org/10.1007/S00216-022-04317-8>.
- [38] Chamlagain B, Edelmann M, Kariluoto S, Ollilainen V, Piironen V. Ultra-high performance liquid chromatographic and mass spectrometric analysis of active vitamin B12 in cells of *Propionibacterium* and fermented cereal matrices. *Food Chem* 2015;166:630–8. <https://doi.org/10.1016/J.FOODCHEM.2014.06.068>.
- [39] Kahoun D, Fojtíková P, Vácha F, Čížková M, Vodička R, Nováková E, et al. Development and validation of an LC-MS/MS method for determination of B vitamins and some its

- derivatives in whole blood. PLoS One 2022;17. <https://doi.org/10.1371/JOURNAL.PONE.0271444>.
- [40] Meisser Redeuil K, Longet K, Bénet S, Munari C, Campos-Giménez E. Simultaneous quantification of 21 water soluble vitamin circulating forms in human plasma by liquid chromatography-mass spectrometry. J Chromatogr A 2015;1422:89–98. <https://doi.org/10.1016/J.CHROMA.2015.09.049>.
- [41] Shetty SA, Young MF, Taneja S, Rangiah K. Quantification of B-vitamins from different fresh milk samples using ultra-high performance liquid chromatography mass spectrometry/selected reaction monitoring methods. J Chromatogr A 2020;1609. <https://doi.org/10.1016/J.CHROMA.2019.460452>.
- [42] Lau SKP, Lam CW, Curreem SOT, Lee KC, Lau CCY, Chow WN, et al. Identification of specific metabolites in culture supernatant of Mycobacterium tuberculosis using metabolomics: exploration of potential biomarkers. Emerg Microbes Infect 2015;4. <https://doi.org/10.1038/EMI.2015.6>.
- [43] Wang M, Asam S, Chen J, Rychlik M. Development of Stable Isotope Dilution Assays for the Analysis of Natural Forms of Vitamin B12 in Meat. J Agric Food Chem 2021;69:10722–30. <https://doi.org/10.1021/ACS.JAFC.1C03803>.
- [44] De Brouwer V, Storozhenko S, Stove CP, Van Daele J, Van Der Straeten D, Lambert WE. Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for the sensitive determination of folates in rice. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:509–13. <https://doi.org/10.1016/J.JCHROMB.2009.12.032>.
- [45] Hampel D, York ER, Allen LH. Ultra-performance liquid chromatography tandem mass-spectrometry (UPLC-MS/MS) for the rapid, simultaneous analysis of thiamin, riboflavin, flavin adenine dinucleotide, nicotinamide and pyridoxal in human milk. J Chromatogr B Analyt Technol Biomed Life Sci 2012;903:7–13. <https://doi.org/10.1016/J.JCHROMB.2012.06.024>.
- [46] Abdu Hussen A. High-Performance Liquid Chromatography (HPLC): A review. Annals of Advances in Chemistry 2022;6:010–20. <https://doi.org/10.29328/JOURNAL.AAC.1001026>.
- [47] Grotzkyj Giorgi M, Howland K, Martin C, Bonner AB. A novel HPLC method for the concurrent analysis and quantitation of seven water-soluble vitamins in biological fluids (plasma and urine): a validation study and application. ScientificWorldJournal 2012;2012. <https://doi.org/10.1100/2012/359721>.
- [48] Ciulu M, Solinas S, Floris I, Panzanelli A, Pilo MI, Piu PC, et al. RP-HPLC determination of water-soluble vitamins in honey. Talanta 2011;83:924–9. <https://doi.org/10.1016/J.TALANTA.2010.10.059>.
- [49] Datta S, Sinha BK, Bhattacharjee S, Seal T. Nutritional composition, mineral content, antioxidant activity and quantitative estimation of water soluble vitamins and phenolics by

- RP-HPLC in some lesser used wild edible plants. *Heliyon* 2019;5. <https://doi.org/10.1016/J.HELİYON.2019.E01431>.
- [50] Tyagi K, Upadhyaya P, Sarma S, Tamboli V, Sreelakshmi Y, Sharma R. High performance liquid chromatography coupled to mass spectrometry for profiling and quantitative analysis of folate monoglutamates in tomato. *Food Chem* 2015;179:76–84. <https://doi.org/10.1016/J.FOODCHEM.2015.01.110>.
- [51] Cheng X, Ma D, Fei G, Ma Z, Xiao F, Yu Q, et al. A single-step method for simultaneous quantification of thiamine and its phosphate esters in whole blood sample by ultra-performance liquid chromatography-mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2018;1095:103–11. <https://doi.org/10.1016/J.JCHROMB.2018.07.030>.
- [52] Gentili A, Caretti F, D'Ascenzo G, Marchese S, Perret D, Di Corcia D, et al. Simultaneous determination of water-soluble vitamins in selected food matrices by liquid chromatography/electrospray ionization tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2008;22:2029–43. <https://doi.org/10.1002/RCM.3583>.
- [53] Sim HJ, Kim B, Lee J. A Systematic Approach for the Determination of B-Group Vitamins in Multivitamin Dietary Supplements by High-Performance Liquid Chromatography with Diode-Array Detection and Mass Spectrometry. *J AOAC Int* 2016;99:1223–32. <https://doi.org/10.5740/JAOACINT.16-0093>.
- [54] Geng C, Guo X, Liu J, Gao M, Yuan G, Bu F, et al. LC–MS/MS for the Determination of Four Water-Soluble Vitamins: Method Development, Validation and Comparison to EC Method. *Chromatographia* 2017;80:259–64. <https://doi.org/10.1007/S10337-016-3232-8/METRICS>.
- [55] Liddicoat C, Hucker B, Liang H, Vriesekoop F. Thiamin analysis in red wine by fluorescence reverse phase-HPLC. *Food Chem* 2015;177:325–9. <https://doi.org/10.1016/J.FOODCHEM.2015.01.009>.
- [56] Annibal A, Tam H, Latza C, Antebi A. Comparison of ESI-MS/MS and APCI-MS methods for the quantification of folic acid analogs in *C. elegans*. *J Mass Spectrom* 2019;54:316–27. <https://doi.org/10.1002/JMS.4337>.
- [57] Khaksari M, Mazzoleni LR, Ruan C, Kennedy RT, Minerick AR. Data representing two separate LC-MS methods for detection and quantification of water-soluble and fat-soluble vitamins in tears and blood serum. *Data Brief* 2017;11:316–30. <https://doi.org/10.1016/J.DIB.2017.02.033>.
- [58] Yilmaz MA, Cakir O, Yener I. A fast, accurate and comprehensive LC-MS/MS method validation for the sensitive quantification of water-soluble vitamins in walnut, almond, hazelnut and pistachio fruits. *Int J Mass Spectrom* 2023;488:117040. <https://doi.org/10.1016/J.IJMS.2023.117040>.

- [59] Rebane R, Krueve A, Liigand P, Liigand J, Herodes K, Leito I. Establishing Atmospheric Pressure Chemical Ionization Efficiency Scale. *Anal Chem* 2016;88:3435–9. <https://doi.org/10.1021/ACS.ANALCHEM.5B04852>.
- [60] Zayed A, Bustami R, Alabsi W, El-Elmat T. Development and Validation of a Rapid High-Performance Liquid Chromatography–Tandem Mass Spectrometric Method for Determination of Folic Acid in Human Plasma. *Pharmaceuticals (Basel)* 2018;11. <https://doi.org/10.3390/PH11020052>.
- [61] Bhandari D, Kertesz V, Van Berkel GJ. Rapid quantitation of ascorbic and folic acids in SRM 3280 multivitamin/multielement tablets using flow-injection tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2013;27:163–8. <https://doi.org/10.1002/RCM.6440>.
- [62] Fenoll J, Martínez A, Hellín P, Flores P. Simultaneous determination of ascorbic and dehydroascorbic acids in vegetables and fruits by liquid chromatography with tandem-mass spectrometry. *Food Chem* 2011;127:340–4. <https://doi.org/10.1016/J.FOODCHEM.2010.12.140>.
- [63] Martin F, Giménez EC, Konings E. New Methods for the Analysis of Water-Soluble Vitamins in Infant Formula and Adult/Pediatric Nutritionals. *J AOAC Int* 2016;99:19–25. <https://doi.org/10.5740/JAOACINT.15-0245>.
- [64] Lugli GA, Alessandri G, Milani C, Viappiani A, Fontana F, Tarracchini C, et al. Genetic insights into the dark matter of the mammalian gut microbiota through targeted genome reconstruction. *Environ Microbiol* 2021;23:3294–305. <https://doi.org/10.1111/1462-2920.15559>.
- [65] Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, et al. Next-Generation Sequencing Technology: Current Trends and Advancements. *Biology (Basel)* 2023;12. <https://doi.org/10.3390/BIOLOGY12070997>.
- [66] Engevik MA, Morra CN, Röth D, Engevik K, Spinler JK, Devaraj S, et al. Microbial Metabolic Capacity for Intestinal Folate Production and Modulation of Host Folate Receptors. *Front Microbiol* 2019;10. <https://doi.org/10.3389/FMICB.2019.02305>.
- [67] Leblanc JG, Laiño JE, del Valle MJ, Vannini V, van Sinderen D, Taranto MP, et al. B-group vitamin production by lactic acid bacteria--current knowledge and potential applications. *J Appl Microbiol* 2011;111:1297–309. <https://doi.org/10.1111/J.1365-2672.2011.05157.X>.
- [68] Balabanova L, Averianova L, Marchenok M, Son O, Tekutyeva L. Microbial and Genetic Resources for Cobalamin (Vitamin B12) Biosynthesis: From Ecosystems to Industrial Biotechnology. *Int J Mol Sci* 2021;22. <https://doi.org/10.3390/IJMS22094522>.
- [69] Levit R, Savoy de Giori G, de Moreno de LeBlanc A, LeBlanc JG. Recent update on lactic acid bacteria producing riboflavin and folates: application for food fortification and treatment of intestinal inflammation. *J Appl Microbiol* 2021;130:1412–24. <https://doi.org/10.1111/JAM.14854>.

- [70] Rodionov DA, Arzamasov AA, Khoroshkin MS, Iablokov SN, Leyn SA, Peterson SN, et al. Micronutrient Requirements and Sharing Capabilities of the Human Gut Microbiome. *Front Microbiol* 2019;10. <https://doi.org/10.3389/FMICB.2019.01316>.
- [71] McCormick DB. Metabolism of vitamins in microbes and mammals. *Biochem Biophys Res Commun* 2003;312:97–101. <https://doi.org/10.1016/j.bbrc.2003.09.241>.
- [72] LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. *Curr Opin Biotechnol* 2013;24:160–8. <https://doi.org/10.1016/J.COPBIO.2012.08.005>.
- [73] Shaffer M, Borton MA, McGivern BB, Zayed AA, La Rosa SL 0003 3527 8101, Solden LM, et al. DRAM for distilling microbial metabolism to automate the curation of microbiome function. *Nucleic Acids Res* 2020;48:8883–900. <https://doi.org/10.1093/NAR/GKAA621>.
- [74] Caspi R, Billington R, Keseler IM, Kothari A, Krummenacker M, Midford PE, et al. The MetaCyc database of metabolic pathways and enzymes - a 2019 update. *Nucleic Acids Res* 2020;48:D445–53. <https://doi.org/10.1093/NAR/GKZ862>.
- [75] Zhou Z, Tran PQ, Breister AM, Liu Y, Kieft K, Cowley ES, et al. METABOLIC: high-throughput profiling of microbial genomes for functional traits, metabolism, biogeochemistry, and community-scale functional networks. *Microbiome* 2022;10. <https://doi.org/10.1186/S40168-021-01213-8>.
- [76] Magnúsdóttir S, Heinken A, Kutt L, Ravcheev DA, Bauer E, Noronha A, et al. Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota. *Nat Biotechnol* 2017;35:81–9. <https://doi.org/10.1038/NBT.3703>.
- [77] Overbeek R, Olson R, Pusch GD, Olsen GJ, Davis JJ, Disz T, et al. The SEED and the Rapid Annotation of microbial genomes using Subsystems Technology (RAST). *Nucleic Acids Res* 2014;42. <https://doi.org/10.1093/NAR/GKT1226>.
- [78] Ebrahim A, Lerman JA, Palsson BO, Hyduke DR. COBRApy: COntstraints-Based Reconstruction and Analysis for Python. *BMC Syst Biol* 2013;7. <https://doi.org/10.1186/1752-0509-7-74>.
- [79] Novichkov PS, Kazakov AE, Ravcheev DA, Leyn SA, Kovaleva GY, Sutormin RA, et al. RegPrecise 3.0--a resource for genome-scale exploration of transcriptional regulation in bacteria. *BMC Genomics* 2013;14. <https://doi.org/10.1186/1471-2164-14-745>.
- [80] Sharma V, Rodionov DA, Leyn SA, Tran D, Iablokov SN, Ding H, et al. B-Vitamin Sharing Promotes Stability of Gut Microbial Communities. *Front Microbiol* 2019;10. <https://doi.org/10.3389/FMICB.2019.01485>.
- [81] Magnúsdóttir S, Ravcheev D, De Crécy-Lagard V, Thiele I. Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. *Front Genet* 2015;6. <https://doi.org/10.3389/FGENE.2015.00148>.

- [82] Shelton AN, Seth EC, Mok KC, Han AW, Jackson SN, Haft DR, et al. Uneven distribution of cobamide biosynthesis and dependence in bacteria predicted by comparative genomics. *ISME J* 2019;13:789–804. <https://doi.org/10.1038/S41396-018-0304-9>.
- [83] Soto-Martin EC, Warnke I, Farquharson FM, Christodoulou M, Horgan G, Derrien M, et al. Vitamin Biosynthesis by Human Gut Butyrate-Producing Bacteria and Cross-Feeding in Synthetic Microbial Communities. *MBio* 2020;11:1–18. <https://doi.org/10.1128/MBIO.00886-20>.
- [84] Zelezniak A, Andrejev S, Ponomarova O, Mende DR, Bork P, Patil KR. Metabolic dependencies drive species co-occurrence in diverse microbial communities. *Proc Natl Acad Sci U S A* 2015;112:6449–54. <https://doi.org/10.1073/PNAS.1421834112>.
- [85] Mansoorabadi SO, Thibodeaux CJ, Liu HW. The diverse roles of flavin coenzymes--nature's most versatile thespians. *J Org Chem* 2007;72:6329–42. <https://doi.org/10.1021/JO0703092>.
- [86] Chen Y, Ying Y, Lalsiamthara J, Zhao Y, Imani S, Li X, et al. From bacteria to biomedicine: Developing therapies exploiting NAD⁺ metabolism. *Bioorg Chem* 2024;142. <https://doi.org/10.1016/J.BIOORG.2023.106974>.
- [87] Degnan PH, Barry NA, Mok KC, Taga ME, Goodman AL. Human gut microbes use multiple transporters to distinguish vitamin B₁₂ analogs and compete in the gut. *Cell Host Microbe* 2014;15:47–57. <https://doi.org/10.1016/J.CHOM.2013.12.007>.
- [88] Zhang Y, Rodionov DA, Gelfand MS, Gladyshev VN. Comparative genomic analyses of nickel, cobalt and vitamin B₁₂ utilization. *BMC Genomics* 2009;10. <https://doi.org/10.1186/1471-2164-10-78>.
- [89] Kundra P, Geirnaert A, Pugin B, Morales Martinez P, Lacroix C, Greppi A. Healthy adult gut microbiota sustains its own vitamin B₁₂ requirement in an in vitro batch fermentation model. *Front Nutr* 2022;9. <https://doi.org/10.3389/FNUT.2022.1070155>.
- [90] Rowley CA, Kendall MM. To B₁₂ or not to B₁₂: Five questions on the role of cobalamin in host-microbial interactions. *PLoS Pathog* 2019;15. <https://doi.org/10.1371/JOURNAL.PPAT.1007479>.
- [91] Culp EJ, Goodman AL. Cross-feeding in the gut microbiome: Ecology and mechanisms. *Cell Host Microbe* 2023;31:485–99. <https://doi.org/10.1016/J.CHOM.2023.03.016>.
- [92] Molina Ortiz JP, Read MN, McClure DD, Holmes A, Dehghani F, Shanahan ER. High throughput genome scale modeling predicts microbial vitamin requirements contribute to gut microbiome community structure. *Gut Microbes* 2022;14. <https://doi.org/10.1080/19490976.2022.2118831>.
- [93] Giordano N, Gaudin M, Trottier C, Delage E, Nef C, Bowler C, et al. Genome-scale community modelling reveals conserved metabolic cross-feedings in epipelagic

- bacterioplankton communities. *Nat Commun* 2024;15. <https://doi.org/10.1038/S41467-024-46374-W>.
- [94] Zimmermann J, Kaleta C, Waschina S. gapseq: informed prediction of bacterial metabolic pathways and reconstruction of accurate metabolic models. *Genome Biol* 2021;22. <https://doi.org/10.1186/S13059-021-02295-1>.
 - [95] Heinken A, Khan MT, Paglia G, Rodionov DA, Harmsen HJM, Thiele I. Functional metabolic map of *Faecalibacterium prausnitzii*, a beneficial human gut microbe. *J Bacteriol* 2014;196:3289–302. <https://doi.org/10.1128/JB.01780-14>.
 - [96] Chung CH, Lin DW, Eames A, Chandrasekaran S. Next-Generation Genome-Scale Metabolic Modeling through Integration of Regulatory Mechanisms. *Metabolites* 2021;11. <https://doi.org/10.3390/METABO11090606>.
 - [97] Arumugam M, Raes J, Pelletier E, Paslier D Le, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. *Nature* 2011;473:174–80. <https://doi.org/10.1038/NATURE09944>.
 - [98] Abreu NA, Taga ME. Decoding molecular interactions in microbial communities. *FEMS Microbiol Rev* 2016;40:648–63. <https://doi.org/10.1093/FEMSRE/FUW019>.
 - [99] Morris BEL, Henneberger R, Huber H, Moissl-Eichinger C. Microbial syntrophy: interaction for the common good. *FEMS Microbiol Rev* 2013;37:384–406. <https://doi.org/10.1111/1574-6976.12019>.
 - [100] Yen S, Johnson JS. Metagenomics: a path to understanding the gut microbiome. *Mamm Genome* 2021;32:282–96. <https://doi.org/10.1007/S00335-021-09889-X>.
 - [101] Sun S, Zhu X, Huang X, Murff HJ, Ness RM, Seidner DL, et al. On the robustness of inference of association with the gut microbiota in stool, rectal swab and mucosal tissue samples. *Sci Rep* 2021;11. <https://doi.org/10.1038/S41598-021-94205-5>.
 - [102] Zierer J, Jackson MA, Kastenmüller G, Mangino M, Long T, Telenti A, et al. The fecal metabolome as a functional readout of the gut microbiome. *Nat Genet* 2018;50:790–5. <https://doi.org/10.1038/S41588-018-0135-7>.
 - [103] Wang WL, Xu SY, Ren ZG, Tao L, Jiang JW, Zheng S Sen. Application of metagenomics in the human gut microbiome. *World J Gastroenterol* 2015;21:803–14. <https://doi.org/10.3748/WJG.V21.I3.803>.
 - [104] Hyatt D, Locascio PF, Hauser LJ, Uberbacher EC. Gene and translation initiation site prediction in metagenomic sequences. *Bioinformatics* 2012;28:2223–30. <https://doi.org/10.1093/BIOINFORMATICS/BTS429>.
 - [105] Li D, Liu CM, Luo R, Sadakane K, Lam TW. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. *Bioinformatics* 2015;31:1674–6. <https://doi.org/10.1093/BIOINFORMATICS/BTV033>.

- [106] Zhu W, Lomsadze A, Borodovsky M. Ab initio gene identification in metagenomic sequences. *Nucleic Acids Res* 2010;38. <https://doi.org/10.1093/NAR/GKQ275>.
- [107] Nurk S, Meleshko D, Korobeynikov A, Pevzner PA. MetaSPAdes: A new versatile metagenomic assembler. *Genome Res* 2017;27:824–34. <https://doi.org/10.1101/GR.213959.116/-/DC1>.
- [108] Malmstrom RR, Eloee-Fadrosh EA. Advancing Genome-Resolved Metagenomics beyond the Shotgun. *MSystems* 2019;4. <https://doi.org/10.1128/MSYSTEMS.00118-19>.
- [109] Rocha UI, Coelho Kasmanas J, Toscan R, Sanches DS, Magnusdottir S, Pedro Saraiva JI. Simulation of 69 microbial communities indicates sequencing depth and false positives are major drivers of bias in prokaryotic metagenome-assembled genome recovery. *PLoS Comput Biol* 2024;20:e1012530. <https://doi.org/10.1371/JOURNAL.PCBI.1012530>.
- [110] Ghurye JS, Cepeda-Espinoza V, Pop M. Metagenomic Assembly: Overview, Challenges and Applications. *Yale J Biol Med* 2016;89:353.
- [111] Ponsero AJ, Miller M, Hurwitz BL. Comparison of k-mer-based de novo comparative metagenomic tools and approaches. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.26>.
- [112] Das P, Babaei P, Nielsen J. Metagenomic analysis of microbe-mediated vitamin metabolism in the human gut microbiome. *BMC Genomics* 2019;20. <https://doi.org/10.1186/S12864-019-5591-7>.
- [113] Hessler T, Huddy RJ, Sachdeva R, Lei S, Harrison STL, Diamond S, et al. Vitamin interdependencies predicted by metagenomics-informed network analyses and validated in microbial community microcosms. *Nat Commun* 2023;14. <https://doi.org/10.1038/S41467-023-40360-4>.
- [114] Dash NR, Al Bataineh MT. Metagenomic Analysis of the Gut Microbiome Reveals Enrichment of Menaquinones (Vitamin K2) Pathway in Diabetes Mellitus. *Diabetes Metab J* 2021;45. <https://doi.org/10.4093/DMJ.2019.0202>.
- [115] Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. *Elife* 2021;10. <https://doi.org/10.7554/ELIFE.65088>.
- [116] Milani C, Lugli GA, Fontana F, Mancabelli L, Alessandri G, Longhi G, et al. METAnnotatorX2: a Comprehensive Tool for Deep and Shallow Metagenomic Data Set Analyses. *MSystems* 2021;6. <https://doi.org/10.1128/MSYSTEMS.00583-21>.
- [117] Keegan KP, Glass EM, Meyer F. MG-RAST, a Metagenomics Service for Analysis of Microbial Community Structure and Function. *Methods Mol Biol* 2016;1399:207–33. https://doi.org/10.1007/978-1-4939-3369-3_13.
- [118] Buchfink B, Xie C, Huson DH. Fast and sensitive protein alignment using DIAMOND. *Nat Methods* 2015;12:59–60. <https://doi.org/10.1038/NMETH.3176>.

- [119] Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 2012;9:357–9. <https://doi.org/10.1038/NMETH.1923>.
- [120] Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009;25:1754–60. <https://doi.org/10.1093/BIOINFORMATICS/BTP324>.
- [121] Sharon I, Bercovici S, Pinter RY, Shlomi T. Pathway-based functional analysis of metagenomes. *J Comput Biol* 2011;18:495–505. <https://doi.org/10.1089/CMB.2010.0260>.
- [122] The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. *Cell Host Microbe* 2014;16:276–89. <https://doi.org/10.1016/J.CHOM.2014.08.014>.
- [123] Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch S V., Knight R. Current understanding of the human microbiome. *Nat Med* 2018;24:392–400. <https://doi.org/10.1038/NM.4517>.
- [124] Tanaka T, Tateno Y, Gojobori T. Evolution of vitamin B6 (pyridoxine) metabolism by gain and loss of genes. *Mol Biol Evol* 2005;22:243–50. <https://doi.org/10.1093/MOLBEV/MSI011>.
- [125] Rodionov DA, Vitreschak AG, Mironov AA, Gelfand MS. Comparative genomics of thiamin biosynthesis in procaryotes. New genes and regulatory mechanisms. *J Biol Chem* 2002;277:48949–59. <https://doi.org/10.1074/JBC.M208965200>.
- [126] Vieira-Silva S, Falony G, Darzi Y, Lima-Mendez G, Garcia Yunta R, Okuda S, et al. Species-function relationships shape ecological properties of the human gut microbiome. *Nat Microbiol* 2016;1. <https://doi.org/10.1038/NMICROBIOL.2016.88>.
- [127] Chandel N, Somvanshi PR, Thakur V. Characterisation of Indian gut microbiome for B-vitamin production and its comparison with Chinese cohort. *Br J Nutr* 2024;131:686–97. <https://doi.org/10.1017/S0007114523002179>.
- [128] Loftus M, Hassounah SAD, Yooseph S. Bacterial associations in the healthy human gut microbiome across populations. *Sci Rep* 2021;11. <https://doi.org/10.1038/S41598-021-82449-0>.
- [129] Zengler K, Zaramela LS. The social network of microorganisms - how auxotrophies shape complex communities. *Nat Rev Microbiol* 2018;16:383–90. <https://doi.org/10.1038/S41579-018-0004-5>.
- [130] Guo B, Zhang L, Sun H, Gao M, Yu N, Zhang Q, et al. Microbial co-occurrence network topological properties link with reactor parameters and reveal importance of low-abundance genera. *NPJ Biofilms Microbiomes* 2022;8. <https://doi.org/10.1038/S41522-021-00263-Y>.
- [131] Faust K, Sathirapongsasuti JF, Izard J, Segata N, Gevers D, Raes J, et al. Microbial co-occurrence relationships in the human microbiome. *PLoS Comput Biol* 2012;8. <https://doi.org/10.1371/JOURNAL.PCBI.1002606>.

- [132] Jiang Q, Lin L, Xie F, Jin W, Zhu W, Wang M, et al. Metagenomic insights into the microbe-mediated B and K2 vitamin biosynthesis in the gastrointestinal microbiome of ruminants. *Microbiome* 2022;10. <https://doi.org/10.1186/S40168-022-01298-9>.
- [133] Tarracchini C, Lugli GA, Mancabelli L, Van Sinderen D, Turrone F, Ventura M, et al. Exploring the vitamin biosynthesis landscape of the human gut microbiota 2024. <https://doi.org/10.1128/MSYSTEMS.00929-24>.
- [134] Franzosa EA, Hsu T, Sirota-Madi A, Shafquat A, Abu-Ali G, Morgan XC, et al. Sequencing and beyond: integrating molecular “omics” for microbial community profiling. *Nat Rev Microbiol* 2015;13:360–72. <https://doi.org/10.1038/NRMICRO3451>.
- [135] Abu-Ali GS, Mehta RS, Lloyd-Price J, Mallick H, Branck T, Ivey KL, et al. Metatranscriptome of human faecal microbial communities in a cohort of adult men. *Nat Microbiol* 2018;3:356–66. <https://doi.org/10.1038/S41564-017-0084-4>.
- [136] Pereira-Marques J, Ferreira RM, Figueiredo C. A metatranscriptomics strategy for efficient characterization of the microbiome in human tissues with low microbial biomass. *Gut Microbes* 2024;16. <https://doi.org/10.1080/19490976.2024.2323235>.
- [137] Jiang Y, Xiong X, Danska J, Parkinson J. Metatranscriptomic analysis of diverse microbial communities reveals core metabolic pathways and microbiome-specific functionality. *Microbiome* 2016;4. <https://doi.org/10.1186/S40168-015-0146-X>.
- [138] Delogu F, Kunath BJ, Evans PN, Arntzen M, Hvidsten TR, Pope PB. Integration of absolute multi-omics reveals dynamic protein-to-RNA ratios and metabolic interplay within mixed-domain microbiomes. *Nat Commun* 2020;11. <https://doi.org/10.1038/S41467-020-18543-0>.
- [139] Long S, Yang Y, Shen C, Wang Y, Deng A, Qin Q, et al. Metaproteomics characterizes human gut microbiome function in colorectal cancer. *NPJ Biofilms Microbiomes* 2020;6. <https://doi.org/10.1038/S41522-020-0123-4>.
- [140] Germerodt S, Bohl K, Lück A, Pande S, Schröter A, Kaleta C, et al. Pervasive Selection for Cooperative Cross-Feeding in Bacterial Communities. *PLoS Comput Biol* 2016;12. <https://doi.org/10.1371/JOURNAL.PCBI.1004986>.
- [141] Mancabelli L, Milani C, De Biase R, Bocchio F, Fontana F, Lugli GA, et al. Taxonomic and metabolic development of the human gut microbiome across life stages: a worldwide metagenomic investigation. *MSystems* 2024. <https://doi.org/10.1128/MSYSTEMS.01294-23>.
- [142] Deo PN, Deshmukh R. Oral microbiome: Unveiling the fundamentals. *J Oral Maxillofac Pathol* 2019;23:122–8. https://doi.org/10.4103/JOMFP.JOMFP_304_18.
- [143] Nasidze I, Li J, Quinque D, Tang K, Stoneking M. Global diversity in the human salivary microbiome. *Genome Res* 2009;19:636–43. <https://doi.org/10.1101/GR.084616.108>.

- [144] Skowron K, Bauza-kaszewska J, Kraszewska Z, Wiktorczyk-kapischke N, Grudlewska-buda K, Kwiecińska-piróg J, et al. Human Skin Microbiome: Impact of Intrinsic and Extrinsic Factors on Skin Microbiota. *Microorganisms* 2021;9:1–20. <https://doi.org/10.3390/MICROORGANISMS9030543>.
- [145] Manzetti S, Zhang J, Van Der Spoel D. Thiamin function, metabolism, uptake, and transport. *Biochemistry* 2014;53:821–35. <https://doi.org/10.1021/BI401618Y>.
- [146] Nemeria NS, Chakraborty S, Balakrishnan A, Jordan F. Reaction mechanisms of thiamin diphosphate enzymes: defining states of ionization and tautomerization of the cofactor at individual steps. *FEBS J* 2009;276:2432–3446. <https://doi.org/10.1111/J.1742-4658.2009.06964.X>.
- [147] Lonsdale D. A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. *Evid Based Complement Alternat Med* 2006;3:49–59. <https://doi.org/10.1093/ECAM/NEK009>.
- [148] Du Q, Wang H, Xie J. Thiamin (vitamin B1) biosynthesis and regulation: a rich source of antimicrobial drug targets? *Int J Biol Sci* 2011;7:41–52. <https://doi.org/10.7150/IJBS.7.41>.
- [149] Park J, Hosomi K, Kawashima H, Chen YA, Mohsen A, Ohno H, et al. Dietary Vitamin B1 Intake Influences Gut Microbial Community and the Consequent Production of Short-Chain Fatty Acids. *Nutrients* 2022;14. <https://doi.org/10.3390/NU14102078>.
- [150] Gibson MI, Chen PYT, Drennan CL. A structural phylogeny for understanding 2-oxoacid oxidoreductase function. *Curr Opin Struct Biol* 2016;41:54–61. <https://doi.org/10.1016/J.SBI.2016.05.011>.
- [151] Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. *Nat Rev Microbiol* 2018;16:143–55. <https://doi.org/10.1038/NRMICRO.2017.157>.
- [152] Rindi G, Laforenza U. Thiamine intestinal transport and related issues: recent aspects. *Proc Soc Exp Biol Med* 2000;224:246–55. <https://doi.org/10.1046/J.1525-1373.2000.22428.X>.
- [153] Nabokina SM, Inoue K, Subramanian VS, Valle JE, Yuasa H, Said HM. Molecular identification and functional characterization of the human colonic thiamine pyrophosphate transporter. *J Biol Chem* 2014;289:4405–16. <https://doi.org/10.1074/JBC.M113.528257>.
- [154] Said HM, Ortiz A, Subramanian VS, Neufeld EJ, Moyer MP, Dudeja PK. Mechanism of thiamine uptake by human colonocytes: studies with cultured colonic epithelial cell line NCM460. *Am J Physiol Gastrointest Liver Physiol* 2001;281. <https://doi.org/10.1152/AJPGI.2001.281.1.G144>.
- [155] Nabokina SM, Said HM. A high-affinity and specific carrier-mediated mechanism for uptake of thiamine pyrophosphate by human colonic epithelial cells. *Am J Physiol Gastrointest Liver Physiol* 2012;303. <https://doi.org/10.1152/AJPGI.00151.2012>.

- [156] Averianova LA, Balabanova LA, Son OM, Podvolotskaya AB, Tekutyeva LA. Production of Vitamin B2 (Riboflavin) by Microorganisms: An Overview. *Front Bioeng Biotechnol* 2020;8. <https://doi.org/10.3389/FBIOE.2020.570828>.
- [157] Corbett AJ, Eckle SBG, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. *Nature* 2014;509:361–5. <https://doi.org/10.1038/NATURE13160>.
- [158] Rajamani S, Bauer WD, Robinson JB, Farrow JM, Pesci EC, Teplitski M, et al. The vitamin riboflavin and its derivative lumichrome activate the LasR bacterial quorum-sensing receptor. *Mol Plant Microbe Interact* 2008;21:1184–92. <https://doi.org/10.1094/MPMI-21-9-1184>.
- [159] García-Angulo VA. Overlapping riboflavin supply pathways in bacteria. *Crit Rev Microbiol* 2017;43:196–209. <https://doi.org/10.1080/1040841X.2016.1192578>.
- [160] Haase I, Gräwert T, Illarionov B, Bacher A, Fischer M. Recent advances in riboflavin biosynthesis. *Methods Mol Biol* 2014;1146:15–40. https://doi.org/10.1007/978-1-4939-0452-5_2.
- [161] Gutiérrez-Preciado A, Torres AG, Merino E, Bonomi HR, Goldbaum FA, García-Angulo VA. Extensive Identification of Bacterial Riboflavin Transporters and Their Distribution across Bacterial Species. *PLoS One* 2015;10. <https://doi.org/10.1371/JOURNAL.PONE.0126124>.
- [162] Mironov AS, Gusarov I, Rafikov R, Lopez LE, Shatalin K, Kreneva RA, et al. Sensing small molecules by nascent RNA: A mechanism to control transcription in bacteria. *Cell* 2002;111:747–56. [https://doi.org/10.1016/S0092-8674\(02\)01134-0](https://doi.org/10.1016/S0092-8674(02)01134-0).
- [163] Vitreschak AG, Rodionov DA, Mironov AA, Gelfand MS. Regulation of riboflavin biosynthesis and transport genes in bacteria by transcriptional and translational attenuation. *Nucleic Acids Res* 2002;30:3141–51. <https://doi.org/10.1093/NAR/GKF433>.
- [164] Vicens Q, Mondragón E, Batey RT. Molecular sensing by the aptamer domain of the FMN riboswitch: a general model for ligand binding by conformational selection. *Nucleic Acids Res* 2011;39:8586–98. <https://doi.org/10.1093/NAR/GKR565>.
- [165] Richter G, Ritz H, Katzenmeier G, Volk R, Kohnle A, Lottspeich F, et al. Biosynthesis of riboflavin: cloning, sequencing, mapping, and expression of the gene coding for GTP cyclohydrolase II in *Escherichia coli*. *J Bacteriol* 1993;175:4045–51. <https://doi.org/10.1128/JB.175.13.4045-4051.1993>.
- [166] Richter G, Volk R, Krieger C, Lahm HW, Rothlisberger U, Bacher A. Biosynthesis of riboflavin: cloning, sequencing, and expression of the gene coding for 3,4-dihydroxy-2-butanone 4-phosphate synthase of *Escherichia coli*. *J Bacteriol* 1992;174:4050–6. <https://doi.org/10.1128/JB.174.12.4050-4056.1992>.

- [167] Tolar JG, Li S, Ajo-Franklin CM. The Differing Roles of Flavins and Quinones in Extracellular Electron Transfer in *Lactiplantibacillus plantarum*. *Appl Environ Microbiol* 2023;89. <https://doi.org/10.1128/AEM.01313-22>.
- [168] Kirmiz N, Galindo K, Cross KL, Luna E, Rhoades N, Podar M, et al. Comparative Genomics Guides Elucidation of Vitamin B12 Biosynthesis in Novel Human-Associated *Akkermansia* Strains. *Appl Environ Microbiol* 2020;86. <https://doi.org/10.1128/AEM.02117-19>.
- [169] Koju N, Qin Z hong, Sheng R. Reduced nicotinamide adenine dinucleotide phosphate in redox balance and diseases: a friend or foe? *Acta Pharmacol Sin* 2022;43:1889–904. <https://doi.org/10.1038/S41401-021-00838-7>.
- [170] Makarov M V., Trammell SAJ, Migaud ME. The chemistry of the vitamin B3 metabolome. *Biochem Soc Trans* 2019;47:131–47. <https://doi.org/10.1042/BST20180420>.
- [171] Kurnasov O, Goral V, Colabroy K, Gerdes S, Anantha S, Osterman A, et al. NAD Biosynthesis: Identification of the Tryptophan to Quinolate Pathway in Bacteria. *Chem Biol* 2003;10:1195–204. <https://doi.org/10.1016/j.chembiol.2003.11.011>.
- [172] Begley TP, Kinsland C, Mehl RA, Osterman A, Dorrestein P. The biosynthesis of nicotinamide adenine dinucleotides in bacteria. *Vitam Horm* 2001;61:103–19. [https://doi.org/10.1016/S0083-6729\(01\)61003-3](https://doi.org/10.1016/S0083-6729(01)61003-3).
- [173] Leonardi R, Jackowski S. Biosynthesis of Pantothenic Acid and Coenzyme A. *EcoSal Plus* 2007;2. <https://doi.org/10.1128/ECOSALPLUS.3.6.3.4>.
- [174] Parra M, Stahl S, Hellmann H. Vitamin B₆ and Its Role in Cell Metabolism and Physiology. *Cells* 2018;7. <https://doi.org/10.3390/CELLS7070084>.
- [175] Tran JU, Brown BL. Structural Basis for Allostery in PLP-dependent Enzymes. *Front Mol Biosci* 2022;9. <https://doi.org/10.3389/FMOLB.2022.884281>.
- [176] Mooney S, Leuendorf JE, Hendrickson C, Hellmann H. Vitamin B₆: a long known compound of surprising complexity. *Molecules* 2009;14:329–51. <https://doi.org/10.3390/MOLECULES14010329>.
- [177] Denise R, Babor J, Gerlt JA, de Crécy-Lagard V. Pyridoxal 5'-phosphate synthesis and salvage in Bacteria and Archaea: predicting pathway variant distributions and holes. *Microb Genom* 2023;9. <https://doi.org/10.1099/MGEN.0.000926>.
- [178] Yang Y, Tsui HCT, Man TK, Winkler ME. Identification and function of the *pdxY* gene, which encodes a novel pyridoxal kinase involved in the salvage pathway of pyridoxal 5'-phosphate biosynthesis in *Escherichia coli* K-12. *J Bacteriol* 1998;180:1814–21. <https://doi.org/10.1128/JB.180.7.1814-1821.1998>.
- [179] Park JH, Burns K, Kinsland C, Begley TP. Characterization of two kinases involved in thiamine pyrophosphate and pyridoxal phosphate biosynthesis in *Bacillus subtilis*: 4-amino-

- 5-hydroxymethyl-2-methylpyrimidine kinase and pyridoxal kinase. *J Bacteriol* 2004;186:1571–3. <https://doi.org/10.1128/JB.186.5.1571-1573.2004>.
- [180] Said ZM, Subramanian VS, Vaziri ND, Said HM. Pyridoxine uptake by colonocytes: a specific and regulated carrier-mediated process. *Am J Physiol Cell Physiol* 2008;294. <https://doi.org/10.1152/AJPCELL.00015.2008>.
- [181] Said HM, Ortiz A, Ma TY. A carrier-mediated mechanism for pyridoxine uptake by human intestinal epithelial Caco-2 cells: regulation by a PKA-mediated pathway. *Am J Physiol Cell Physiol* 2003;285. <https://doi.org/10.1152/AJPCELL.00204.2003>.
- [182] Fonda ML. Purification and characterization of vitamin B6-phosphate phosphatase from human erythrocytes. *Journal of Biological Chemistry* 1992;267:15978–83. [https://doi.org/10.1016/S0021-9258\(19\)49630-0](https://doi.org/10.1016/S0021-9258(19)49630-0).
- [183] Dempsey E, Corr SC. *Lactobacillus* spp. for Gastrointestinal Health: Current and Future Perspectives. *Front Immunol* 2022;13. <https://doi.org/10.3389/FIMMU.2022.840245>.
- [184] Tong L. Structure and function of biotin-dependent carboxylases. *Cell Mol Life Sci* 2013;70:863–91. <https://doi.org/10.1007/S00018-012-1096-0>.
- [185] Sirithanakorn C, Cronan JE. Biotin, a universal and essential cofactor: synthesis, ligation and regulation. *FEMS Microbiol Rev* 2021;45. <https://doi.org/10.1093/FEMSRE/FUAB003>.
- [186] Lin S, Hanson RE, Cronan JE. Biotin synthesis begins by hijacking the fatty acid synthetic pathway. *Nat Chem Biol* 2010;6:682–8. <https://doi.org/10.1038/NCHEMBIO.420>.
- [187] Wei W, Guan H, Zhu T, Zhang S, Fan C, Ouyang S, et al. Molecular Basis of BioJ, a Unique Gatekeeper in Bacterial Biotin Synthesis. *IScience* 2019;19:796–808. <https://doi.org/10.1016/J.ISCI.2019.08.028>.
- [188] Shapiro MM, Chakravartty V, Cronan JE. Remarkable diversity in the enzymes catalyzing the last step in synthesis of the pimelate moiety of biotin. *PLoS One* 2012;7. <https://doi.org/10.1371/JOURNAL.PONE.0049440>.
- [189] Estrada P, Manandhar M, Dong SH, Deveryshetty J, Agarwal V, Cronan JE, et al. The pimeloyl-CoA synthetase BioW defines a new fold for adenylate-forming enzymes. *Nat Chem Biol* 2017;13:668–74. <https://doi.org/10.1038/NCHEMBIO.2359>.
- [190] Manandhar M, Cronan JE. Pimelic acid, the first precursor of the *Bacillus subtilis* biotin synthesis pathway, exists as the free acid and is assembled by fatty acid synthesis. *Mol Microbiol* 2017;104:595–607. <https://doi.org/10.1111/MMI.13648>.
- [191] Zempleni J, Wijeratne SSK, Hassan YI. Biotin. *Biofactors* 2009;35:36–46. <https://doi.org/10.1002/BIOF.8>.

- [192] Cronan JE. Biotin protein ligase as you like it: Either extraordinarily specific or promiscuous protein biotinylation. *Proteins* 2024;92:435–48. <https://doi.org/10.1002/PROT.26642>.
- [193] Sugahara H, Odamaki T, Fukuda S, Kato T, Xiao JZ, Abe F, et al. Probiotic *Bifidobacterium longum* alters gut luminal metabolism through modification of the gut microbial community. *Sci Rep* 2015;5. <https://doi.org/10.1038/SREP13548>.
- [194] Shulpekova Y, Nechaev V, Kardasheva S, Sedova A, Kurbatova A, Bueverova E, et al. The Concept of Folic Acid in Health and Disease. *Molecules* 2021;26. <https://doi.org/10.3390/MOLECULES26123731>.
- [195] Tjong E, Dimri M, Mohiuddin SS. Biochemistry, Tetrahydrofolate. *StatPearls* 2023.
- [196] Rossi M, Amaretti A, Raimondi S. Folate production by probiotic bacteria. *Nutrients* 2011;3:118–34. <https://doi.org/10.3390/NU3010118>.
- [197] D'aimmo MR, Satti M, Scarafile D, Modesto M, Pascarelli S, Biagini SA, et al. Folate-producing bifidobacteria: metabolism, genetics, and relevance. *Microbiome Research Reports* 2023;3. <https://doi.org/10.20517/MRR.2023.59>.
- [198] Sugahara H, Odamaki T, Hashikura N, Abe F, Xiao JZ. Differences in folate production by bifidobacteria of different origins. *Biosci Microbiota Food Health* 2015;34:87–93. <https://doi.org/10.12938/BMFH.2015-003>.
- [199] Pompei A, Cordisco L, Amaretti A, Zanoni S, Matteuzzi D, Rossi M. Folate production by bifidobacteria as a potential probiotic property. *Appl Environ Microbiol* 2007;73:179–85. <https://doi.org/10.1128/AEM.01763-06>.
- [200] Zhao R, Diop-Bove N, Visentin M, Goldman ID. Mechanisms of membrane transport of folates into cells and across epithelia. *Annu Rev Nutr* 2011;31:177–201. <https://doi.org/10.1146/ANNUREV-NUTR-072610-145133>.
- [201] Osman D, Cooke A, Young TR, Deery E, Robinson NJ, Warren MJ. The requirement for cobalt in vitamin B12: A paradigm for protein metalation. *Biochim Biophys Acta Mol Cell Res* 2021;1868:118896. <https://doi.org/10.1016/J.BBAMCR.2020.118896>.
- [202] Kundra P, Rachmühl C, Lacroix C, Geirnaert A. Role of Dietary Micronutrients on Gut Microbial Dysbiosis and Modulation in Inflammatory Bowel Disease. *Mol Nutr Food Res* 2021;65:1901271. <https://doi.org/10.1002/MNFR.201901271>.
- [203] Ragsdale SW, Pierce E. Acetogenesis and the Wood-Ljungdahl pathway of CO(2) fixation. *Biochim Biophys Acta* 2008;1784:1873–98. <https://doi.org/10.1016/J.BBAPAP.2008.08.012>.
- [204] Men Y, Seth EC, Yi S, Crofts TS, Allen RH, Taga ME, et al. Identification of specific corrinoids reveals corrinoid modification in dechlorinating microbial communities. *Environ Microbiol* 2015;17:4873–84. <https://doi.org/10.1111/1462-2920.12500>.

- [205] Warren MJ, Raux E, Schubert HL, Escalante-Semerena JC. The biosynthesis of adenosylcobalamin (vitamin B12). *Nat Prod Rep* 2002;19:390–412. <https://doi.org/10.1039/B108967F>.
- [206] Lawrence JG, Roth JR. The cobalamin (coenzyme B12) biosynthetic genes of *Escherichia coli*. *J Bacteriol* 1995;177:6371–80. <https://doi.org/10.1128/JB.177.22.6371-6380.1995>.
- [207] Chimento DP, Mohanty AK, Kadner RJ, Wiener MC. Substrate-induced transmembrane signaling in the cobalamin transporter BtuB. *Nat Struct Biol* 2003;10:394–401. <https://doi.org/10.1038/NSB914>.
- [208] Hiratsuka T, Furihata K, Ishikawa J, Yamashita H, Itoh N, Seto H, et al. An alternative menaquinone biosynthetic pathway operating in microorganisms. *Science* 2008;321:1670–3. <https://doi.org/10.1126/SCIENCE.1160446>.
- [209] Walther B, Philip Karl J, Booth SL, Boyaval P. Menaquinones, bacteria, and the food supply: the relevance of dairy and fermented food products to vitamin K requirements. *Adv Nutr* 2013;4:463–73. <https://doi.org/10.3945/AN.113.003855>.
- [210] Kurosu M, Begari E. Vitamin K2 in Electron Transport System: Are Enzymes Involved in Vitamin K2 Biosynthesis Promising Drug Targets? *Molecules* 2010;15:1531. <https://doi.org/10.3390/MOLECULES15031531>.
- [211] Kurosu M, Begari E. Vitamin K2 in electron transport system: are enzymes involved in vitamin K2 biosynthesis promising drug targets? *Molecules* 2010;15:1531–53. <https://doi.org/10.3390/MOLECULES15031531>.
- [212] Bonaldo F, Leroy F. Review: Bacterially produced vitamin K2 and its potential to generate health benefits in humans. *Trends Food Sci Technol* 2024;147:104461. <https://doi.org/10.1016/J.TIFS.2024.104461>.
- [213] Simes DC, Viegas CSB, Araújo N, Marreiros C. Vitamin K as a Diet Supplement with Impact in Human Health: Current Evidence in Age-Related Diseases. *Nutrients* 2020;12. <https://doi.org/10.3390/NU12010138>.
- [214] Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nature Reviews Microbiology* 2020 19:1 2020;19:55–71. <https://doi.org/10.1038/s41579-020-0433-9>.
- [215] Mohajeri MH, Brummer RJM, Rastall RA, Weersma RK, Harmsen HJM, Faas M, et al. The role of the microbiome for human health: from basic science to clinical applications. *Eur J Nutr* 2018;57:1–14. <https://doi.org/10.1007/S00394-018-1703-4>.
- [216] Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, et al. Human gut microbiota in health and disease: Unveiling the relationship. *Front Microbiol* 2022;13:999001. <https://doi.org/10.3389/FMICB.2022.999001/BIBTEX>.
- [217] Koren O, Knights D, Gonzalez A, Waldron L, Segata N, Knight R, et al. A guide to enterotypes across the human body: meta-analysis of microbial community structures in

- human microbiome datasets. *PLoS Comput Biol* 2013;9. <https://doi.org/10.1371/JOURNAL.PCBI.1002863>.
- [218] Gibson TE, Bashan A, Cao HT, Weiss ST, Liu YY. On the Origins and Control of Community Types in the Human Microbiome. *PLoS Comput Biol* 2016;12. <https://doi.org/10.1371/JOURNAL.PCBI.1004688>.
- [219] Jeffery IB, Claesson MJ, O'Toole PW, Shanahan F. Categorization of the gut microbiota: enterotypes or gradients? *Nat Rev Microbiol* 2012;10:591–2. <https://doi.org/10.1038/NRMICRO2859>.
- [220] Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, et al. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* 2011;108:4680–7. <https://doi.org/10.1073/PNAS.1002611107/-/DCSUPPLEMENTAL/PNAS.201002611SI.PDF>.
- [221] Gajer P, Brotman RM, Bai G, Sakamoto J, Schütte UME, Zhong X, et al. Temporal dynamics of the human vaginal microbiota. *Sci Transl Med* 2012;4. <https://doi.org/10.1126/SCITRANSLMED.3003605>.
- [222] Mancabelli L, Tarracchini C, Milani C, Lugli GA, Fontana F, Turrone F, et al. Vaginotypes of the human vaginal microbiome. *Environ Microbiol* 2021;23:1780–92. <https://doi.org/10.1111/1462-2920.15441>.
- [223] Hildebrand F, Nguyen TLA, Brinkman B, Yunta RG, Cauwe B, Vandenabeele P, et al. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. *Genome Biol* 2013;14. <https://doi.org/10.1186/GB-2013-14-1-R4>.
- [224] Moeller AH, Degnan PH, Pusey AE, Wilson ML, Hahn BH, Ochman H. Chimpanzees and humans harbour compositionally similar gut enterotypes. *Nat Commun* 2012;3. <https://doi.org/10.1038/NCOMMS2159>.
- [225] Li J, Powell JE, Guo J, Evans JD, Wu J, Williams P, et al. Two gut community enterotypes recur in diverse bumblebee species. *Curr Biol* 2015;25:R652–3. <https://doi.org/10.1016/J.CUB.2015.06.031>.
- [226] Mach N, Berri M, Estellé J, Levenez F, Lemonnier G, Denis C, et al. Early-life establishment of the swine gut microbiome and impact on host phenotypes. *Environ Microbiol Rep* 2015;7:554–69. <https://doi.org/10.1111/1758-2229.12285>.
- [227] Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science* 2011;334:105–8. <https://doi.org/10.1126/SCIENCE.1208344>.
- [228] Costea PI, Hildebrand F, Manimozhiyan A, Bäckhed F, Blaser MJ, Bushman FD, et al. Enterotypes in the landscape of gut microbial community composition. *Nature Microbiology* 2017 3:1 2017;3:8–16. <https://doi.org/10.1038/s41564-017-0072-8>.

- [229] Zhou Y, Mihindukulasuriya KA, Gao H, La Rosa PS, Wylie KM, Martin JC, et al. Exploration of bacterial community classes in major human habitats. *Genome Biol* 2014;15:R66. <https://doi.org/10.1186/GB-2014-15-5-R66>.
- [230] Karlsson FH, Nookaew I, Nielsen J. Metagenomic data utilization and analysis (MEDUSA) and construction of a global gut microbial gene catalogue. *PLoS Comput Biol* 2014;10. <https://doi.org/10.1371/JOURNAL.PCBI.1003706>.
- [231] Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. *Science* 2016;352:560–4. <https://doi.org/10.1126/SCIENCE.AAD3503>.
- [232] Zupancic ML, Cantarel BL, Liu Z, Drabek EF, Ryan KA, Cirimotich S, et al. Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome. *PLoS One* 2012;7. <https://doi.org/10.1371/JOURNAL.PONE.0043052>.
- [233] Claesson MJ, Jeffery IB, Conde S, Power SE, O’connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. *Nature* 2012;488:178–84. <https://doi.org/10.1038/NATURE11319>.
- [234] Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. *Front Microbiol* 2016;7. <https://doi.org/10.3389/FMICB.2016.00979>.
- [235] O’Neill I, Schofield Z, Hall LJ. Exploring the role of the microbiota member Bifidobacterium in modulating immune-linked diseases. *Emerg Top Life Sci* 2017;1:333–49. <https://doi.org/10.1042/ETLS20170058>.
- [236] Procaccianti G, Roggiani S, Conti G, Brigidi P, Turrone S, D’amico F. Bifidobacterium in anticancer immunochemotherapy: friend or foe? *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.23>.
- [237] Gutierrez A, Pucket B, Engevik MA. Bifidobacterium and the intestinal mucus layer. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.37>.
- [238] Tarracchini C, Milani C, Lugli GA, Mancabelli L, Turrone F, van Sinderen D, et al. The infant gut microbiota as the cornerstone for future gastrointestinal health. *Adv Appl Microbiol* 2024;126:93–119. <https://doi.org/10.1016/BS.AAMBS.2024.02.001>.
- [239] Sharma D, Gajjar D, Seshadri S. Understanding the role of gut microfloral bifidobacterium in cancer and its potential therapeutic applications. *Microbiome Research Reports* 2023;3. <https://doi.org/10.20517/MRR.2023.51>.
- [240] Hidalgo-Cantabrana C, Delgado S, Ruiz L, Ruas-Madiedo P, Sánchez B, Margolles A. Bifidobacteria and Their Health-Promoting Effects. *Microbiol Spectr* 2017;5. <https://doi.org/10.1128/MICROBIOLSPEC.BAD-0010-2016>.

- [241] Martin AJM, Serebrinsky-Duek K, Riquelme E, Saa PA, Garrido D. Microbial interactions and the homeostasis of the gut microbiome: the role of *Bifidobacterium*. *Microbiome Research Reports* 2023;2:null-null. <https://doi.org/10.20517/MRR.2023.10>.
- [242] Chen J, Chen X, Ho CL. Recent Development of Probiotic *Bifidobacteria* for Treating Human Diseases. *Front Bioeng Biotechnol* 2021;9. <https://doi.org/10.3389/FBIOE.2021.770248>.
- [243] Avershina E, Storrø O, Øien T, Johnsen R, Wilson R, Egeland T, et al. *Bifidobacterial* succession and correlation networks in a large unselected cohort of mothers and their children. *Appl Environ Microbiol* 2013;79:497–507. <https://doi.org/10.1128/AEM.02359-12>.
- [244] Casaburi G, Duar RM, Brown H, Mitchell RD, Kazi S, Chew S, et al. Metagenomic insights of the infant microbiome community structure and function across multiple sites in the United States. *Sci Rep* 2021;11. <https://doi.org/10.1038/S41598-020-80583-9>.
- [245] Odamaki T, Bottacini F, Kato K, Mitsuyama E, Yoshida K, Horigome A, et al. Genomic diversity and distribution of *Bifidobacterium longum* subsp. *longum* across the human lifespan. *Sci Rep* 2018;8. <https://doi.org/10.1038/S41598-017-18391-X>.
- [246] Ladeira R, Tap J, Derrien M. Exploring *Bifidobacterium* species community and functional variations with human gut microbiome structure and health beyond infancy. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.01>.
- [247] Schöpping M, Gaspar P, Neves AR, Franzén CJ, Zeidan AA. Identifying the essential nutritional requirements of the probiotic bacteria *Bifidobacterium animalis* and *Bifidobacterium longum* through genome-scale modeling. *NPJ Syst Biol Appl* 2021;7. <https://doi.org/10.1038/S41540-021-00207-4>.
- [248] Pompei A, Cordisco L, Amaretti A, Zanoni S, Raimondi S, Matteuzzi D, et al. Administration of folate-producing bifidobacteria enhances folate status in Wistar rats. *J Nutr* 2007;137:2742–6. <https://doi.org/10.1093/JN/137.12.2742>.
- [249] Strozzi GP, Mogna L. Quantification of folic acid in human feces after administration of *Bifidobacterium* probiotic strains. *J Clin Gastroenterol* 2008;42 Suppl 3 Pt 2. <https://doi.org/10.1097/MCG.0B013E31818087D8>.
- [250] Milani C, Duranti S, Napoli S, Alessandri G, Mancabelli L, Anzalone R, et al. Colonization of the human gut by bovine bacteria present in Parmesan cheese. *Nat Commun* 2019;10. <https://doi.org/10.1038/S41467-019-09303-W>.
- [251] Fontana F, Longhi G, Carli E, Alessandri G, Mancabelli L, Lugli GA, et al. Revealing the genetic traits of the foodborne microbial genus *hafnia*: Implications for the human gut microbiome. *Environ Microbiol* 2024;26. <https://doi.org/10.1111/1462-2920.16626>.

- [252] Vélez MP, De Keersmaecker SCJ, Vanderleyden J. Adherence factors of *Lactobacillus* in the human gastrointestinal tract. *FEMS Microbiol Lett* 2007;276:140–8. <https://doi.org/10.1111/J.1574-6968.2007.00908.X>.
- [253] Nistal E, Caminero A, Herrán AR, Pérez-Andres J, Vivas S, Ruiz de Morales JM, et al. Study of duodenal bacterial communities by 16S rRNA gene analysis in adults with active celiac disease vs non-celiac disease controls. *J Appl Microbiol* 2016;120:1691–700. <https://doi.org/10.1111/JAM.13111>.
- [254] Wegkamp A, Teusink B, De Vos WM, Smid EJ. Development of a minimal growth medium for *Lactobacillus plantarum*. *Lett Appl Microbiol* 2010;50:57–64. <https://doi.org/10.1111/J.1472-765X.2009.02752.X>.
- [255] Albert AYK, Chaban B, Wagner EC, Schellenberg JJ, Links MG, Van Schalkwyk J, et al. A Study of the Vaginal Microbiome in Healthy Canadian Women Utilizing cpn60-Based Molecular Profiling Reveals Distinct *Gardnerella* Subgroup Community State Types. *PLoS One* 2015;10. <https://doi.org/10.1371/JOURNAL.PONE.0135620>.
- [256] Ma Z (Sam), Li L. Quantifying the human vaginal community state types (CSTs) with the species specificity index. *PeerJ* 2017;5:e3366. <https://doi.org/10.7717/PEERJ.3366>.
- [257] France M, Alizadeh M, Brown S, Ma B, Ravel J. Towards a deeper understanding of the vaginal microbiota. *Nat Microbiol* 2022;7:367–78. <https://doi.org/10.1038/S41564-022-01083-2>.
- [258] France MT, Ma B, Gajer P, Brown S, Humphrys MS, Holm JB, et al. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. *Microbiome* 2020;8. <https://doi.org/10.1186/S40168-020-00934-6>.
- [259] Dricot CEMK, Erreygers I, Cauwenberghs E, De Paz J, Spacova I, Verhoeven V, et al. Riboflavin for women's health and emerging microbiome strategies. *Npj Biofilms and Microbiomes* 2024 10:1 2024;10:1–14. <https://doi.org/10.1038/s41522-024-00579-5>.
- [260] Stahler F. The effect of lactoflavin, vitamin B2, on the biology of the vagina. 1940.
- [261] Brotman RM, Ravel J, Cone RA, Zenilman JM. Rapid fluctuation of the vaginal microbiota measured by Gram stain analysis. *Sex Transm Infect* 2010;86:297–302. <https://doi.org/10.1136/STI.2009.040592>.
- [262] Srinivasan S, Liu C, Mitchell CM, Fiedler TL, Thomas KK, Agnew KJ, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. *PLoS One* 2010;5. <https://doi.org/10.1371/JOURNAL.PONE.0010197>.
- [263] Archer D, Perez-Muñoz ME, Tollenaar S, Veniamin S, Cheng CC, Richard C, et al. The importance of the timing of microbial signals for perinatal immune system development. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.03>.
- [264] Mancabelli L, Milani C, Fontana F, Liotto N, Tabasso C, Perrone M, et al. A pilot study to disentangle the infant gut microbiota composition and identification of bacteria correlates

- with high fat mass. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.11>.
- [265] Wernroth ML, Peura S, Hedman AM, Hetty S, Vicenzi S, Kennedy B, et al. Development of gut microbiota during the first 2 years of life. *Sci Rep* 2022;12. <https://doi.org/10.1038/S41598-022-13009-3>.
 - [266] Al KF, Allen L, Bedell S, Burton JP, de Vrijer B. Assessing the impact of pregnancy and birth factors on the maternal and infant microbiota. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.32>.
 - [267] Lordan C, Roche AK, Delsing D, Nauta A, Groeneveld A, MacSharry J, et al. Linking human milk oligosaccharide metabolism and early life gut microbiota: bifidobacteria and beyond. *Microbiol Mol Biol Rev* 2024;88. <https://doi.org/10.1128/MMBR.00094-23>.
 - [268] Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. *Pediatr Clin North Am* 2013;60:49–74. <https://doi.org/10.1016/J.PCL.2012.10.002>.
 - [269] Murakami R, Yoshida K, Sakanaka M, Urashima T, Xiao JZ, Katayama T, et al. Preferential sugar utilization by bifidobacterial species. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.19>.
 - [270] Bode L. Human milk oligosaccharides: every baby needs a sugar mama. *Glycobiology* 2012;22:1147–62. <https://doi.org/10.1093/GLYCOB/CWS074>.
 - [271] Dror DK, Allen LH. Overview of Nutrients in Human Milk. *Adv Nutr* 2018;9:278S-294S. <https://doi.org/10.1093/ADVANCES/NMY022>.
 - [272] Cortes-Macías E, Selma-Royo M, García-Mantrana I, Calatayud M, González S, Martínez-Costa C, et al. Maternal Diet Shapes the Breast Milk Microbiota Composition and Diversity: Impact of Mode of Delivery and Antibiotic Exposure. *J Nutr* 2021;151:330–40. <https://doi.org/10.1093/JN/NXAA310>.
 - [273] Chong HY, Tan LTH, Law JWF, Hong KW, Ratnasingam V, Ab Mutalib NS, et al. Exploring the Potential of Human Milk and Formula Milk on Infants' Gut and Health. *Nutrients* 2022;14. <https://doi.org/10.3390/NU14173554>.
 - [274] Oddi S, Mantziari A, Huber P, Binetti A, Salminen S, Collado MC, et al. Human Milk Microbiota Profile Affected by Prematurity in Argentinian Lactating Women. *Microorganisms* 2023;11. <https://doi.org/10.3390/MICROORGANISMS11041090>.
 - [275] Martín V, Maldonado-Barragán A, Moles L, Rodríguez-Baños M, Campo R Del, Fernández L, et al. Sharing of bacterial strains between breast milk and infant feces. *J Hum Lact* 2012;28:36–44. <https://doi.org/10.1177/0890334411424729>.
 - [276] Selma-Royo M, Dubois L, Manara S, Armanini F, Cabrera-Rubio R, Valles-Colomer M, et al. Birthmode and environment-dependent microbiota transmission dynamics are complemented by breastfeeding during the first year. *Cell Host Microbe* 2024;32:996-1010.e4. <https://doi.org/10.1016/J.CHOM.2024.05.005>.

- [277] Moore RL, Feehily C, Killeen SL, Yelverton CA, Geraghty AA, Walsh CJ, et al. Ability of *Bifidobacterium breve* 702258 to transfer from mother to infant: the MicrobeMom randomized controlled trial. *Am J Obstet Gynecol MFM* 2023;5:100994. <https://doi.org/10.1016/J.AJOGMF.2023.100994>.
- [278] Feehily C, O'Neill IJ, Walsh CJ, Moore RL, Killeen SL, Geraghty AA, et al. Detailed mapping of *Bifidobacterium* strain transmission from mother to infant via a dual culture-based and metagenomic approach. *Nat Commun* 2023;14. <https://doi.org/10.1038/S41467-023-38694-0>.
- [279] Tarracchini C, Alessandri G, Fontana F, Rizzo SM, Lugli GA, Bianchi MG, et al. Genetic strategies for sex-biased persistence of gut microbes across human life. *Nat Commun* 2023;14. <https://doi.org/10.1038/S41467-023-39931-2>.
- [280] Yassour M, Jason E, Hogstrom LJ, Arthur TD, Tripathi S, Siljander H, et al. Strain-Level Analysis of Mother-to-Child Bacterial Transmission during the First Few Months of Life. *Cell Host Microbe* 2018;24:146-154.e4. <https://doi.org/10.1016/J.CHOM.2018.06.007>.
- [281] Marcobal A, Barboza M, Froehlich JW, Block DE, German JB, Lebrilla CB, et al. Consumption of human milk oligosaccharides by gut-related microbes. *J Agric Food Chem* 2010;58:5334–40. <https://doi.org/10.1021/JF9044205>.
- [282] Tarracchini C, Milani C, Lugli GA, Mancabelli L, Fontana F, Alessandri G, et al. Phylogenomic disentangling of the *bifidobacterium longum* subsp. *infantis* taxon. *Microb Genom* 2021;7. <https://doi.org/10.1099/MGEN.0.000609>.
- [283] Seki D, Errerd T, Hall LJ. The role of human milk fats in shaping neonatal development and the early life gut microbiota. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.09>.
- [284] Sela DA, Mills DA. Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. *Trends Microbiol* 2010;18:298–307. <https://doi.org/10.1016/J.TIM.2010.03.008>.
- [285] Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao JZ, et al. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. *BMC Microbiol* 2016;16. <https://doi.org/10.1186/S12866-016-0708-5>.
- [286] Pedroza Matute S, Iyavoo S. Exploring the gut microbiota: lifestyle choices, disease associations, and personal genomics. *Front Nutr* 2023;10. <https://doi.org/10.3389/FNUT.2023.1225120>.
- [287] Hrnecir T. Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options. *Microorganisms* 2022;10. <https://doi.org/10.3390/MICROORGANISMS10030578>.

- [288] David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 2014;505:559–63. <https://doi.org/10.1038/NATURE12820>.
- [289] De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc Natl Acad Sci U S A* 2010;107:14691–6. <https://doi.org/10.1073/PNAS.1005963107>.
- [290] Pellanda P, Ghosh TS, O'Toole PW. Understanding the impact of age-related changes in the gut microbiome on chronic diseases and the prospect of elderly-specific dietary interventions. *Curr Opin Biotechnol* 2021;70:48–55. <https://doi.org/10.1016/J.COPBIO.2020.11.001>.
- [291] Ticinesi A, Nouvenne A, Cerundolo N, Catania P, Prati B, Tana C, et al. Gut Microbiota, Muscle Mass and Function in Aging: A Focus on Physical Frailty and Sarcopenia. *Nutrients* 2019;11. <https://doi.org/10.3390/NU11071633>.
- [292] Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe* 2015;17:690–703. <https://doi.org/10.1016/j.chom.2015.04.004>.
- [293] Vacca M, Raspini B, Calabrese FM, Porri D, De Giuseppe R, Chieppa M, et al. The establishment of the gut microbiota in 1-year-aged infants: from birth to family food. *Eur J Nutr* 2022;61:2517–30. <https://doi.org/10.1007/S00394-022-02822-1>.
- [294] Leblanc JG, Laiño JE, del Valle MJ, Vannini V, van Sinderen D, Taranto MP, et al. B-group vitamin production by lactic acid bacteria--current knowledge and potential applications. *J Appl Microbiol* 2011;111:1297–309. <https://doi.org/10.1111/J.1365-2672.2011.05157.X>.
- [295] Oliphant K, Cruz Ayala W, Ilyumzhinova R, Mbayiwa K, Sroka A, Xie B, et al. Microbiome function and neurodevelopment in Black infants: vitamin B12 emerges as a key factor. *Gut Microbes* 2024;16. <https://doi.org/10.1080/19490976.2023.2298697>.
- [296] Nyangahu DD, Happel AU, Wendoh J, Kiravu A, Wang Y, Feng C, et al. Bifidobacterium infantis associates with T cell immunity in human infants and is sufficient to enhance antigen-specific T cells in mice. *Sci Adv* 2023;9. <https://doi.org/10.1126/SCIADV.ADE1370>.
- [297] Turrone F, Peano C, Pass DA, Foroni E, Severgnini M, Claesson MJ, et al. Diversity of bifidobacteria within the infant gut microbiota. *PLoS One* 2012;7. <https://doi.org/10.1371/JOURNAL.PONE.0036957>.
- [298] Woo V, Eshleman EM, Hashimoto-Hill S, Whitt J, Wu S en, Engleman L, et al. Commensal segmented filamentous bacteria-derived retinoic acid primes host defense to intestinal infection. *Cell Host Microbe* 2021;29:1744-1756.e5. <https://doi.org/10.1016/J.CHOM.2021.09.010>.

- [299] Peake JN, Copp AJ, Shawe J. Knowledge and periconceptional use of folic acid for the prevention of neural tube defects in ethnic communities in the United Kingdom: systematic review and meta-analysis. *Birth Defects Res A Clin Mol Teratol* 2013;97:444–51. <https://doi.org/10.1002/BDRA.23154>.
- [300] Obeid R, Warnke I, Bendik I, Troesch B, Schoop R, Chenal E, et al. Infants' Folate Markers and Postnatal Growth in the First 4 Months of Life in Relation to Breastmilk and Maternal Plasma Folate. *Nutrients* 2023;15. <https://doi.org/10.3390/NU15061495>.
- [301] Worthington-White DA, Behnke M, Gross S. Premature infants require additional folate and vitamin B-12 to reduce the severity of the anemia of prematurity. *Am J Clin Nutr* 1994;60:930–5. <https://doi.org/10.1093/AJCN/60.6.930>.
- [302] D'Aimmo MR, Mattarelli P, Biavati B, Carlsson NG, Andlid T. The potential of bifidobacteria as a source of natural folate. *J Appl Microbiol* 2012;112:975–84. <https://doi.org/10.1111/J.1365-2672.2012.05261.X>.
- [303] Biol-Aquino MA, Perdiz CJ, Borlagdan M, Alcantara JD, Mallillin A. Differences in the bacterial profiles of infant gut by birth process, milk diet, and choice of 16S rRNA gene target region. *Hum Microb J* 2019;13:100062. <https://doi.org/10.1016/J.HUMIC.2019.100062>.
- [304] Yatsunencko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. *Nature* 2012;486:222–7. <https://doi.org/10.1038/NATURE11053>.
- [305] Roswall J, Olsson LM, Kovatcheva-Datchary P, Nilsson S, Tremaroli V, Simon MC, et al. Developmental trajectory of the healthy human gut microbiota during the first 5 years of life. *Cell Host Microbe* 2021;29:765-776.e3. <https://doi.org/10.1016/J.CHOM.2021.02.021>.
- [306] Wan Z, Zheng J, Zhu Z, Sang L, Zhu J, Luo S, et al. Intermediate role of gut microbiota in vitamin B nutrition and its influences on human health. *Front Nutr* 2022;9. <https://doi.org/10.3389/FNUT.2022.1031502>.
- [307] Schauer K, Stolz J, Scherer S, Fuchs TM. Both thiamine uptake and biosynthesis of thiamine precursors are required for intracellular replication of *Listeria monocytogenes*. *J Bacteriol* 2009;191:2218–27. <https://doi.org/10.1128/JB.01636-08>.
- [308] Gude S, Pherribo GJ, Taga ME. Emergence of Metabolite Provisioning as a By-Product of Evolved Biological Functions. *MSystems* 2020;5. <https://doi.org/10.1128/MSYSTEMS.00259-20>.
- [309] Leylabadlo HE, Ghotaslou R, Feizabadi MM, Farajnia S, Moaddab SY, Ganbarov K, et al. The critical role of *Faecalibacterium prausnitzii* in human health: An overview. *Microb Pathog* 2020;149. <https://doi.org/10.1016/J.MICPATH.2020.104344>.

- [310] Kundra P, Geirnaert A, Pugin B, Plüss S, Kariluoto S, Lacroix C, et al. Microbially-produced folate forms support the growth of *Roseburia intestinalis* but not its competitive fitness in fecal batch fermentations. *BMC Microbiol* 2024;24:366. <https://doi.org/10.1186/S12866-024-03528-6>.
- [311] Fallani M, Amarri S, Uusijarvi A, Adam R, Khanna S, Aguilera M, et al. Determinants of the human infant intestinal microbiota after the introduction of first complementary foods in infant samples from five European centres. *Microbiology (N Y)* 2011;157:1385–92. <https://doi.org/10.1099/mic.0.042143-0>.
- [312] McKeen S, Roy NC, Mullaney JA, Eriksen H, Lovell A, Kussman M, et al. Adaptation of the infant gut microbiome during the complementary feeding transition. *PLoS One* 2022;17. <https://doi.org/10.1371/JOURNAL.PONE.0270213>.
- [313] Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature* 2018;562:589–94. <https://doi.org/10.1038/S41586-018-0620-2>.
- [314] Sokolovskaya OM, Shelton AN, Taga ME. Sharing vitamins: Cobamides unveil microbial interactions. *Science* 2020;369. <https://doi.org/10.1126/SCIENCE.ABA0165>.
- [315] Hochuli N, Kadyan S, Park G, Patoine C, Nagpal R. Pathways linking microbiota-gut-brain axis with neuroinflammatory mechanisms in Alzheimer’s pathophysiology. *Microbiome Research Reports* 2023;3. <https://doi.org/10.20517/MRR.2023.39>.
- [316] Henderickx JGE, Crobach MJT, Terveer EM, Smits WK, Kuijper EJ, Zwartink RD. Fungal and bacterial gut microbiota differ between *Clostridioides difficile* colonization and infection. *Microbiome Research Reports* 2023;3. <https://doi.org/10.20517/MRR.2023.52>.
- [317] Ticinesi A, Parise A, Nouvenne A, Cerundolo N, Prati B, Meschi T. The possible role of gut microbiota dysbiosis in the pathophysiology of delirium in older persons. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.15>.
- [318] Thomas C, Minty M, Vinel A, Canceill T, Loubières P, Burcelin R, et al. Oral Microbiota: A Major Player in the Diagnosis of Systemic Diseases. *Diagnostics (Basel)* 2021;11. <https://doi.org/10.3390/DIAGNOSTICS11081376>.
- [319] Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. *Nat Rev Dis Primers* 2019;5. <https://doi.org/10.1038/S41572-019-0106-Z>.
- [320] Xiao Z, Pan M, Li X, Zhao C. Impact of SARS-CoV2 infection on gut microbiota dysbiosis. *Microbiome Research Reports* 2023;3. <https://doi.org/10.20517/MRR.2023.48>.
- [321] Shi CY, Yu CH, Yu WY, Ying HZ. Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics. *Can J Infect Dis Med Microbiol* 2021;2021. <https://doi.org/10.1155/2021/9278441>.

- [322] Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. *Ann Clin Microbiol Antimicrob* 2020;19:5. <https://doi.org/10.1186/S12941-020-0347-4>.
- [323] Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. *Nature* 2012;491:717–23. <https://doi.org/10.1038/NATURE11605>.
- [324] Godfrey DI, Koay HF, McCluskey J, Gherardin NA. The biology and functional importance of MAIT cells. *Nat Immunol* 2019;20:1110–28. <https://doi.org/10.1038/S41590-019-0444-8>.
- [325] Constantinides MG, Link VM, Tamoutounour S, Wong AC, Perez-Chaparro PJ, Han SJ, et al. MAIT cells are imprinted by the microbiota in early life and promote tissue repair. *Science* 2019;366. <https://doi.org/10.1126/SCIENCE.AAX6624>.
- [326] Hartmann N, Harrieff MJ, McMurtrey CP, Hildebrand WH, Lewinsohn DM, Kronenberg M. Role of MAIT cells in pulmonary bacterial infection. *Mol Immunol* 2018;101:155–9. <https://doi.org/10.1016/J.MOLIMM.2018.06.270>.
- [327] Patel O, Kjer-Nielsen L, Le Nours J, Eckle SBG, Birkinshaw R, Beddoe T, et al. Recognition of vitamin B metabolites by mucosal-associated invariant T cells. *Nat Commun* 2013;4. <https://doi.org/10.1038/NCOMMS3142>.
- [328] Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Falkowski NR, Huffnagle GB, et al. Bacterial Topography of the Healthy Human Lower Respiratory Tract. *MBio* 2017;8. <https://doi.org/10.1128/MBIO.02287-16>.
- [329] Li R, Li J, Zhou X. Lung microbiome: new insights into the pathogenesis of respiratory diseases. *Signal Transduct Target Ther* 2024;9. <https://doi.org/10.1038/S41392-023-01722-Y>.
- [330] Pereira PM de CC, Vicente AF dos RB. Meat nutritional composition and nutritive role in the human diet. *Meat Sci* 2013;93:586–92. <https://doi.org/10.1016/J.MEATSCI.2012.09.018>.
- [331] Roje S. Vitamin B biosynthesis in plants. *Phytochemistry* 2007;68:1904–21. <https://doi.org/10.1016/J.PHYTOCHEM.2007.03.038>.
- [332] Mladěnka P, Macáková K, Kujovská Krčmová L, Javorská L, Mrštná K, Carazo A, et al. Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. *Nutr Rev* 2022;80:677–98. <https://doi.org/10.1093/NUTRIT/NUAB061>.
- [333] Gaucheron F. Milk and dairy products: a unique micronutrient combination. *J Am Coll Nutr* 2011;30:400S-409S. <https://doi.org/10.1080/07315724.2011.10719983>.
- [334] Magan JB, O’Callaghan TF, Zheng J, Zhang L, Mandal R, Hennessy D, et al. Effect of Diet on the Vitamin B Profile of Bovine Milk-Based Protein Ingredients. *Foods* 2020;9. <https://doi.org/10.3390/FOODS9050578>.

- [335] Alrubaye HS, Kohl KD. Abundance and Compositions of B-Vitamin-Producing Microbes in the Mammalian Gut Vary Based on Feeding Strategies. *MSystems* 2021;6. <https://doi.org/10.1128/MSYSTEMS.00313-21>.
- [336] Mengoli M, Conti G, Fabbrini M, Candela M, Brigidi P, Turrone S, et al. Microbiota-gut-brain axis and ketogenic diet: how close are we to tackling epilepsy? *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.24>.
- [337] Bennett E, Peters SAE, Woodward M. Sex differences in macronutrient intake and adherence to dietary recommendations: findings from the UK Biobank. *BMJ Open* 2018;8. <https://doi.org/10.1136/BMJOPEN-2017-020017>.
- [338] Kim YS, Unno T, Kim BY, Park MS. Sex Differences in Gut Microbiota. *World J Mens Health* 2020;38:48. <https://doi.org/10.5534/WJMH.190009>.
- [339] Grant ET, Parrish A, Boudaud M, Hunewald O, Hirayama A, Ollert M, et al. Dietary fibers boost gut microbiota-produced B vitamin pool and alter host immune landscape. *Microbiome* 2024;12:179. <https://doi.org/10.1186/S40168-024-01898-7>.
- [340] Pham VT, Dold S, Rehman A, Bird JK, Steinert RE. Vitamins, the gut microbiome and gastrointestinal health in humans. *Nutr Res* 2021;95:35–53. <https://doi.org/10.1016/J.NUTRES.2021.09.001>.
- [341] Seura T, Yoshino Y, Fukuwatari T. The Relationship between Habitual Dietary Intake and Gut Microbiota in Young Japanese Women. *J Nutr Sci Vitaminol (Tokyo)* 2017;63:396–404. <https://doi.org/10.3177/JNSV.63.396>.
- [342] Zemleni J, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. *Am J Clin Nutr* 1996;63:54–66. <https://doi.org/10.1093/AJCN/63.1.54>.
- [343] Steinert RE, Sadaghian Sadabad M, Harmsen HJM, Weber P. The prebiotic concept and human health: a changing landscape with riboflavin as a novel prebiotic candidate? *Eur J Clin Nutr* 2016;70:1348–53. <https://doi.org/10.1038/EJCN.2016.119>.
- [344] Carrothers JM, York MA, Brooker SL, Lackey KA, Williams JE, Shafii B, et al. Fecal Microbial Community Structure Is Stable over Time and Related to Variation in Macronutrient and Micronutrient Intakes in Lactating Women. *J Nutr* 2015;145:2379–88. <https://doi.org/10.3945/JN.115.211110>.
- [345] Fangmann D, Theismann EM, Turk K, Schulte DM, Relling I, Hartmann K, et al. Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans. *Diabetes Care* 2018;41:398–405. <https://doi.org/10.2337/DC17-1967>.
- [346] Jaehme M, Slotboom DJ. Diversity of membrane transport proteins for vitamins in bacteria and archaea. *Biochim Biophys Acta* 2015;1850:565–76. <https://doi.org/10.1016/J.BBAGEN.2014.05.006>.

- [347] Erkens GB, Slotboom DJ. Biochemical characterization of ThiT from *Lactococcus lactis*: a thiamin transporter with picomolar substrate binding affinity. *Biochemistry* 2010;49:3203–12. <https://doi.org/10.1021/BI100154R>.
- [348] Rodionov DA, Hebbeln P, Eudes A, Ter Beek J, Rodionova IA, Erkens GB, et al. A novel class of modular transporters for vitamins in prokaryotes. *J Bacteriol* 2009;191:42–51. <https://doi.org/10.1128/JB.01208-08>.
- [349] Hebbeln P, Rodionov DA, Aliandega A, Eitinger T. Biotin uptake in prokaryotes by solute transporters with an optional ATP-binding cassette-containing module. *Proc Natl Acad Sci U S A* 2007;104:2909–14. <https://doi.org/10.1073/PNAS.0609905104>.
- [350] Eudes A, Erkens GB, Slotboom DJ, Rodionov DA, Naponelli V, Hanson AD. Identification of genes encoding the folate- and thiamine-binding membrane proteins in Firmicutes. *J Bacteriol* 2008;190:7591–4. <https://doi.org/10.1128/JB.01070-08>.
- [351] Webb E, Claas K, Downs D. thiBPQ encodes an ABC transporter required for transport of thiamine and thiamine pyrophosphate in *Salmonella typhimurium*. *J Biol Chem* 1998;273:8946–50. <https://doi.org/10.1074/JBC.273.15.8946>.
- [352] Jaehme M, Singh R, Garaeva AA, Duurkens RH, Slotboom DJ. PnuT uses a facilitated diffusion mechanism for thiamine uptake. *J Gen Physiol* 2018;150:41–50. <https://doi.org/10.1085/JGP.201711850>.
- [353] Josts I, Almeida Hernandez Y, Andreeva A, Tidow H. Crystal Structure of a Group I Energy Coupling Factor Vitamin Transporter S Component in Complex with Its Cognate Substrate. *Cell Chem Biol* 2016;23:827–36. <https://doi.org/10.1016/J.CHEMBIOL.2016.06.008>.
- [354] Burgess CM, Slotboom DJ, Geertsma ER, Duurkens RH, Poolman B, Van Sinderen D. The riboflavin transporter RibU in *Lactococcus lactis*: molecular characterization of gene expression and the transport mechanism. *J Bacteriol* 2006;188:2752–60. <https://doi.org/10.1128/JB.188.8.2752-2760.2006>.
- [355] Vogl C, Grill S, Schilling O, Stülke J, Mack M, Stolz J. Characterization of riboflavin (vitamin B2) transport proteins from *Bacillus subtilis* and *Corynebacterium glutamicum*. *J Bacteriol* 2007;189:7367–75. <https://doi.org/10.1128/JB.00590-07>.
- [356] García Angulo VA, Bonomi HR, Posadas DM, Serer MI, Torres AG, Zorreguieta Á, et al. Identification and characterization of RibN, a novel family of riboflavin transporters from *Rhizobium leguminosarum* and other proteobacteria. *J Bacteriol* 2013;195:4611–9. <https://doi.org/10.1128/JB.00644-13>.
- [357] Rodionov DA, Li X, Rodionova IA, Yang C, Sorci L, Dervyn E, et al. Transcriptional regulation of NAD metabolism in bacteria: genomic reconstruction of NiaR (YrxA) regulon. *Nucleic Acids Res* 2008;36:2032–46. <https://doi.org/10.1093/NAR/GKN046>.

- [358] Jackowski S, Alix JH. Cloning, sequence, and expression of the pantothenate permease (panF) gene of *Escherichia coli*. *J Bacteriol* 1990;172:3842–8. <https://doi.org/10.1128/JB.172.7.3842-3848.1990>.
- [359] Suvorova IA, Rodionov DA. Comparative genomics of pyridoxal 5'-phosphate-dependent transcription factor regulons in Bacteria. *Microb Genom* 2016;2:e000047. <https://doi.org/10.1099/MGEN.0.000047>.
- [360] Finkenwirth F, Kirsch F, Eitinger T. A versatile *Escherichia coli* strain for identification of biotin transporters and for biotin quantification. *Bioengineered* 2014;5. <https://doi.org/10.4161/BIOE.26887>.
- [361] Santos JA, Rempel S, Mous STM, Pereira CT, Beek J Ter, de Gier JW, et al. Functional and structural characterization of an ECF-type ABC transporter for vitamin B12. *Elife* 2018;7. <https://doi.org/10.7554/ELIFE.35828>.
- [362] Wexler AG, Schofield WB, Degnan PH, Folta-Stogniew E, Barry NA, Goodman AL. Human gut *Bacteroides* capture vitamin B12 via cell surface-exposed lipoproteins. *Elife* 2018;7. <https://doi.org/10.7554/ELIFE.37138>.
- [363] Abellon-Ruiz J, Jana K, Silale A, Frey AM, Baslé A, Trost M, et al. BtuB TonB-dependent transporters and BtuG surface lipoproteins form stable complexes for vitamin B12 uptake in gut *Bacteroides*. *Nat Commun* 2023;14. <https://doi.org/10.1038/S41467-023-40427-2>.
- [364] Putnam EE, Abellon-Ruiz J, Killinger BJ, Rosnow JJ, Wexler AG, Folta-Stogniew E, et al. Gut Commensal *Bacteroidetes* Encode a Novel Class of Vitamin B12-Binding Proteins. *MBio* 2022;13:e02845-21. <https://doi.org/10.1128/MBIO.02845-21>.
- [365] Radjabzadeh D, Boer CG, Beth SA, van der Wal P, Kiefte-De Jong JC, Jansen MAE, et al. Diversity, compositional and functional differences between gut microbiota of children and adults. *Scientific Reports* 2020 10:1 2020;10:1–13. <https://doi.org/10.1038/s41598-020-57734-z>.
- [366] Hrubša M, Siatka T, Nejmanová I, Vopršalová M, Krčmová LK, Matoušová K, et al. Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1, B2, B3, and B5. *Nutrients* 2022;14. <https://doi.org/10.3390/NU14030484>.
- [367] U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th Edition. December 2020. Available at <https://www.dietaryguidelines.gov/> n.d. <https://www.dietaryguidelines.gov/>.
- [368] Venegas DP, De La Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. *Front Immunol* 2019;10. <https://doi.org/10.3389/FIMMU.2019.00277>.

- [369] Luo P, Lednovich K, Xu K, Nnyamah C, Layden BT, Xu P. Central and peripheral regulations mediated by short-chain fatty acids on energy homeostasis. *Translational Research* 2022;248:128–50. <https://doi.org/10.1016/J.TRSL.2022.06.003>.
- [370] Barber C, Sabater C, Guarner F, Margolles A, Azpiroz F. Metabolic response of intestinal microbiota to guar gum consumption. *Front Nutr* 2023;10. <https://doi.org/10.3389/FNUT.2023.1160694>.
- [371] Asnicar F, Berry SE, Valdes AM, Nguyen LH, Piccinno G, Drew DA, et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. *Nat Med* 2021;27:321–32. <https://doi.org/10.1038/S41591-020-01183-8>.
- [372] Thakur K, Tomar SK, Singh AK, Mandal S, Arora S. Riboflavin and health: A review of recent human research. *Crit Rev Food Sci Nutr* 2017;57:3650–60. <https://doi.org/10.1080/10408398.2016.1145104>.
- [373] Powers HJ. Riboflavin (vitamin B-2) and health. *Am J Clin Nutr* 2003;77:1352–60. <https://doi.org/10.1093/AJCN/77.6.1352>.
- [374] Pham VT, Fehlbaum S, Seifert N, Richard N, Bruins MJ, Sybesma W, et al. Effects of colon-targeted vitamins on the composition and metabolic activity of the human gut microbiome—a pilot study. *Gut Microbes* 2021;13:1–20. <https://doi.org/10.1080/19490976.2021.1875774>.
- [375] Maitiniyazi G, Cao X, Chen Y, Zhang R, Liu Y, Li Z, et al. Impact of Gut Microbiota on the Association between Diet and Depressive Symptoms in Breast Cancer. *Nutrients* 2022;14. <https://doi.org/10.3390/NU14061186>.
- [376] Lopez-Siles M, Khan TM, Duncan SH, Harmsen HJM, Garcia-Gil LJ, Flint HJ. Cultured representatives of two major phylogroups of human colonic *Faecalibacterium prausnitzii* can utilize pectin, uronic acids, and host-derived substrates for growth. *Appl Environ Microbiol* 2012;78:420–8. <https://doi.org/10.1128/AEM.06858-11>.
- [377] Plöger S, Stumpff F, Penner GB, Schulzke JD, Gäbel G, Martens H, et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract. *Ann N Y Acad Sci* 2012;1258:52–9. <https://doi.org/10.1111/J.1749-6632.2012.06553.X>.
- [378] Buckel W, Thauer RK. Flavin-Based Electron Bifurcation, A New Mechanism of Biological Energy Coupling. *Chem Rev* 2018;118:3862–86. <https://doi.org/10.1021/ACS.CHEMREV.7B00707>.
- [379] Liu H, Wang J, He T, Becker S, Zhang G, Li D, et al. Butyrate: A Double-Edged Sword for Health? *Adv Nutr* 2018;9:21–9. <https://doi.org/10.1093/ADVANCES/NMX009>.
- [380] Duncan SH, Louis P, Flint HJ. Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. *Appl Environ Microbiol* 2004;70:5810–7. <https://doi.org/10.1128/AEM.70.10.5810-5817.2004>.

- [381] Liu L, Sadaghian Sadabad M, Gabarrini G, Lisotto P, Von Martels JZH, Wardill HR, et al. Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota. *Antioxid Redox Signal* 2023;38:282–97. <https://doi.org/10.1089/ARS.2022.0033>.
- [382] Zhang S, Ning R, Zeng B, Deng F, Kong F, Guo W, et al. Gut Microbiota Composition and Metabolic Potential of Long-Living People in China. *Front Aging Neurosci* 2022;14. <https://doi.org/10.3389/FNAGI.2022.820108>.
- [383] Wu L, Zeng T, Zinellu A, Rubino S, Kelvin DJ, Carru C. A Cross-Sectional Study of Compositional and Functional Profiles of Gut Microbiota in Sardinian Centenarians. *MSystems* 2019;4. <https://doi.org/10.1128/MSYSTEMS.00325-19>.
- [384] Lynch S V., Pedersen O. The Human Intestinal Microbiome in Health and Disease. *N Engl J Med* 2016;375:2369–79. <https://doi.org/10.1056/NEJMRA1600266>.
- [385] Mohedano ML, Hernández-Recio S, Yépez A, Requena T, Martínez-Cuesta MC, Peláez C, et al. Real-Time Detection of Riboflavin Production by *Lactobacillus plantarum* Strains and Tracking of Their Gastrointestinal Survival and Functionality in vitro and in vivo Using mCherry Labeling. *Front Microbiol* 2019;10. <https://doi.org/10.3389/FMICB.2019.01748>.
- [386] Thakur K, Tomar SK, De S. Lactic acid bacteria as a cell factory for riboflavin production. *Microb Biotechnol* 2016;9:441–51. <https://doi.org/10.1111/1751-7915.12335>.
- [387] Spacova I, Ahannach S, Breynaert A, Erreygers I, Wittouck S, Bron PA, et al. Spontaneous Riboflavin-Overproducing *Limosilactobacillus reuteri* for Biofortification of Fermented Foods. *Front Nutr* 2022;9. <https://doi.org/10.3389/FNUT.2022.916607>.
- [388] Ghosal A, Said HM. Mechanism and regulation of vitamin B2 (riboflavin) uptake by mouse and human pancreatic β -cells/islets: physiological and molecular aspects. *Am J Physiol Gastrointest Liver Physiol* 2012;303. <https://doi.org/10.1152/AJPGI.00314.2012>.
- [389] Gazzaniga F, Stebbins R, Chang SZ, McPeck MA, Brenner C. Microbial NAD metabolism: lessons from comparative genomics. *Microbiol Mol Biol Rev* 2009;73:529–41. <https://doi.org/10.1128/MMBR.00042-08>.
- [390] Lapébie P, Lombard V, Drula E, Terrapon N, Henrissat B. Bacteroidetes use thousands of enzyme combinations to break down glycans. *Nature Communications* 2019 10:1 2019;10:1–7. <https://doi.org/10.1038/s41467-019-10068-5>.
- [391] McKee LS, La Rosa SL, Westereng B, Eijssink VG, Pope PB, Larsbrink J. Polysaccharide degradation by the Bacteroidetes: mechanisms and nomenclature. *Environ Microbiol Rep* 2021;13:559–81. <https://doi.org/10.1111/1758-2229.12980>.
- [392] Jiang L, Song C, Ai C, Wen C, Song S. Modulation effect of sulfated polysaccharide from *Sargassum fusiforme* on gut microbiota and their metabolites in vitro fermentation. *Front Nutr* 2024;11. <https://doi.org/10.3389/FNUT.2024.1400063>.

- [393] Le Roy C, Bowyer R, Steves C, Spector T, Jordana B. Dissecting the Role of the Gut Microbiota and Diet on Visceral Fat Mass Accumulation (OR31-07-19). *Curr Dev Nutr* 2019;3:nzz037. OR31-07-19. <https://doi.org/10.1093/CDN/NZZ037.0R31-07-19>.
- [394] Malinowska AM, Schmidt M, Kok DE, Chmurzynska A. Ex vivo folate production by fecal bacteria does not predict human blood folate status: Associations between dietary patterns, gut microbiota, and folate metabolism. *Food Res Int* 2022;156. <https://doi.org/10.1016/J.FOODRES.2022.111290>.
- [395] Valentini L, Pinto A, Bourdel-Marchasson I, Ostan R, Brigidi P, Turrone S, et al. Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota - The "RISTOMED project": Randomized controlled trial in healthy older people. *Clin Nutr* 2015;34:593–602. <https://doi.org/10.1016/J.CLNU.2014.09.023>.
- [396] Lionaki E, Ploumi C, Tavernarakis N. One-Carbon Metabolism: Pulling the Strings behind Aging and Neurodegeneration. *Cells* 2022;11. <https://doi.org/10.3390/CELLS11020214>.
- [397] Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. *Nat Commun* 2014;5. <https://doi.org/10.1038/NCOMMS4611>.
- [398] Card DJ, Gorska R, Cutler J, Harrington DJ. Vitamin K metabolism: current knowledge and future research. *Mol Nutr Food Res* 2014;58:1590–600. <https://doi.org/10.1002/MNFR.201300683>.
- [399] Castaneda M, Strong JM, Alabi DA, Hernandez CJ. The Gut Microbiome and Bone Strength. *Curr Osteoporos Rep* 2020;18:677–83. <https://doi.org/10.1007/S11914-020-00627-X>.
- [400] Riviere AJ, Smith KS, Schaberg MN, Greene MW, Frugé AD. Plasma and fecal zonulin are not altered by a high green leafy vegetable dietary intervention: secondary analysis of a randomized control crossover trial. *BMC Gastroenterol* 2022;22. <https://doi.org/10.1186/S12876-022-02248-3>.
- [401] Karl JP, Meydani M, Barnett JB, Vanegas SM, Barger K, Fu X, et al. Fecal concentrations of bacterially derived vitamin K forms are associated with gut microbiota composition but not plasma or fecal cytokine concentrations in healthy adults. *Am J Clin Nutr* 2017;106:1052–61. <https://doi.org/10.3945/AJCN.117.155424>.
- [402] Hojo K, Nagaoka S, Murata S, Taketomo N, Ohshima T, Maeda N. Reduction of vitamin K concentration by salivary Bifidobacterium strains and their possible nutritional competition with Porphyromonas gingivalis. *J Appl Microbiol* 2007;103:1969–74. <https://doi.org/10.1111/J.1365-2672.2007.03436.X>.
- [403] McCann A, Jeffery IB, Ouliass B, Ferland G, Fu X, Booth SL, et al. Exploratory analysis of covariation of microbiota-derived vitamin K and cognition in older adults. *Am J Clin Nutr* 2019;110:1404–15. <https://doi.org/10.1093/AJCN/NQZ220>.

- [404] Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. *Signal Transduction and Targeted Therapy* 2022 7:1 2022;7:1–28. <https://doi.org/10.1038/s41392-022-00974-4>.
- [405] O'reilly C, Mills S, Rea MC, Lavelle A, Ghosh S, Hill C, et al. Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.41>.
- [406] Madhogaria B, Bhowmik P, Kundu A. Correlation between human gut microbiome and diseases. *Infectious Medicine* 2022;1:180–91. <https://doi.org/10.1016/J.IMJ.2022.08.004>.
- [407] Ruiz-Saavedra S, Zapico A, González S, Salazar N, de los Reyes-Gavilán CG. Role of the intestinal microbiota and diet in the onset and progression of colorectal and breast cancers and the interconnection between both types of tumours. *Microbiome Research Reports* 2023;3. <https://doi.org/10.20517/MRR.2023.36>.
- [408] Peng Z, Zhuang J, Shen B. The role of microbiota in tumorigenesis, progression and treatment of bladder cancer. *Microbiome Research Reports* 2023;3. <https://doi.org/10.20517/MRR.2023.47>.
- [409] Berding K, Vlckova K, Marx W, Schellekens H, Stanton C, Clarke G, et al. Diet and the Microbiota-Gut-Brain Axis: Sowing the Seeds of Good Mental Health. *Adv Nutr* 2021;12:1239–85. <https://doi.org/10.1093/ADVANCES/NMAA181>.
- [410] Selin JZ, Lindblad BE, Bottai M, Morgenstern R, Wolk A. High-dose B-vitamin supplements and risk for age-related cataract: a population-based prospective study of men and women. *Br J Nutr* 2017;118:154–60. <https://doi.org/10.1017/S0007114517001994>.
- [411] Alam MM, Iqbal S, Naseem I. Ameliorative effect of riboflavin on hyperglycemia, oxidative stress and DNA damage in type-2 diabetic mice: Mechanistic and therapeutic strategies. *Arch Biochem Biophys* 2015;584:10–9. <https://doi.org/10.1016/J.ABB.2015.08.013>.
- [412] Toyosawa T, Suzuki M, Kodama K, Araki S. Highly purified vitamin B2 presents a promising therapeutic strategy for sepsis and septic shock. *Infect Immun* 2004;72:1820–3. <https://doi.org/10.1128/IAI.72.3.1820-1823.2004>.
- [413] Shen X, Shi C, Xu J, Zhi F, Luo K, Di Y, et al. Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease. *Commun Biol* 2024;7. <https://doi.org/10.1038/S42003-024-06722-4>.
- [414] Seekamp A, Hultquist DE, Till GO. Protection by vitamin B2 against oxidant-mediated acute lung injury. *Inflammation* 1999;23:449–60. <https://doi.org/10.1023/A:1021965026580>.
- [415] Al-Harbi NO, Imam F, Nadeem A, Al-Harbi MM, Korashy HM, Sayed-Ahmed MM, et al. Riboflavin attenuates lipopolysaccharide-induced lung injury in rats. *Toxicol Mech Methods* 2015;25:417–23. <https://doi.org/10.3109/15376516.2015.1045662>.

- [416] Horigan G, McNulty H, Ward M, Strain JJJ, Purvis J, Scott JM. Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR. *J Hypertens* 2010;28:478–86. <https://doi.org/10.1097/HJH.0B013E328334C126>.
- [417] Shi Z, Yuan B, Taylor AW, Zhen S, Zuo H, Dai Y, et al. Riboflavin intake and 5-year blood pressure change in Chinese adults: interaction with hypertensive medication. *Food Nutr Bull* 2014;35:33–42. <https://doi.org/10.1177/156482651403500105>.
- [418] Karakoyun B, Ertaş B, Yüksel M, Akakın D, Çevik Ö, Şener G. Ameliorative effects of riboflavin on acetic acid-induced colonic injury in rats. *Clin Exp Pharmacol Physiol* 2018;45:563–72. <https://doi.org/10.1111/1440-1681.12894>.
- [419] Al-Harbi NO, Imam F, Nadeem A, Al-Harbi MM, Iqbal M, Ahmad SF. Carbon tetrachloride-induced hepatotoxicity in rat is reversed by treatment with riboflavin. *Int Immunopharmacol* 2014;21:383–8. <https://doi.org/10.1016/J.INTIMP.2014.05.014>.
- [420] Novaković R, Geelen A, Ristić-Medić D, Nikolić M, Souverein OW, McNulty H, et al. Systematic Review of Observational Studies with Dose-Response Meta-Analysis between Folate Intake and Status Biomarkers in Adults and the Elderly. *Ann Nutr Metab* 2018;73:30–43. <https://doi.org/10.1159/000490003>.
- [421] Makino E, Fukuyama T, Watanabe Y, Tajiki-Nishino R, Tajima H, Ohnuma-Koyama A, et al. Subacute oral administration of folic acid elicits anti-inflammatory response in a mouse model of allergic dermatitis. *J Nutr Biochem* 2019;67:14–9. <https://doi.org/10.1016/J.JNUTBIO.2019.01.009>.
- [422] Sid V, Siow YL, Karmin O. Role of folate in nonalcoholic fatty liver disease. *Can J Physiol Pharmacol* 2017;95:1141–8. <https://doi.org/10.1139/CJPP-2016-0681>.
- [423] Baszczuk A, Thielemann A, Musialik K, Kopczyński J, Bielawska L, Dżumak A, et al. The Impact of Supplementation with Folic Acid on Homocysteine Concentration and Selected Lipoprotein Parameters in Patients with Primary Hypertension. *J Nutr Sci Vitaminol (Tokyo)* 2017;63:96–103. <https://doi.org/10.3177/JNSV.63.96>.
- [424] Dehkordi Hashemi E, Sattari F, Khoshdel A, Kasiri K. Effect of folic acid and metformin on insulin resistance and inflammatory factors of obese children and adolescents. *J Res Med Sci* 2016;21:32–7. <https://doi.org/10.4103/1735-1995.189669>.
- [425] Paul S, Bhattacharjee P, Giri AK, Bhattacharjee P. Arsenic toxicity and epimutagenicity: the new LINEage. *Biometals* 2017;30:505–15. <https://doi.org/10.1007/S10534-017-0021-2>.
- [426] Burr NE, Hull MA, Subramanian V. Folic Acid Supplementation May Reduce Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. *J Clin Gastroenterol* 2017;51:247–53. <https://doi.org/10.1097/MCG.0000000000000498>.

- [427] Fu H, He J, Li C, Deng Z, Chang H. Folate intake and risk of colorectal cancer: a systematic review and up-to-date meta-analysis of prospective studies. *Eur J Cancer Prev* 2023;32:103–12. <https://doi.org/10.1097/CEJ.0000000000000744>.
- [428] Gurwara S, Ajami NJ, Jang A, Hessel FC, Chen L, Plew S, et al. Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. *Nutrients* 2019;11. <https://doi.org/10.3390/NU11030613>.
- [429] Niederreiter L, Adolph TE, Tilg H. Food, microbiome and colorectal cancer. *Dig Liver Dis* 2018;50:647–52. <https://doi.org/10.1016/J.DLD.2018.03.030>.
- [430] Agim ZS, Cannon JR. Dietary factors in the etiology of Parkinson’s disease. *Biomed Res Int* 2015;2015. <https://doi.org/10.1155/2015/672838>.
- [431] Marashly ET, Bohlega SA. Riboflavin Has Neuroprotective Potential: Focus on Parkinson’s Disease and Migraine. *Front Neurol* 2017;8. <https://doi.org/10.3389/FNEUR.2017.00333>.
- [432] Coimbra CG, Junqueira VBC. High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson’s disease patients. *Braz J Med Biol Res* 2003;36:1409–17. <https://doi.org/10.1590/S0100-879X2003001000019>.
- [433] Miller DB, O’Callaghan JP. Biomarkers of Parkinson’s disease: present and future. *Metabolism* 2015;64:S40–6. <https://doi.org/10.1016/J.METABOL.2014.10.030>.
- [434] Rojo-Sebastián A, González-Robles C, Garcíá De Yébenes J. Vitamin B6 Deficiency in Patients With Parkinson Disease Treated With Levodopa/Carbidopa. *Clin Neuropharmacol* 2020;43:151–7. <https://doi.org/10.1097/WNF.0000000000000408>.
- [435] Al-Habsi N, Al-Khalili M, Haque SA, Elias M, Olqi N Al, Al Uraimi T. Health Benefits of Prebiotics, Probiotics, Synbiotics, and Postbiotics. *Nutrients* 2024;16. <https://doi.org/10.3390/NU16223955>.
- [436] Żółkiewicz J, Marzec A, Ruszczyński M, Feleszko W. Postbiotics-A Step Beyond Pre- and Probiotics. *Nutrients* 2020;12:1–17. <https://doi.org/10.3390/NU12082189>.
- [437] Ikram A, Safdar SZ, Arshad MT, Rasheed A, Gnedeka KT. An overview of postbiotics: unveiling their distinct role in gut health. *Food Agric Immunol* 2024;35. <https://doi.org/10.1080/09540105.2024.2434463>.
- [438] LeBlanc JG, Levit R, Savoy de Giori G, de Moreno de LeBlanc A. Application of vitamin-producing lactic acid bacteria to treat intestinal inflammatory diseases. *Appl Microbiol Biotechnol* 2020;104:3331–7. <https://doi.org/10.1007/S00253-020-10487-1>.
- [439] Chen Y, Gao H, Zhao J, Ross RP, Stanton C, Zhang H, et al. Exploiting lactic acid bacteria for inflammatory bowel disease: A recent update. *Trends Food Sci Technol* 2023;138:126–40. <https://doi.org/10.1016/J.TIFS.2023.06.007>.

- [440] de Moreno de LeBlanc A, Levit R, de Giori GS, LeBlanc JG. Vitamin Producing Lactic Acid Bacteria as Complementary Treatments for Intestinal Inflammation. *Antiinflamm Antiallergy Agents Med Chem* 2018;17:50–6. <https://doi.org/10.2174/1871523017666180502170659>.
- [441] Levit R, de Giori GS, de LeBlanc A de M, LeBlanc JG. Evaluation of the effect of soymilk fermented by a riboflavin-producing *Lactobacillus plantarum* strain in a murine model of colitis. *Benef Microbes* 2017;8:65–72. <https://doi.org/10.3920/BM2016.0063>.
- [442] Levit R, Savoy de Giori G, de Moreno de LeBlanc A, LeBlanc JG. Protective effect of the riboflavin-overproducing strain *Lactobacillus plantarum* CRL2130 on intestinal mucositis in mice. *Nutrition* 2018;54:165–72. <https://doi.org/10.1016/J.NUT.2018.03.056>.
- [443] Levit R, Savoy de Giori G, de Moreno de LeBlanc A, LeBlanc JG. Folate-producing lactic acid bacteria reduce inflammation in mice with induced intestinal mucositis. *J Appl Microbiol* 2018;125:1494–501. <https://doi.org/10.1111/JAM.14038>.
- [444] Perez Visňuk D, Teran M del M, Savoy de Giori G, LeBlanc JG, de Moreno de LeBlanc A. Neuroprotective Effect of Riboflavin Producing Lactic Acid Bacteria in Parkinsonian Models. *Neurochem Res* 2022;47:1269–79. <https://doi.org/10.1007/S11064-021-03520-W>.
- [445] Perez Visňuk D, Savoy de Giori G, LeBlanc JG, de Moreno de LeBlanc A. Neuroprotective effects associated with immune modulation by selected lactic acid bacteria in a Parkinson's disease model. *Nutrition* 2020;79–80. <https://doi.org/10.1016/J.NUT.2020.110995>.
- [446] Aguilar-Toalá JE, Garcia-Varela R, Garcia HS, Mata-Haro V, González-Córdova AF, Vallejo-Cordoba B, et al. Postbiotics: An evolving term within the functional foods field. *Trends Food Sci Technol* 2018;75:105–14. <https://doi.org/10.1016/J.TIFS.2018.03.009>.
- [447] Yang Q, Liang Q, Balakrishnan B, Belobrajdic DP, Feng QJ, Zhang W. Role of Dietary Nutrients in the Modulation of Gut Microbiota: A Narrative Review. *Nutrients* 2020;12. <https://doi.org/10.3390/NU12020381>.
- [448] Aggeletopoulou I, Tsounis EP, Mouzaki A, Triantos C. Exploring the Role of Vitamin D and the Vitamin D Receptor in the Composition of the Gut Microbiota. *Front Biosci (Landmark Ed)* 2023;28. <https://doi.org/10.31083/J.FBL2806116>.
- [449] Bellerba F, Muzio V, Gnagnarella P, Facciotti F, Chiocca S, Bossi P, et al. The association between Vitamin D and gut microbiota: A systematic review of human studies. *Nutrients* 2021;13:3378. <https://doi.org/10.3390/NU13103378/S1>.
- [450] Longhi G, Lugli GA, Bianchi MG, Rizzo SM, Tarracchini C, Mancabelli L, et al. Highly conserved bifidobacteria in the human gut: *Bifidobacterium longum* subsp. *longum* as a potential modulator of elderly innate immunity. *Benef Microbes* 2024;15:241–58. <https://doi.org/10.1163/18762891-BJA00013>.

- [451] Layeghifard M, Hwang DM, Guttman DS. Disentangling Interactions in the Microbiome: A Network Perspective. *Trends Microbiol* 2017;25:217–28. <https://doi.org/10.1016/J.TIM.2016.11.008>.
- [452] Fabbrini M, Scicchitano D, Candela M, Turroni S, Rampelli S. Connect the dots: sketching out microbiome interactions through networking approaches. *Microbiome Research Reports* 2023;2. <https://doi.org/10.20517/MRR.2023.25>.
- [453] Hooper L V., Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science* 2012;336:1268–73. <https://doi.org/10.1126/SCIENCE.1223490>.
- [454] Swaney MH, Sandstrom S, Kalan LR. Cobamide Sharing Is Predicted in the Human Skin Microbiome. *MSystems* 2022;7. <https://doi.org/10.1128/MSYSTEMS.00677-22>.
- [455] Kang D, Shi B, Erfe MC, Craft N, Li H. Vitamin B12 modulates the transcriptome of the skin microbiota in acne pathogenesis. *Sci Transl Med* 2015;7. <https://doi.org/10.1126/SCITRANSLMED.AAB2009>.
- [456] Longhi G, Lugli GA, Tarracchini C, Fontana F, Bianchi MG, Carli E, et al. From raw milk cheese to the gut: investigating the colonization strategies of *Bifidobacterium mongoliense*. *Appl Environ Microbiol* 2024;90. <https://doi.org/10.1128/AEM.01244-24>.

BIOGRAPHICAL TEXT

Chiara Tarracchini is a Post-Doc Research Fellow in Microbiology at University of Parma, Italy. She obtained her PhD in Biotechnology and Biosciences at the University of Parma, where she continues her postdoctoral research. Her work focuses on the analysis of human microbial communities in both health and disease, employing advanced metagenomic, genomic, and transcriptomic approaches to dissect microbe-microbe and host-microbe interactions. In particular, she investigates the early-life gut microbiota with the goal of unraveling its colonization dynamics, development, and interplay with the human host, as well as its short- and long-term implications for health.

Beyond the gut, her research extends to microbial communities in other human body districts, such as the vaginal and respiratory tracts.

She is the author or co-author of 50 scientific articles published in peer-reviewed journals.

Francesca Turroni is Associate Professor of Microbiology at the University of Parma, Italy. Francesca Turroni holds a PhD in Food Sciences and Technology at the University of Parma, Italy. She carried out her postdoctoral research work at the Dept. of Microbiology, National University of Ireland, Cork before joining the Department of Biosciences at the University of Parma in 2015. Prof. Turroni has been co-investigator or principal investigator in several research projects based on public or private founding.

She participated as a speaker in International Conferences. She is involved in the biotechnological transfer for industrial food companies.

Turroni's research theme can be described as “omics” (genomics and functional genomics) of probiotic bacteria and host-microbe interactions in the human gut. She has been involved in scientific research related to applied Microbiology and Biotechnology.

She is the author or co-author of 204 scientific articles published in peer-reviewed scientific journals.

Dr. Gabriele Andrea Lugli is an Assistant Professor at the University of Parma, Italy. Dr. Lugli received his Ph.D. in Biotechnology at the University of Parma. Then, he carried out his postdoctoral research work at the Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy. He is a member of the Interdepartmental Research Center “Microbiome Research Hub” and an associate editor of BMC Microbiology, Microorganisms, and Microbiome Research Reports.

The research interests of Dr. Lugli focus on the computational microbiology applied to complex microbial communities and specifically on bifidobacteria. He also explored the functionality of the microbiome in terms of microbe-microbe interactions and microbe-host cross talk in humans and other mammals.

He is the author or co-author of 170 scientific articles published in peer-reviewed journals.

Leonardo Mancabelli is Assistant Professor of Microbiology at the University of Parma, Italy. Leonardo Mancabelli holds a PhD in Biotechnology and Life Science at the University of Parma, Italy. Mancabelli's research focuses on the use of omics techniques, primarily metagenomics, genomics, and transcriptomics, to study the correlations between the microbiota of different regions of the human body and various diseases, as well as other hosts, including livestock and companion animals, in relation to their relevance to human health. Additionally, his research activity includes studies on the genomics and functional genomics of gut bacteria and those residing in other human body districts (e.g., vaginal microbiota). His research also covers the study of the biology of bifidobacteria and lactic acid bacteria (Lactic Acid Bacteria). He is the author or co-author of 138 scientific articles published in peer-reviewed journals.

Giulia Longhi is a Post-Doc Research Fellow in Microbiology at the Probiogenomics Laboratory of the Department of Chemistry, Life Sciences, and Environmental Sustainability, University of Parma. After her master's degree in Biology and Biomedical Applications, she obtained her industrial PhD in Biotechnology and Biosciences at the University of Parma. She participates as a speaker at International Conferences in the field of Microbiology. Her primary research interests focus on the investigation of the biology of key gut microorganisms, their interaction with the human intestinal microbiota, and their functional impact on host health. In her work, she aims to develop and refine methodologies for studying the composition and functionality of microbial communities in intestinal and food ecosystems. She is the author or co-author of 43 scientific articles published in peer-reviewed journals.

Prof. **Jennifer Mahony** is a Principal Investigator in the APC Microbiome Ireland research Centre based in the School of Microbiology at University College Cork. She was recently appointed as affiliated Professor at the University of Copenhagen. Her primary research interests include functional genomics pertaining to lactic acid bacteria and food-associated bacteria. Furthermore, she is interested in bacteriophage-host interactions in the context of food fermentations and the human gastrointestinal niche, among others. Additionally, her team is focused on defining the cell surface structures that are central to the interactions of lactic acid bacteria and how knowledge of these may be exploited to (a) improve the sustainability of food production systems, (b) develop novel phage-based therapeutic products and (c) define the impact of phages and bacterial cell surface polysaccharides on complex microbial communities and human health.

Dr. **Kanishka N. Nilaweera** is a Senior Research Scientist in Teagasc (The Agriculture and Food Development Authority, Ireland), a Funded Investigator in the VistaMilk Research Centre (Ireland) and an Associate Faculty member in the APC Microbiome Institute (Ireland). Prior to his move to Ireland, he previously worked in the industry (Zeneca Pharmaceuticals, UK and Servier Pharmaceuticals, France), and the academia (Rowett Research Institute and the University of Nottingham, UK). In his current role, Dr. Nilaweera undertakes research to understand how diet affects the mechanisms controlling body weight and fat stores, with the view to developing dietary

interventions that will support healthy growth. The related work has been published in Journals covering the areas of nutrition, microbiology, endocrinology, neuroscience and physiology, with broader public reached through different media outputs.

Prof. **Paul Cotter** is the Head of Food Biosciences at Teagasc (the Irish Agriculture and Food Development Authority), is a Principal Investigator with the large Irish Research Centres, APC Microbiome Ireland, VistaMilk and Food for Health Ireland and head of microbiology/co-founder of SeqBiome, a microbiome sequencing and bioinformatics service provider. He is a molecular microbiologist, with a particular focus on the microbiology of foods (especially fermented foods), the food systems and of humans, especially athletes, as well as probiotics and postbiotics. Prof Cotter is the author of >400 peer-reviewed, was included in the Clarivate list of highly cited researchers for 2018-2024, received an honorary doctorate from the University of Antwerp in 2024 and is the Field Chief Editor of Frontiers in Microbiology.

Douwe van Sinderen is Full Professor of Molecular Microbiology at University College Cork, Ireland, and holds a PhD in Molecular Genetics from the University of Groningen, The Netherlands. He is a founding Principal Investigator of APC Microbiome Ireland, a multi-institutional, cross-disciplinary research center aimed at investigating the role of the gut microbiota in health and disease.

Van Sinderen's research endeavors revolve around fundamental and applied aspects of bifidobacteria, in particular their comparative and functional genomics, as well as of the molecular interactions between dairy lactic acid bacteria and their infecting bacteriophages.

He is (co-)author on approximately 600 scientific papers published in peer-reviewed journals, editor of several text books on bifidobacteria and lactic acid bacterial phages, listed as inventor on 24 patents, and was designated as a Clarivate highly cited scientist in the last five consecutive years (2020-2024).

Marco Ventura is Full Professor of Microbiology at the University of Parma, Italy. Marco Ventura holds a PhD in Natural Sciences at the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. He is the Head of the Microbiome Research hub, representing an Interdepartmental Research Centre of the University of Parma focusing on the characterization of the human microbiome.

Ventura's research is focused on the molecular analysis of bifidobacteria, as well as the diversity and host significance of the gut microbiota.

He is the author or co-author of 334 scientific articles published in journals. Marco Ventura was nominated among the highly cited researchers in 2020, 2021 2022, 2023 and 2024 (Top 1% by citation per field and year by Clarivate Analytics Web of Science Clarivate Web of Science).

FIGURE LEGENDS

Figure 1. Schematic overview of key methodological approaches to evaluate vitamin production in currently culturable and not yet cultured bacteria. Culture-dependent approaches include microbiological assays based on test microorganisms listed in the left-bottom part of the figure, HPLC methods for direct vitamin quantification, and whole-bacteria genome sequencing followed by functional annotation. Culture-independent methods rely on genome sequence collections and metagenomic sequencing data to query reference databases of known functional features to infer the potential biosynthetic abilities of a wide range of readily culturable and not-yet-cultured bacteria.

Figure 2. Biosynthesis pathways and salvage routes of menaquinone and B-group vitamins in bacteria. A thick light-purple border indicates genes that are not essential, as they were not detected in all prototrophs. The blue background denotes genes or entire alternative metabolic pathways. Salvage routes are indicated with red arrows and lines. Universal portion pathways, i.e., sets of biosynthetic genes also present in auxotrophic microorganisms, are highlighted with a yellow background.

Figure 3. Schematic representation of the vitamin biosynthetic potential of key members of human microbiomes. Colored bar plot depicts the occurrence of vitamin biosynthetic genes in the main bacterial phyla associated with the human gut. The prevalence of biosynthetic pathways for vitamin biosynthesis is represented across various bacterial taxa through circles. Filled circles indicate the presence of complete vitamin biosynthetic pathways in all members of the given taxon, while empty circles represent their absence. Circles filled three-quarters or three-quarters empty indicate that the majority (more than 50%) of members of the given taxon possess or lack,

respectively, complete vitamin biosynthetic pathways (based on a genome comparative analysis of more than 2,000 reference bacterial genomes).

Figure 4. Schematic representation of the vitamin biosynthetic potential of human-associated bacterial taxa. The prevalence of biosynthetic pathways for vitamin biosynthesis is represented across various bacterial taxa through circles. Colored filled circles indicate the presence of complete vitamin biosynthetic pathways in all members of the given taxon, while empty circles represent their absence. Filled three-quarters or three-quarters empty indicate that the majority members (more than 50%) of the given taxon possess or lack, respectively, complete vitamin biosynthetic pathways (based on a genome comparative analysis of more than 2,000 reference bacterial genomes).

Figure 5. Overview of variation in microbial vitamin biosynthesis throughout human lifespan. Panel (a) shows the relative abundance of global and individual vitamin biosynthetic pathways in the gut microbiota of infants, adults, and elderly, highlighting marked age-associated differences. The phylogenetic tree on panel (b) depicts the distribution of vitamin biosynthetic potential across key bacterial genera of the infant gut microbiota. Colored filled circles indicate the presence of complete vitamin biosynthetic pathways in all members of the given taxon, while empty circles represent their absence. Circles filled three-quarters or three-quarters empty indicate that the majority of members (more than 50%) of the given taxon possess or lack, respectively, complete vitamin biosynthetic pathways (based on a genome comparative analysis of more than 2,000 reference bacterial genomes).

Figure 6. Atlas of microbial vitamin production across human body sites. The schematic representation illustrates the relative average abundance of microbial biosynthetic pathways

involved in the production of B-group vitamins and vitamin K2 across the microbiomes residing in various human body compartments.

Figure 7. Characterization of bacterial phyla as consumers of vitamins. The schematic representation illustrates the interactions between bacterial producers, consumers or cross-feeders, and host cells centered around sharing vitamins or their precursors. Below, the occurrence of predicted bacterial vitamin consumers is represented for the main phyla constituting the human gut microbiota, based on the genomic absence of *de novo* biosynthesis pathways (auxotrophy), coupled with the presence of known transporters for the uptake of exogenous vitamins and related intermediates. The distribution of currently known B-group vitamin transporter systems is presented across a collection of over 2,000 bacterial genomes from human gut-associated species, alongside the occurrence of these systems in corresponding vitamin auxotrophs and prototrophs. These data are reproduced from reference [70].